

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	5111	carbon near2 (flux or flow)	US-PGPUB; USPAT	OR	OFF	2005/05/13 15:33
L2	374	1 near4 (modif\$8 or alter\$8 or increas\$8)	US-PGPUB; USPAT	OR	OFF	2005/05/13 15:33
L3	233	(phosphoenol adj pyruvate or pep or phosphoenolpyruvate or phospho adj enol adj pyruvate) near4 (suppl\$4 or availab\$8)	US-PGPUB; USPAT	OR	OFF	2005/05/13 15:34
L4	11	2 and 3	US-PGPUB; USPAT	OR	OFF	2005/05/13 15:34
L5	8702	phosphotransferase\$1 or phospho adj transferase\$1	US-PGPUB; USPAT	OR	OFF	2005/05/13 15:51
L6	58	(2 or 3) and 5	US-PGPUB; USPAT	ADJ	OFF	2005/05/13 15:51
L7	43	(2 or 3) same (aromatic or shikimate)	US-PGPUB; USPAT	OR	OFF	2005/05/13 16:07

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	5111	carbon near2 (flux or flow)	US-PGPUB; USPAT	OR	OFF	2005/05/13 15:33
L2	374	1 near4 (modif\$8 or alter\$8 or increas\$8)	US-PGPUB; USPAT	OR	OFF	2005/05/13 15:33
L3	233	(phosphoenol adj pyruvate or pep or phosphoenolpyruvate or phospho adj enol adj pyruvate) near4 (suppl\$4 or availab\$8)	US-PGPUB; USPAT	OR	OFF	2005/05/13 15:34
(L4)	11	2 and 3	US-PGPUB; USPAT	OR	OFF	2005/05/13 15:34

PGPUB-DOCUMENT-NUMBER: 20050079617

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050079617 A1

TITLE: Glucose transport mutants for production of biomaterial

PUBLICATION-DATE: April 14, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cervin, Marguerite A.	Redwood City	CA	US	
Soucaille, Philippe	Deyme	CA	FR	
Valle, Fernando	Burlingame	CA	US	
Whited, Gregory M.	Belmont		US	

APPL-NO: 10/ 728337

DATE FILED: December 3, 2003

FOREIGN-APPL-PRIORITY-DATA:

COUNTRY	APPL-NO	DOC-ID	APPL-DATE
WO	PCT/US03/31544	2003WO-PCT/US03/31544	October 3, 2003

US-CL-CURRENT: 435/471

ABSTRACT:

A method is disclosed for restoring a Glu.sup.+ phenotype to a PTS.sup.-/Glu.sup.- bacterial cell which was originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport. Bacterial cells comprising the Glu.sup.+ phenotype have modified endogenous chromosomal regulatory regions which are operably linked to polynucleotides encoding galactose permeases and glucokinases.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to application PCT/US03/31544, filed Oct. 3, 2003, U.S. Provisional Application 60/416,166 filed Oct. 4, 2002 and U.S. Provisional Application 60/374,931 filed Oct. 4, 2002, which are hereby incorporated by reference.

----- KWIC -----

Summary of Invention Paragraph - BSTX (6):

[0005] In addition to the Embden-Meyerhof pathway, many bacteria possess an active transport system known as the phosphoenolpyruvate (PEP)-dependent phosphotransferase transport system (PTS). This system couples the transport of a carbon source, such as glucose to its phosphorylation. The phosphoryl group is transferred sequentially from PEP to enzyme I and from enzyme I to protein HPr. The actual translocation step is catalyzed by a family of membrane bound enzymes (called enzyme II), each of which is specific for one or a few carbon sources. Reference is made to Postma et al., (1993) Phosphoenolpyruvate: Carbohydrate Phosphotransferase Systems in Bacteria, Microbiol. Reviews. 57:543-594 and Postma P. W. (1996) Phosphotransferase System for Glucose and Other Sugars. In: Neidhardt et al., Eds. ESCHERICHIA

COLI AND SALMONELLA TYPHIMURIUM: CELLULAR AND MOLECULAR BIOLOGY. Vol.1. Washington, D.C. ASM Press pp 127-141. However, due to the fact that PTS metabolizes PEP to phosphorylate the carbon source, the PTS system decreases the efficiency of carbon substrate conversion to a desired product. In glycolysis, two molecules of PEP are formed for every molecule of glucose catabolized. However, one molecule of PEP is required for PTS to function, leaving only one molecule of PEP available for other biosynthetic reactions.

Summary of Invention Paragraph - BSTX (7):

[0006] Due to the role of PEP as a central metabolite, numerous approaches have been utilized to increase PEP supply in the cell and some of these are listed below:

Summary of Invention Paragraph - BSTX (16):

[0015] Contrary to the methods previously described, the present invention increases carbon flow to metabolic pathways in bacterial strains capable of transporting glucose without consuming PEP during the process. The conserved PEP or PEP precursors can then be redirected into a given metabolic pathway for enhanced production of a desired product. These strains are generated in cells having an inactivated PEP-dependent PTS by modifying an endogenous chromosomal regulatory region that is operably linked to a glucose assimilation protein and more specifically to a glucose transporter and/or a glucose phosphorylating protein, to restore or re-attain the ability of the cell to use glucose as a carbon source while maintaining an inactivated PTS. These cells are designated PTS.sup.-/Glu.sup.+.

Summary of Invention Paragraph - BSTX (18):

[0016] Accordingly, there is provided by the present invention a method for increasing carbon flow into a metabolic pathway of a bacterial host cell wherein the host cell was originally capable of utilizing a PTS for carbohydrate transport. The method comprises selecting a bacterial host cell which is phenotypically PTS.sup.-/Glu.sup.- and modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a polypeptide involved in glucose assimilation to restore the Glu.sup.+ phenotype.

Summary of Invention Paragraph - BSTX (19):

[0017] In a first aspect, the invention pertains to a method of increasing carbon flow into a metabolic pathway of a PTS.sup.-/Glu.sup.- bacterial host cell which was originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport which comprises a) modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a glucose assimilation protein in a PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a DNA construct comprising a promoter and DNA flanking sequences corresponding to upstream (5') regions of the glucose assimilation protein; b) allowing integration of the DNA construct to restore a Glu+ phenotype; and c) culturing the transformed host cell under suitable culture conditions, wherein the carbon flow into a metabolic pathway of the transformed host cell is increased compared to the carbon flow into the same metabolic pathway in a corresponding PTS bacterial host cell cultured under essentially the same culture conditions. In one embodiment of the method the promoter is a non-host cell promoter or a modified endogenous promoter. In a second embodiment the glucose assimilation protein is a glucose transporter, preferably a galactose permease obtained from E. coli or a glucose transporter having at least 80% sequence identity thereto. In a third embodiment the glucose assimilation protein is a phosphorylating protein, preferably a glucokinase obtained from E. coli or a glucokinase having at least 80% sequence identity thereto. In a fourth embodiment of the method the bacterial host cell is selected from the group consisting of E. coli cells,

Bacillus cells and Pantoea cells. In a fifth embodiment, the PTS.sup.-/Glu.sup.- host cell is obtained from a PTS cell by deletion of one or more genes selected from the group consisting of ptsI, ptsH and crr. In a sixth embodiment, the PTS.sup.-/Glu.sup.+ host cell is transformed with a polynucleotide encoding a protein selected from the group consisting of a transketolase, a transaldolase, a phosphoenolpyruvate synthase, DAHP synthase, DHQ synthase, DHQ dehydratase, shikimate dehydrogenase, shikimate kinase EPSP synthase and chorismate synthase.

Summary of Invention Paragraph - BSTX (22):

[0020] In a fourth aspect, the invention pertains to a method of increasing carbon flow into a metabolic pathway of a PTS.sup.-/Glu.sup.- bacterial host cell originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport which comprises a) modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a galactose permease in a PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a first DNA construct comprising a promoter and DNA flanking sequences corresponding to upstream (5') regions of the galactose permease; b) modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a glucokinase in the PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a second DNA construct comprising a promoter and DNA flanking sequences corresponding to upstream (5') regions of the glucokinase; c) allowing integration of the first and the second DNA constructs, wherein the first DNA construct replaces an endogenous promoter of the nucleic acid encoding the galactose permease and the second DNA construct replaces an endogenous promoter of the nucleic acid encoding the glucokinase wherein both the galactose permease and the glucokinase are expressed in the host cell and wherein said expression results in an increase in carbon flow into a metabolic pathway of the transformed host cell compared to carbon flow into the same metabolic pathway in the corresponding unaltered PTS.sup.-/Glu.sup.- bacterial cell. In one embodiment the metabolic pathway is the common aromatic pathway. In a second embodiment the method further comprises transforming the PTS.sup.-/Glu.sup.- host cell with a polynucleotide encoding a protein selected from the group consisting of a transketolase, a transaldolase and a phosphoenolpyruvate synthase.

Summary of Invention Paragraph - BSTX (24):

[0022] In a sixth aspect the invention pertains to a method of increasing phosphoenolpyruvate (PEP) availability in a bacterial host cell which comprises a) selecting a bacterial host cell having a PTS.sup.-/Glu.sup.- phenotype, wherein the bacterial host was originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport; b) modifying an endogenous chromosomal regulatory sequence of the selected bacterial host cell comprising transforming said selected bacterial host cell with a DNA construct comprising a promoter, wherein said DNA construct is chromosomally integrated into the selected bacterial host cell replacing an endogenous promoter which is operably linked to a nucleic acid encoding a glucose assimilation protein; c) culturing the transformed bacterial host cell under suitable conditions; and d) allowing expression of the glucose assimilation protein to obtain an altered host cell having a PTS.sup.-/Glu.sup.+ phenotype, wherein the PEP availability is increased compared to the PEP availability in a corresponding unaltered PTS bacterial host cell cultured under essentially the same culture conditions. In one embodiment the glucose assimilation protein is a galactose permease and the DNA construct comprises an exogenous promoter which replaces the endogenous promoter of the galactose permease. In another embodiment the glucose assimilation protein is a glucokinase and the DNA construct comprises an exogenous promoter which replaces the endogenous promoter of a glucokinase.

#### Brief Description of Drawings Paragraph - DRTX

(3):

[0027] The following abbreviations are used in the figure and throughout the disclosure: PEP=phosphoenolpyruvate; DAHP=3-deoxy-D-arabino-heptulosonate 7-phosphate; DHQ=3-dehydroquinate; DHS=3-dehydroshikimate; SHK=shikimate; S3P=shikimate 3-phosphate; EPSP=5-enolpyruvyl shikimate 3-phosphate; PHE=phenylalanine; TYR=tyrosine; TRP=tryptophan; Pyk=pyruvate kinase, which is encoded by the gene pyk; and Ppc=PEP carboxylase, which is encoded by the gene ppc. Further, the following genes are illustrated for the common aromatic pathway: aroB which encodes DHQ synthase; aroD which encodes DHQ dehydratase; aroE which encodes shikimate dehydrogenase; aroL and aroK which encode shikimate kinase; aroA which encodes EPSP synthase and aroC which encodes chorismate synthase. While not specifically illustrated, one skilled in the art is aware that aroG, aroF and aroH encode the three isozymes of DAHP synthase which catalyzes the conversion of Erythrose-4P (E4P) and PEP to DAHP in *E. coli*. FIG. 1B illustrates the varied compounds, the production of which, may be enhanced by an increase in carbon flux and PEP availability according to the methods encompassed by the invention.

#### Detail Description Paragraph - DETX (12):

[0051] "Increased phosphoenolpyruvate (PEP) availability" means increasing the amount of intracellular PEP which enhances carbon committed to a metabolic or productive pathway, said PEP which would otherwise have been metabolized in the PTS for phosphorylation of glucose.

#### Detail Description Paragraph - DETX (13):

[0052] The phrase "increasing carbon flow" means increasing the availability of carbon substrates to metabolic or productive pathways, said carbon substrate which would otherwise be diverted by the metabolism of PEP in the PTS. Carbon flow to a particular pathway can be measured by well known methods such as gas chromatography and mass spectroscopy. Carbon flow as measured by produced product may be at least 2%, 5%, 10%, 15%, 20%, 25%, 30%, or greater than the carbon flow in a corresponding PTS cell grown under essentially the same growth conditions.

#### Detail Description Paragraph - DETX (62):

[0100] The present invention is directed to a method for increasing carbon flow into a desired metabolic pathway of a host cell originally capable of utilizing a PTS for carbohydrate transport, said method including the steps of selecting a host cell which is effectively phenotypically PTS<sup>sup.-</sup> and modifying at least one homologous chromosomal regulatory region, which is operably linked to a chromosomal nucleic acid which encodes a polypeptide involved in glucose assimilation, resulting in the restoration of a glucose<sup>sup.+</sup> phenotype and thereby increasing the carbon flow into and through a desired metabolic pathway.

#### Detail Description Paragraph - DETX (64):

[0102] A general review of the PTS can be found in (Postma et al., 1993, Microbiol. Rev. 57:543-594; Romano et al., 1979, J. Bacteriol. 139:93-97 and Saier et al. 1990, In: BACTERIAL ENERGETICS pp. 273-299, T. A. Krulwich, Ed. Academic Press, NY). Host cells or strains useful in the present invention include any organism capable of utilizing a PTS system for carbohydrate transport. This includes prokaryotes belonging to the genus *Escherichia*, *Corynebacterium*, *Brevibacterium*, *Bacillus*, *Pseudomonas*, *Streptomyces*, *Pantoea* or *Staphylococcus*. A list of suitable organisms is provided in Table 1. The inactivation of the PTS in any of these organisms should potentially increase carbon flux and PEP (and PEP precursor) availability in the cell for alternative metabolic routes and consequently could increase production of

desired compounds (e.g., aromatics) from such cells.

Detail Description Paragraph - DETX (75):

[0113] However, to increase or redirect carbon flow to desired metabolic pathways in inactivated PTS host cells, glucose transport and phosphorylation must be deregulated or amplified.

Detail Description Paragraph - DETX (124):

[0162] It should be noted that as the host cell is cultured in conditions which create an increase in carbon flow into the aromatic pathway, it may be necessary to identify and overcome rate-limiting steps in the pathway. This methodology is available to the artisan, see, for example, U.S. Pat. Nos. 5,168,056 and 5,776,736.

Detail Description Paragraph - DETX (127):

[0165] In addition to increasing the carbon flux through the aromatic pathway, the following genes may be overexpressed in PTS.sup.-/Glu.sup.+ cells according to the invention: pps which encodes PEP synthase in E. coli (see U.S. Pat. No. 5,985,617) and talA which encodes transaldolase (Iida et al. (1993) J. Bacterial. 175:5375-5383). Further any gene encoding an enzyme that catalyzes reactions within the common aromatic pathway (for example, DAHP synthase (aroF, aroG, aroH), DHQ synthase (aroB), DHQ dehydratase (aroD), shikimate dehydrogenase (aroE), shikimate kinase (aroL, aroK), EPSP synthase (aroA) and chorismate synthase (aroC) may be amplified in the PTS.sup.-/Glu.sup.+ cells encompassed by the present invention.

Detail Description Paragraph - DETX (135):

[0173] Thus, having provided a PTS.sup.-/Glu.sup.+ strain which conserves PEP resulting in an increase in carbon flux into a metabolic pathway, such as the aromatic amino acid pathway, glycolysis, the TCA cycle, and the pentose phosphate pathway, by redirecting PEP and PEP precursors, the inventors have provided a host system which can be utilized for enhanced production of desired compounds in comparison to the production of the same compounds in a corresponding PTS host cell.

Detail Description Paragraph - DETX (187):

[0220] By constitutively expressing galP on the chromosome from the trc promoter the flux of carbon from glucose was increased into the pathway for the desired products, glycerol and 1,3-propanediol rather than into pathways to produce cell mass.

Claims Text - CLTX (1):

1. A method of increasing carbon flow into a metabolic pathway of a PTS.sup.-/Glu.sup.- bacterial host cell which was originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport comprising, a) modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a glucose assimilation protein in a PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a DNA construct comprising a promoter and DNA flanking sequences corresponding to upstream (5') regions of the glucose assimilation protein; b) allowing integration of the DNA construct to restore a Glu+ phenotype; and c) culturing the transformed host cell under suitable culture conditions, wherein the carbon flow into a metabolic pathway of the transformed host cell is increased compared to the carbon flow into the same metabolic pathway in a corresponding PTS bacterial host cell cultured under essentially the same culture conditions.

Claims Text - CLTX (22):

22. A method of increasing carbon flow into a metabolic pathway of a

PTS.sup.-/Glu.sup.- bacterial host cell originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport comprising, a) modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a galactose permease in a PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a first DNA construct comprising a promoter and DNA flanking sequences corresponding to upstream (5') regions of the galactose permease; b) modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a glucokinase in the PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a second DNA construct comprising a promoter and DNA flanking sequences corresponding to upstream (5') regions of the glucokinase; c) allowing integration of the first and the second DNA constructs, wherein the first DNA construct replaces an endogenous promoter of the nucleic acid encoding the galactose permease and the second DNA construct replaces an endogenous promoter of the nucleic acid encoding the glucokinase wherein both the galactose permease and the glucokinase are expressed in the host cell and wherein said expression results in an increase in carbon flow into a metabolic pathway of the transformed host cell compared to carbon flow into the same metabolic pathway in a corresponding unaltered PTS.sup.-/Glu.sup.- bacterial cell.

Claims Text - CLTX (34):

34. A method of increasing phosphoenolpyruvate (PEP) availability in a bacterial host cell comprising, a) selecting a bacterial host cell having a PTS.sup.-/Glu.sup.- phenotype, wherein the bacterial host was originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport; b) modifying an endogenous chromosomal regulatory sequence of the selected bacterial host cell comprising transforming said selected bacterial host cell with a DNA construct comprising a promoter, wherein said DNA construct is chromosomally integrated into the selected bacterial host cell replacing an endogenous promoter which is operably linked to a nucleic acid encoding a glucose assimilation protein; c) culturing the transformed bacterial host cell under suitable conditions; and d) allowing expression of the glucose assimilation protein to obtain an altered host cell having a PTS.sup.-/Glu.sup.+ phenotype, wherein the PEP availability is increased compared to the PEP availability in a corresponding unaltered PTS bacterial host cell cultured under essentially the same culture conditions.



PGPUB-DOCUMENT-NUMBER: 20040019931

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040019931 A1

TITLE: Methods and compositions for modifying oil and protein  
content in plants

PUBLICATION-DATE: January 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tarczynski, Mitchell C.	West Des Moines	IA	US	
Li, Changjiang	Urbandale	IA	US	

APPL-NO: 09/ 930906

DATE FILED: August 16, 2001

RELATED-US-APPL-DATA:

non-provisional-of-provisional 60226142 20000818 US

US-CL-CURRENT: 800/281, 435/194 , 435/320.1 , 435/419 , 435/69.1 , 536/23.2

ABSTRACT:

Compositions and methods for altering pyruvate synthesis in plants are provided. The compositions and methods find use in increasing the oil or protein content of plant tissues, particularly seeds. Novel isolated nucleotide molecules encoding cytosolic and plastidic pyruvate kinases are provided. The methods involve introducing into a plant nucleotide sequences encoding enzymes that alter pyruvate synthesis. Additionally provided are isolated pyruvate kinases and transformed plants, plant tissues, plant cells, and seeds thereof.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 60/226,142, filed Aug. 18, 2000, which is hereby incorporated herein in its entirety by reference.

----- KWIC -----

Summary of Invention Paragraph - BSTX (24):

[0021] If desired, one or more additional nucleotide constructs may be introduced into the plant. Such additional nucleotide constructs can comprise, for example, at least a portion of a nucleotide sequence of an enzyme, or other protein, that is capable of affecting the synthesis of pyruvate in the cytosol. If expression of the nucleotide sequence is desired, the nucleotide construct can additionally comprise an operably linked promoter. The invention does not depend on a particular nucleotide sequence. Any nucleotide sequence originating from a gene or transcript that encodes an enzyme or protein that is capable of increasing or decreasing the synthesis and/or level of pyruvate in the cytosol can be employed. Typically, such an enzyme or protein is capable of altering the amount of PEP that is available in the cytosol for the

formation of pyruvate. If a decreased level or activity of such an enzyme or protein is desired, the methods of the invention may additionally comprise anti-sense suppression, co-suppression, or chimeraplasty.

Summary of Invention Paragraph - BSTX (29):

[0026] Methods are provided for altering the metabolism of pyruvate in plastids. The methods find use in increasing the synthesis of fatty acids and/or oil in a plant, or part thereof. In particular, the methods find use in the production of improved cultivars of crop plants having seeds with increased levels of oil. By increasing the flux of carbon toward oil biosynthesis, increased levels of oil, fatty acids, oil precursors, and specialty molecules that are synthesized from oil precursors can be achieved in a plant, or part thereof. The methods involve introducing into a plant at least one nucleotide construct comprising at least a portion of a nucleotide sequence encoding a pyruvate kinase or an NADP.sup.+ -dependent malic enzyme. In some embodiments of the invention, both a pyruvate kinase nucleotide sequence and a NADP.sup.+ -dependent malic enzyme nucleotide sequence are introduced into the plant. Such nucleotide sequences can be introduced into the plant as a single nucleotide molecule comprising both the pyruvate kinase and a NADP.sup.+ -dependent malic enzyme nucleotide sequences. Alternatively, the pyruvate kinase and a NADP.sup.+ -dependent malic enzyme nucleotide sequences can be introduced into the plant on two separate nucleotide molecules.

Summary of Invention Paragraph - BSTX (33):

[0030] If desired, one or more additional nucleotide constructs may be introduced into the plant. Such additional nucleotide constructs can comprise, for example, at least a portion of a nucleotide sequence encoding an enzyme, or other protein, that is capable of affecting the synthesis or the level of pyruvate in the plastid. If expression of the nucleotide sequence is desired, the nucleotide construct can additionally comprise an operably linked promoter. The invention does not depend on a particular nucleotide sequence. Any nucleotide sequence that encodes an enzyme, or protein, that is capable of increasing or decreasing the synthesis of pyruvate in the cytosol can be employed. Typically, such an enzyme or protein is capable of altering the amount of PEP, malate, or both that is available for the formation of pyruvate within the plastid. Such an enzyme can be localized in any compartment or organelle of the cell, including, but not limited to, the cytosol, plastids, mitochondria, and vacuoles. If a decreased level or activity of such an enzyme or protein is desired, the methods of the invention may additionally comprise anti-sense suppression, co-suppression, chimeraplasty, and dominant-negative strategies.

Summary of Invention Paragraph - BSTX (38):

[0035] To reduce or eliminate the conversion of malate to pyruvate in mitochondria, the plant can be transformed with a nucleotide construct comprising at least a portion of an NAD.sup.+ -dependent malic enzyme nucleotide sequence. Malate that is formed in the cytosol, instead of entering the chloroplast, can enter the mitochondria where it can be decarboxylated to form pyruvate, which can then be converted into acetyl-CoA. Acetyl-CoA can then enter the TCA cycle. Reducing or eliminating the decarboxylation of malate in plant mitochondria by antisense suppression of mitochondrial NAD.sup.+ -dependent malic enzyme is known to increase the flux of carbon to plastids in plant storage tissues. See WO 98/23757, herein incorporated by reference.

Summary of Invention Paragraph - BSTX (40):

[0037] While the methods of the present invention do not depend on a particular biological mechanism for increasing the oil or other desired product, it is recognized the methods of the present invention can lead to a

disruption in the metabolism of the plant leading to an increased flux of carbon flux to the plastids. This increased carbon flux may be the result of an increased rate of transport of malate from the cytosol to the plastids. Other cytosolic metabolites may, however, contribute to the increased flux of carbon to the plastid. Such metabolites include, but are not limited to, 3-phosphoglyceric acid and dihydroxyacetone phosphate.

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	5111	carbon near2 (flux or flow)	US-PGPUB; USPAT	OR	OFF	2005/05/13 15:33
L2	374	1 near4 (modif\$8 or alter\$8 or increas\$8)	US-PGPUB; USPAT	OR	OFF	2005/05/13 15:33
L3	233	(phosphoenol adj pyruvate or pep or phosphoenolpyruvate or phospho adj enol adj pyruvate) near4 (suppl\$4 or availab\$8)	US-PGPUB; USPAT	OR	OFF	2005/05/13 15:34
L4	11	2 and 3	US-PGPUB; USPAT	OR	OFF	2005/05/13 15:34
L5	8702	phosphotransferase\$1 or phospho adj transferase\$1	US-PGPUB; USPAT	OR	OFF	2005/05/13 15:51
L6	58	(2 or 3) and 5	US-PGPUB; USPAT	ADJ	OFF	2005/05/13 15:51

PGPUB-DOCUMENT-NUMBER: 20050102716

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050102716 A1

TITLE: Transgenic plants containing altered levels of sterol compounds and tocopherols

PUBLICATION-DATE: May 12, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Venkatramesh, Mylavarapu	Ballwin	MO	US	
Corbin, David R.	Chesterfield	MO	US	
Bhat, B. Ganesh	St. Louis	MO	US	
Boddupalli, Sekhar S.	San Jose	CA	US	
Grebenok, Robert J.	East Amherst	NY	US	
Kishore, Ganesh M.	Creve Coeur	MO	US	
Lardizabal, Kathryn D.	Woodland	CA	US	
Lassner, Michael W.	Foster City	CA	US	
Rangwala, Shaikat H.	Chesterfield	MO	US	
Karunanandaa, Balsulojini	Creve Coeur	MO	US	

APPL-NO: 10/ 647517

DATE FILED: January 16, 2004

RELATED-US-APPL-DATA:

child 10647517 A1 20040116

parent continuation-of 09548256 20000412 US ABANDONED

non-provisional-of-provisional 60128995 19990412 US

US-CL-CURRENT: 800/287, 435/468

ABSTRACT:

Provided are recombinant constructs comprising DNA sequences encoding enzymes effective in altering the biosynthesis and accumulation of sterol compounds and tocopherols in transgenic plants. Also provided are methods of using such constructs to produce transgenic plants, seeds of which contain elevated levels of sitostanol and/or sitostanol esters, and .alpha.-tocopherol, as well as reduced levels of campesterol and campestanol and their corresponding esters. These seeds also contain the novel sterol brassicastanol. Oil obtained from seeds of such transgenic plants is also provided. This oil can be used to prepare food and pharmaceutical compositions effective in lowering the level of low density lipoprotein cholesterol in blood serum. In addition, novel DNA sequences encoding plant steroid 5.alpha.-reductases are also disclosed.

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation of Ser. No. 09/548,256, filed Apr. 12, 2000 and claims priority from provisional application 60/128,995, filed Apr. 12, 1999, which is hereby incorporated by reference in its entirety for all purposes.

----- KWIC -----

Detail Description Paragraph - DETX (252):

[0360] All of the enzymes discussed herein can be modified for plastid targeting by employing plant cell nuclear transformation constructs wherein DNA coding sequences of interest are fused to any of the available transit peptide sequences capable of facilitating transport of the encoded enzymes into plant plastids, and driving expression by employing an appropriate promoter such as any of those discussed above. Targeting of enzymes involved in altering sterol compound and tocopherol quantity and/or quality to plastids can be achieved by fusing DNA encoding plastid, e.g., chloroplast, leucoplast, amyloplast, etc., transit peptide sequences to the 5'-ATG of DNAs encoding enzymes affecting the biosynthesis and accumulation of these compounds. The sequences that encode a transit peptide region can be obtained, for example, from plant nuclear-encoded plastid proteins, such as the small subunit (SSU) of ribulose biphosphate carboxylase, EPSP synthase, plant fatty acid biosynthesis related genes including fatty acyl-ACP thioesterases, acyl carrier protein (ACP), stearyl-ACP desaturase, .beta.-ketoacyl-ACP synthase and acyl-ACP thioesterase, or LHCP II genes, etc. Plastid transit peptide sequences can also be obtained from nucleic acid sequences encoding carotenoid biosynthetic enzymes, such as GGPP synthase, phytoene synthase, and phytoene desaturase. Other transit peptide sequences useful in the present invention are disclosed in Von Heijne et al. (1991) Plant Mol. Biol. Rep. 9: 104; Clark et al. (1989) J. Biol. Chem. 264: 17544; della-Cioppa et al. (1987) Plant Physiol. 84: 965; Romer et al. (1993) Biochem. Biophys. Res. Commun. 196: 1414; and Shah et al. (1986) Science 233: 478. Plant sterol compound/tocopherol biosynthetic enzyme-encoding sequences useful in the present invention can utilize native or heterologous transit peptides. The encoding sequence for a transit peptide effective in transport to plastids can include all or a portion of the encoding sequence for a particular transit peptide, and may also contain portions of the mature protein encoding sequence associated with a particular transit peptide. Numerous examples of transit peptides that can be used to deliver target proteins into plastids exist, and the particular transit peptide encoding sequences useful in the present invention are not critical as long as delivery into a plastid is obtained. Proteolytic processing within the plastid then produces the mature enzyme. This technique has proven successful not only with enzymes involved in polyhydroxyalkanoate biosynthesis (Nawrath et al. (1994) Proc. Natl. Acad. Sci. USA 91: 12760), but also with neomycin phosphotransferase II (NPT-II) and CP4 EPSPS (Padgett et al. (1995) Crop Sci. 35: 1451), for example.

Detail Description Paragraph - DETX (296):

[0398] Total sterols increased by 3.2- and 3.9-fold in the best performing plants (transgenic events 3 and 4). These two events also showed the highest increases of individual sterols. Campesterol increased by 2.7-fold, sitosterol by 3.4-fold, sitostanol by 3.2-fold and other sterols by 6.5-fold in event 3 while stigmasterol increased by 2.3-fold in event 4. The other sterols, which account for the highest increase in total sterols, were pathway intermediates that included squalene, cycloartenol, 24-methylene cycloartenol, obtusifoliol, isofucosterol, and stigmasta-7-enol. These pathway intermediates normally form minor constituents in the sterol composition of seeds. However, in the transgenic seeds, probably due to increased carbon flux through the pathway, they accumulate in significant amounts. This suggests additional control points for sterol biosynthesis in plants such as squalene epoxidase, C-24 sterol methyltransferase, and C-14 obtusifoliol demethylase.

Detail Description Paragraph - DETX (306):

[0404] The decrease in the amount of campesterol is consistent with the expected activity of the SMTII enzyme. This enzyme catalyzes the reaction 18 in Scheme 1. The substrate for this reaction, which is 24-methylene lophenol, can also undergo reaction 18b which is a C-4 demethylation. This latter route leads to the formation of 24-niethyl sterols such as campesterol. It is presumed that increased activity of SMTII due to the higher expression of the introduced *Arabidopsis thaliana* SMTII gene allows for increased carbon flux through the pathway leading to sitosterol and thus reducing the availability of 24-methylene lophenol for reaction 18b which reduces the amount of campesterol formed.

PGPUB-DOCUMENT-NUMBER: 20050089974

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050089974 A1

TITLE: Fermentative production of d-hydroxyphenylglycine and  
d-phenylglycine

PUBLICATION-DATE: April 28, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Townsend, Craig A.	Baltimore	MD	US	
Gunsior, Michele	Owings Mills	MD	US	
Muller, Ulrike	Linnich-Rurdorf		DE	
Assema Van, Friso B J	Geleen		NL	
Sonke, Theodorus	Guttecoven		NL	

APPL-NO: 10/ 399693

DATE FILED: August 19, 2003

FOREIGN-APPL-PRIORITY-DATA:

COUNTRY	APPL-NO	DOC-ID	APPL-DATE
US	09697769	2000US-09697769	October 27, 2000

PCT-DATA:

APPL-NO: PCT/NL01/00772  
DATE-FILED: Oct 22, 2001  
PUB-NO:  
PUB-DATE:  
371-DATE:  
102(E)-DATE:

US-CL-CURRENT: 435/108

ABSTRACT:

A new fermentative process for the preparation of D-p-hydroxyphenylglycine (D-HPG) or D-phenylglycine (D-pG) in enantiomerically pure form is disclosed. Precursors for the formation of D-HPG and D-pG are withdrawn from the common aromatic amino acid pathway, converted to p-hydroxyphenylglyoxylate or phenylglyoxylate, and are finally converted to D-HPG or D-pG by the action of a stereo-inverting D-aminotransferase.

----- KWIC -----

Summary of Invention Paragraph - BSTX (20):

[0019] Suitable measures to increase the availability of HPP and PP in said microorganisms comprise the selection of microorganisms showing a beneficial spontaneous mutation, the selection of microorganisms that evolve from classical strain improvement programs involving random mutagenesis, and the selection of microorganisms with improved production capabilities that evolved from application of recombinant DNA technology. Suitable measures to increase the availability of HPP and PP, e.g., can be the introduction of feedback



resistant mutants of key enzymes or the overexpression of one or several pathway enzymes as reviewed by Berry (1996, TIBTECH, 14: 250-256). Application of recombinant DNA technology can also be directed towards the introduction of phosphoenolpyruvate-independent sugar uptake systems (WO 98/18936), towards the deletion of the phosphotransferase system (PTS) (Berry, 1996, TIBTECH, 14: 250-256) and/or towards an increased availability of phosphoenolpyruvate by modifications of reactions acting on the intracellular phosphoenolpyruvate concentration (Berry, 1996, TIBTECH, 14: 250-256). Application of recombinant DNA technology can also be directed towards introducing increased intracellular transketolase and/or transaldolase activity (WO 98/18936).

PGPUB-DOCUMENT-NUMBER: 20050086713

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050086713 A1

TITLE: Transgenic plants containing altered levels of steroid compounds

PUBLICATION-DATE: April 21, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Karunanandaa, Balasulojini	St. Louis	MO	US	
Post-Beittenmiller, Martha	St. Louis	MO	US	
Venkatramesh, Mylavarapu	St. Louis	MO	US	
Kishore, Ganesh M.	St. Louis	MO	US	
Thorne, Gregory M.	St. Louis	MO	US	
LeDeaux, John R.	St. Louis	MO	US	

APPL-NO: 10/ 862907

DATE FILED: June 7, 2004

RELATED-US-APPL-DATA:

child 10862907 A1 20040607

parent division-of 09885723 20010620 US GRANTED

parent-patent 6822142 US

non-provisional-of-provisional 60260114 20010105 US

US-CL-CURRENT: 800/278, 435/189 , 435/419 , 435/468

ABSTRACT:

Disclosed are constructs comprising sequences encoding 3-hydroxy-3methylglutaryl-Coenzyme A reductase and at least one other sterol synthesis pathway enzyme. Also disclosed are methods for using such constructs to alter sterol production and content in cells, plants, seeds and storage organs of plants. Also provided are oils and compositions containing altered sterol levels produced by use of the disclosed constructs. Novel nucleotide sequences useful in the alteration of sterol production are also provided. Also provided are cells, plants, seeds and storage organs of plants comprising sequences encoding 3-hydroxy-3methylglutaryl-Coenzyme A reductase, at least one other sterol synthesis pathway enzyme and at least one tocopherol synthesis enzyme.

----- KWIC -----

Brief Description of Drawings Paragraph - DRTX  
(8):

[0052] FIG. 6 is a map showing the structure of construct pMON43818. pMON43818 is a recombinant binary vector carrying the gene encoding rubber hydroxymethyl glutaryl CoA reductase1 (HMGR1) in sense orientation driven by

the soybean alpha' beta conglycinin promoter. P-NOS: nopaline synthase gene promoter; kan: coding region for neomycin phosphotransferase protein to confer resistance to kanamycin; NOS 3': 3' termination end of nopaline synthase coding region; Soy Alpha' Beta Conglycinin: 7S alpha' beta conglycinin gene promoter from soybean; Rubber HMGR1 gene: coding sequence for HMGR1 gene from Hevea brasiliensis; E9 3': 3' end of pea rbcS E9 gene; Left border: octopine left border, sequence essential for transfer of T-DNA into Agrobacterium; ori-V: plasmid origin of replication in Agrobacterium; rop: coding sequence for repressor of primer; Ori-322: origin of replication in E.coli; Spc/Str: coding region for Tn7 adenyllyltransferase (AAD(3'')) conferring resistance to spectinomycin and streptomycin; Right Border: right border sequence of T-DNA essential for integration into Agrobacterium.

#### Brief Description of Drawings Paragraph - DRTX

(9):

[0053] FIG. 7 is a map showing the structure of construct pMON43052. pMON43052 is a recombinant shuttle vector, carrying the cDNA fragment encoding the catalytic domain of Arabidopsis HMGR1 in sense orientation driven by the soybean alpha' beta conglycinin promoter. P-NOS: nopaline synthase gene promoter; kan: coding region for neomycin phosphotransferase protein to confer resistance to kanamycin; NOS 3': 3' termination end of nopaline synthase coding region; Soy Alpha' Beta Conglycinin: 7S alpha' beta conglycinin gene promoter from soybean; Arabidopsis HMGR catalytic domain: coding sequence for the catalytic domain of Arabidopsis HMGR1 protein; E9 3': 3' end of pea rbcS E9 gene; Left border: octopine left border, sequence essential for transfer of T-DNA into Agrobacterium; ori-V: plasmid origin of replication in Agrobacterium; rop: coding sequence for repressor of primer; Ori-322: origin of replication in E.coli; Spc/Str: coding region for Tn7 adenyllyltransferase (AAD(3'')) conferring resistance to spectinomycin and streptomycin; Right Border: right border sequence of T-DNA essential for integration into Agrobacterium.

#### Brief Description of Drawings Paragraph - DRTX

(10):

[0054] FIG. 8 is a map showing the structure of construct pMON51850. pMON51850 is a binary vector for Agrobacterium mediated transformation of soybean. P-NOS: nopaline synthase gene promoter; kan: coding region for neomycin phosphotransferase protein to confer resistance to kanamycin; NOS 3': 3' termination end of nopaline synthase coding region; Left border: octopine left border sequence essential for transfer of T-DNA into Agrobacterium; ori-V: plasmid origin of replication in Agrobacterium; rop: coding sequence for repressor of primer; ori-322: origin of replication in E.coli; Spc/Str: coding region for Tn7 adenyllyltransferase (AAD(3'')) conferring resistance to spectinomycin and streptomycin; Right Border: right border sequence of T-DNA essential for integration into Agrobacterium.

#### Brief Description of Drawings Paragraph - DRTX

(11):

[0055] FIG. 9 is a map showing the structure of construct pMON43057. pMON43057 is a recombinant binary vector for Agrobacterium mediated transformation of soybean, carrying the gene cassette for expressing catalytic domain of HMGR1 from Arabidopsis thaliana. The catalytic domain of the HMGR1 cDNA is driven by soybean 7S alpha' beta conglycinin promoter. P-NOS: nopaline synthase gene promoter; kan: coding region for neomycin phosphotransferase protein to confer resistance to kanamycin; NOS 3': 3' termination end of nopaline synthase coding region; Left border: octopine left border sequence essential for transfer of T-DNA into Agrobacterium; ori-V: plasmid origin of replication in Agrobacterium; rop: coding sequence for repressor of primer; ori-322: origin of replication in E.coli; Spc/Str: coding region for Tn7

adenylyltransferase (AAD(3")) conferring resistance to spectinomycin and streptomycin; Right Border: right border sequence essential for transfer of T-DNA into Agrobacterium; Soy Alpha' Beta Conglycinin: soybean 7S alpha' beta conglycinin gene promoter; Arabidopsis HMGR catalytic domain: coding sequence for Arabidopsis HMGR1 catalytic domain; E9 3': 3' end of pea rbcS E9 gene.

Brief Description of Drawings Paragraph - DRTX  
(12):

[0056] FIG. 10 is a map showing the structure of construct pMON43058. pMON43058 is a recombinant binary vector for Agrobacterium-mediated soybean transformation, carrying gene expression cassettes for catalytic domain of HMGR1 from Arabidopsis thaliana and SMTII from Arabidopsis thaliana. P-NOS: nopaline synthase gene promoter; kan: coding region for neomycin phosphotransferase protein to confer resistance to kanamycin; NOS 3': 3' termination end of nopaline synthase coding region; Left border: octopine left border sequence essential for transfer of T-DNA into Agrobacterium; ori-V: plasmid origin of replication in Agrobacterium; rop: coding sequence for repressor of primer; ori-322: origin of replication in E.coli; Spc/Str: coding region for Tn7 adenylyltransferase (AAD(3")) conferring resistance to spectinomycin and streptomycin; Right Border: right border sequence essential for transfer of T-DNA into Agrobacterium; Soy Alpha' Beta Conglycinin: 7S alpha' beta conglycinin gene promoter from soybean; Arabidopsis HMGR catalytic domain: sequence encoding the catalytic domain of Arabidopsis HMGR1; E9 3': 3' end of pea rbcS E9 gene; Soy Alpha' Beta Conglycinin: soybean 7S alpha'beta conglycinin gene promoter; Arabidopsis SMT2: cDNA encoding sterol methyl transferase II enzyme from Arabidopsis thaliana (accession no: X89867); NOS 3': 3' termination end of nopaline synthase coding region.

Detail Description Paragraph - DETX (208):

[0285] In preferred embodiments, the vector used to express the polypeptide coding gene includes a selection marker that is effective in a plant cell, preferably a drug resistance selection marker. One preferred drug resistance marker is the gene whose expression results in kanamycin resistance; i.e., the chimeric gene containing the nopaline synthase promoter, Tn5 neomycin phosphotransferase II and nopaline synthase 3' nontranslated region described by Rogers et al., in Methods for Plant Molecular Biology, A. Weissbach and H. Weissbach eds., Academic Press Inc., San Diego, Calif. (1988).

Detail Description Paragraph - DETX (344):

[0419] Total sterols increased by 3.2- and 3.9-fold in the best performing plants (transgenic events 3 and 4). These two events also showed the highest increases of individual sterols. Campesterol increased by 2.7-fold, sitosterol by 3.4-fold, sitostanol by 3.2-fold and other sterols by 6.5-fold in event 3 while stigmasterol increased by 2.3-fold in event 4. The other sterols, which account for the highest increase in total sterols were pathway intermediates that included squalene, cycloartenol, 24-methylene cycloartenol, obtusifoliol, isofucosterol, and stigmasta-7-enol. These pathway intermediates normally form minor constituents in the sterol composition of seeds. However, in the transgenic seeds, probably due to increased carbon flux through the pathway, they accumulate in significant amounts. This suggests additional control points for sterol biosynthesis in plants such as squalene epoxidase, C-24 sterol methyltransferase, and C-14 obtusifoliol demethylase.

Detail Description Paragraph - DETX (356):

[0430] Six transgenic lines harboring pMON43058 produced 5.8- to 6-fold increase in total sterols and the rest of the 10 transgenic lines with the pMON43058 showed 3- to 5-fold increase in total sterols. The best performing transgenic lines showed about 2- to 3-fold increase in sitosterol and 4.5- to 6-fold increase in sitostanol levels. However, the campesterol accumulation

was reduced by 50% in these lines. This was due to overexpression of the Arabidopsis SMTII enzyme which enhances the carbon flux towards the synthesis of 24-ethyl sterols thereby reducing the carbon flux through the pathway leading to the synthesis of 24-methyl sterols. As seen in pMON43057 transgenic lines, all of the transgenic lines harboring the pMON43058 also accumulated 50-60% of the total sterols in the form of pathway intermediates which are squalene, cycloartenol, 24-methylene cycloartenol, obtusifolol, isofucosterol, and stigmasta-7-enol. These pathway intermediates normally form minor constituents in the sterol composition of seeds. However, in the transgenic seeds, probably due to increased carbon flux through the pathway, they accumulate in significant amounts. The pathway intermediates accumulation is highly significant when the truncated form of HMGR is overexpressed as compared to the full length form of HMGR suggesting that the overexpression of the truncated form of HMGR creates even greater increase in carbon flux through the pathway. This provides further evidence for additional control points for sterol biosynthesis in plants such as squalene epoxidase, sterol methyltransferase I, sterol C4-demethylase, obtusifolol C14.alpha.-demethylase, sterol C5-desaturase, and sterol methyl transferase II.

PGPUB-DOCUMENT-NUMBER: 20050079617

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050079617 A1

TITLE: Glucose transport mutants for production of biomaterial

PUBLICATION-DATE: April 14, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cervin, Marguerite A.	Redwood City	CA	US	
Soucaille, Philippe	Deyme	CA	FR	
Valle, Fernando	Burlingame	CA	US	
Whited, Gregory M.	Belmont		US	

APPL-NO: 10/ 728337

DATE FILED: December 3, 2003

FOREIGN-APPL-PRIORITY-DATA:

COUNTRY	APPL-NO	DOC-ID	APPL-DATE
WO	PCT/US03/31544	2003WO-PCT/US03/31544	October 3, 2003

US-CL-CURRENT: 435/471

ABSTRACT:

A method is disclosed for restoring a Glu.sup.+ phenotype to a PTS.sup.-/Glu.sup.- bacterial cell which was originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport. Bacterial cells comprising the Glu.sup.+ phenotype have modified endogenous chromosomal regulatory regions which are operably linked to polynucleotides encoding galactose permeases and glucokinases.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to application PCT/US03/31544, filed Oct. 3, 2003, U.S. Provisional Application 60/416,166 filed Oct. 4, 2002 and U.S. Provisional Application 60/374,931 filed Oct. 4, 2002, which are hereby incorporated by reference.

----- KWIC -----

Abstract Paragraph - ABTX (1):

A method is disclosed for restoring a Glu.sup.+ phenotype to a PTS.sup.-/Glu.sup.- bacterial cell which was originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport. Bacterial cells comprising the Glu.sup.+ phenotype have modified endogenous chromosomal regulatory regions which are operably linked to polynucleotides encoding galactose permeases and glucokinases.

Summary of Invention Paragraph - BSTX (2):

[0002] The present invention relates to genetically engineering metabolic pathways in bacterial host cells and provides methods and systems for the production of desired products in the engineered host cells. In particular,

the invention relates to the enhancement of glucose transport in host strains, which were originally capable of using a phosphoenolpyruvate (PEP):phosphotransferase transport system (PTS) for glucose transport, by reducing PTS phosphoenolpyruvate (PEP) consumption and redirecting PEP or PEP precursors into a desired metabolic pathway, such as the common aromatic amino acid pathway.

Summary of Invention Paragraph - BSTX (6):

[0005] In addition to the Embden-Meyerhof pathway, many bacteria possess an active transport system known as the phosphoenolpyruvate (PEP)-dependent phosphotransferase transport system (PTS). This system couples the transport of a carbon source, such as glucose to its phosphorylation. The phosphoryl group is transferred sequentially from PEP to enzyme I and from enzyme I to protein HPr. The actual translocation step is catalyzed by a family of membrane bound enzymes (called enzyme II), each of which is specific for one or a few carbon sources. Reference is made to Postma et al., (1993) Phosphoenolpyruvate: Carbohydrate Phosphotransferase Systems in Bacteria, Microbiol. Reviews. 57:543-594 and Postma P. W. (1996) Phosphotransferase System for Glucose and Other Sugars. In: Neidhardt et al., Eds. ESCHERICHIA COLI AND SALMONELLA TYPHIMURIUM: CELLULAR AND MOLECULAR BIOLOGY. Vol.1. Washington, D.C. ASM Press pp 127-141. However, due to the fact that PTS metabolizes PEP to phosphorylate the carbon source, the PTS system decreases the efficiency of carbon substrate conversion to a desired product. In glycolysis, two molecules of PEP are formed for every molecule of glucose catabolized. However, one molecule of PEP is required for PTS to function, leaving only one molecule of PEP available for other biosynthetic reactions.

Summary of Invention Paragraph - BSTX (7):

[0006] Due to the role of PEP as a central metabolite, numerous approaches have been utilized to increase PEP supply in the cell and some of these are listed below:

Summary of Invention Paragraph - BSTX (16):

[0015] Contrary to the methods previously described, the present invention increases carbon flow to metabolic pathways in bacterial strains capable of transporting glucose without consuming PEP during the process. The conserved PEP or PEP precursors can then be redirected into a given metabolic pathway for enhanced production of a desired product. These strains are generated in cells having an inactivated PEP-dependent PTS by modifying an endogenous chromosomal regulatory region that is operably linked to a glucose assimilation protein and more specifically to a glucose transporter and/or a glucose phosphorylating protein, to restore or re-attain the ability of the cell to use glucose as a carbon source while maintaining an inactivated PTS. These cells are designated PTS.sup.-/Glu.sup.+.

Summary of Invention Paragraph - BSTX (18):

[0016] Accordingly, there is provided by the present invention a method for increasing carbon flow into a metabolic pathway of a bacterial host cell wherein the host cell was originally capable of utilizing a PTS for carbohydrate transport. The method comprises selecting a bacterial host cell which is phenotypically PTS.sup.-/Glu.sup.- and modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a polypeptide involved in glucose assimilation to restore the Glu.sup.+ phenotype.

Summary of Invention Paragraph - BSTX (19):

[0017] In a first aspect, the invention pertains to a method of increasing carbon flow into a metabolic pathway of a PTS.sup.-/Glu.sup.- bacterial host cell which was originally capable of utilizing a phosphotransferase transport

system (PTS) for carbohydrate transport which comprises a) modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a glucose assimilation protein in a PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a DNA construct comprising a promoter and DNA flanking sequences corresponding to upstream (5') regions of the glucose assimilation protein; b) allowing integration of the DNA construct to restore a Glu+ phenotype; and c) culturing the transformed host cell under suitable culture conditions, wherein the carbon flow into a metabolic pathway of the transformed host cell is increased compared to the carbon flow into the same metabolic pathway in a corresponding PTS bacterial host cell cultured under essentially the same culture conditions. In one embodiment of the method the promoter is a non-host cell promoter or a modified endogenous promoter. In a second embodiment the glucose assimilation protein is a glucose transporter, preferably a galactose permease obtained from E. coli or a glucose transporter having at least 80% sequence identity thereto. In a third embodiment the glucose assimilation protein is a phosphorylating protein, preferably a glucokinase obtained from E. coli or a glucokinase having at least 80% sequence identity thereto. In a fourth embodiment of the method the bacterial host cell is selected from the group consisting of E. coli cells, Bacillus cells and Pantoea cells. In a fifth embodiment, the PTS.sup.-/Glu.sup.- host cell is obtained from a PTS cell by deletion of one or more genes selected from the group consisting of ptsI, ptsH and crr. In a sixth embodiment, the PTS.sup.-/Glu.sup.+ host cell is transformed with a polynucleotide encoding a protein selected from the group consisting of a transketolase, a transaldolase, a phosphoenolpyruvate synthase, DAHP synthase, DHQ synthase, DHQ dehydratase, shikimate dehydrogenase, shikimate kinase EPSP synthase and chorismate synthase.

Summary of Invention Paragraph - BSTX (22):

[0020] In a fourth aspect, the invention pertains to a method of increasing carbon flow into a metabolic pathway of a PTS.sup.-/Glu.sup.- bacterial host cell originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport which comprises a) modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a galactose permease in a PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a first DNA construct comprising a promoter and DNA flanking sequences corresponding to upstream (5') regions of the galactose permease; b) modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a glucokinase in the PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a second DNA construct comprising a promoter and DNA flanking sequences corresponding to upstream (5') regions of the glucokinase; c) allowing integration of the first and the second DNA constructs, wherein the first DNA construct replaces an endogenous promoter of the nucleic acid encoding the galactose permease and the second DNA construct replaces an endogenous promoter of the nucleic acid encoding the glucokinase wherein both the galactose permease and the glucokinase are expressed in the host cell and wherein said expression results in an increase in carbon flow into a metabolic pathway of the transformed host cell compared to carbon flow into the same metabolic pathway in the corresponding unaltered PTS.sup.-/Glu.sup.- bacterial cell. In one embodiment the metabolic pathway is the common aromatic pathway. In a second embodiment the method further comprises transforming the PTS.sup.-/Glu.sup.- host cell with a polynucleotide encoding a protein selected from the group consisting of a transketolase, a transaldolase and a phosphoenolpyruvate synthase.

Summary of Invention Paragraph - BSTX (23):

[0021] In a fifth aspect, the invention pertains to a method of restoring a Glu+phenotype to a PTS.sup.-/Glu.sup.- bacterial host cell which was originally



capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport which comprises a) modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a glucose transporter in a PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a first DNA construct comprising a promoter and DNA flanking sequences corresponding to upstream (5') regions of the glucose transporter; b) allowing integration of the first DNA construct, wherein the first DNA construct replaces an endogenous promoter of the nucleic acid encoding the glucose transporter; and c) allowing expression of the glucose transporter, wherein said expression restores a Glu+ phenotype to the PTS.sup.-/Glu.sup.- host cell. In a preferred embodiment the method according to this aspect further comprises modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a glucokinase in the PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a second DNA construct comprising an exogenous promoter and DNA flanking sequences corresponding to upstream (5') regions of the glucokinase; allowing integration of the second DNA construct wherein the second DNA construct replaces an endogenous promoter of the nucleic acid encoding the glucokinase; and allowing expression of the glucokinase. In one embodiment the restored Glu.sup.+ cells have a specific growth rate of at least about 0.4 hr.sup.-1. In another embodiment the glucose transporter is a galactose permease.

Summary of Invention Paragraph - BSTX (24):

[0022] In a sixth aspect the invention pertains to a method of increasing phosphoenolpyruvate (PEP) availability in a bacterial host cell which comprises a) selecting a bacterial host cell having a PTS.sup.-/Glu.sup.- phenotype, wherein the bacterial host was originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport; b) modifying an endogenous chromosomal regulatory sequence of the selected bacterial host cell comprising transforming said selected bacterial host cell with a DNA construct comprising a promoter, wherein said DNA construct is chromosomally integrated into the selected bacterial host cell replacing an endogenous promoter which is operably linked to a nucleic acid encoding a glucose assimilation protein; c) culturing the transformed bacterial host cell under suitable conditions; and d) allowing expression of the glucose assimilation protein to obtain an altered host cell having a PTS.sup.-/Glu.sup.+ phenotype, wherein the PEP availability is increased compared to the PEP availability in a corresponding unaltered PTS bacterial host cell cultured under essentially the same culture conditions. In one embodiment the glucose assimilation protein is a galactose permease and the DNA construct comprises an exogenous promoter which replaces the endogenous promoter of the galactose permease. In another embodiment the glucose assimilation protein is a glucokinase and the DNA construct comprises an exogenous promoter which replaces the endogenous promoter of a glucokinase.

Summary of Invention Paragraph - BSTX (25):

[0023] In an eighth aspect, the invention pertains to a method for increasing the growth rate of a PTS.sup.-/Glu.sup.- bacterial host cell originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport which comprises, a) modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a galactose permease in a PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a first DNA construct comprising an exogenous promoter and DNA flanking sequences corresponding to (5') upstream region of the galactose permease; b) modifying an endogenous regulatory region which is operably linked to a nucleic acid encoding a glucokinase in the PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a second DNA construct comprising an exogenous promoter and DNA flanking sequences corresponding to upstream (5') regions of the glucokinase; c)

allowing integration of the first and the second DNA constructs, wherein the first DNA construct replaces the endogenous promoter of the nucleic acid encoding the galactose permease and the second DNA construct replaces the endogenous promoter of the nucleic acid encoding the glucokinase d) culturing the transformed bacterial host cell under suitable conditions; and e) allowing expression of the galactose permease and the glucokinase from the modified regulatory regions to obtain an altered bacterial cell having an increase specific growth rate compared to the specific growth rate of a corresponding unaltered PTS bacterial host cell cultured under essentially the same culture conditions.

#### Brief Description of Drawings Paragraph - DRTX

(3):

[0027] The following abbreviations are used in the figure and throughout the disclosure: PEP=phosphoenolpyruvate; DAHP=3-deoxy-D-arabino-heptulosonate 7-phosphate; DHQ=3-dehydroquinate; DHS=3-dehydroshikimate; SHK=shikimate; S3P=shikimate 3-phosphate; EPSP=5-enolpyruvyl shikimate 3-phosphate; PHE=phenylalanine; TYR=tyrosine; TRP=tryptophan; Pyk=pyruvate kinase, which is encoded by the gene pyk; and Ppc=PEP carboxylase, which is encoded by the gene ppc. Further, the following genes are illustrated for the common aromatic pathway: aroB which encodes DHQ synthase; aroD which encodes DHQ dehydratase; aroE which encodes shikimate dehydrogenase; aroL and aroK which encode shikimate kinase; aroA which encodes EPSP synthase and aroC which encodes chorismate synthase. While not specifically illustrated, one skilled in the art is aware that aroG, aroF and aroH encode the three isozymes of DAHP synthase which catalyzes the conversion of Erythrose-4P (E4P) and PEP to DAHP in E. coli. FIG. 1B illustrates the varied compounds, the production of which, may be enhanced by an increase in carbon flux and PEP availability according to the methods encompassed by the invention.

#### Detail Description Paragraph - DETX (8):

[0047] The phosphotransferase system (PTS) (E.C. 2.7.1.69) refers to the phosphoenolpyruvate-dependent sugar uptake system. This is a system of transporter proteins that participate in transport and phosphoenolpyruvate dependent phosphorylation of several sugars. The system is comprised of two phosphoproteins, enzyme I and HPr, which are common to all PTS carbohydrates and catalyze the transfer of a phosphoryl group from PEP to the carbohydrate specific membrane bound enzyme II and then to the carbohydrate. In some cases enzyme III is positioned between HPr and enzyme II. To distinguish the various enzymes II and enzymes III, a three letter superscript is used to indicate which carbohydrate is the preferred substrate. For example Enzyme II.sup.glc means glucose is the preferred substrate. However other substrates may be used.

#### Detail Description Paragraph - DETX (9):

[0048] The terms "PtsI" and "Enzyme I" refer to the phosphotransferase EC 2.7.3.9 encoded by ptsI in E. coli. The terms "HPr" and "PtsH" refer to the phosphocarrier protein encoded by ptsH in E. coli. The terms "glucose-specific IIA component", "Enzyme II.sup.glc" and "Crr" refer to EC 2.7.1.69 encoded by crr in E. coli. The PTS comprises PtsI, PtsH and Crr and functionally equivalent proteins.

#### Detail Description Paragraph - DETX (12):

[0051] "Increased phosphoenolpyruvate (PEP) availability" means increasing the amount of intracellular PEP which enhances carbon committed to a metabolic or productive pathway, said PEP which would otherwise have been metabolized in the PTS for phosphorylation of glucose.

#### Detail Description Paragraph - DETX (13):

[0052] The phrase "increasing carbon flow" means increasing the availability of carbon substrates to metabolic or productive pathways, said carbon substrate which would otherwise be diverted by the metabolism of PEP in the PTS. Carbon flow to a particular pathway can be measured by well know methods such as gas chromatography and mass spectroscopy. Carbon flow as measured by produced product may be at least 2%, 5%, 10%, 15%, 20%, 25%, 30%, or greater than the carbon flow in a corresponding PTS cell grown under essentially the same growth conditions.

Detail Description Paragraph - DETX (62):

[0100] The present invention is directed to a method for increasing carbon flow into a desired metabolic pathway of a host cell originally capable of utilizing a PTS for carbohydrate transport, said method including the steps of selecting a host cell which is effectively phenotypically PTS.sup.- and modifying at least one homologous chromosomal regulatory region, which is operably linked to a chromosomal nucleic acid which encodes a polypeptide involved in glucose assimilation, resulting in the restoration of a glucose.sup.+ phenotype and thereby increasing the carbon flow into and through a desired metabolic pathway.

Detail Description Paragraph - DETX (64):

[0102] A general review of the PTS can be found in (Postma et al., 1993, Microbiol. Rev. 57:543-594; Romano et al., 1979, J. Bacteriol. 139:93-97 and Saier et al. 1990, In: BACTERIAL ENERGETICS pp. 273-299, T. A. Krulwich, Ed. Academic Press, NY). Host cells or strains useful in the present invention include any organism capable of utilizing a PTS system for carbohydrate transport. This includes prokaryotes belonging to the genus Escherichia, Corynebacterium, Brevibacterium, Bacillus, Pseudomonas, Streptomyces, Pantoea or Staphylococcus. A list of suitable organisms is provided in Table 1. The inactivation of the PTS in any of these organisms should potentially increase carbon flux and PEP (and PEP precursor) availability in the cell for alternative metabolic routes and consequently could increase production of desired compounds (e.g., aromatics) from such cells.

Detail Description Paragraph - DETX (75):

[0113] However, to increase or redirect carbon flow to desired metabolic pathways in inactivated PTS host cells, glucose transport and phosphorylation must be deregulated or amplified.

Detail Description Paragraph - DETX (124):

[0162] It should be noted that as the host cell is cultured in conditions which create an increase in carbon flow into the aromatic pathway, it may be necessary to identify and overcome rate-limiting steps in the pathway. This methodology is available to the artisan, see, for example, U.S. Pat. Nos. 5,168,056 and 5,776,736.

Detail Description Paragraph - DETX (127):

[0165] In addition to increasing the carbon flux through the aromatic pathway, the following genes may be overexpressed in PTS.sup.-/Glu.sup.+ cells according to the invention: pps which encodes PEP synthase in E. coli (see U.S. Pat. No. 5,985,617) and talA which encodes transaldolase (Iida et al. (1993) J. Bacteriol. 175:5375-5383). Further any gene encoding an enzyme that catalyzes reactions within the common aromatic pathway (for example, DAHP synthase (aroF, aroG, aroH), DHQ synthase (aroB), DHQ dehydratase (aroD), shikimate dehydrogenase (aroE), shikimate kinase (aroL, aroK), EPSP synthase (aroA) and chorismate synthase (aroC) may be amplified in the PTS.sup.-/Glu.sup.+ cells encompassed by the present invention.

Detail Description Paragraph - DETX (135):

[0173] Thus, having provided a PTS.sup.-/Glu.sup.+ strain which conserves PEP resulting in an increase in carbon flux into a metabolic pathway, such as the aromatic amino acid pathway, glycolysis, the TCA cycle, and the pentose phosphate pathway, by redirecting PEP and PEP precursors, the inventors have provided a host system which can be utilized for enhanced production of desired compounds in comparison to the production of the same compounds in a corresponding PTS host cell.

Detail Description Paragraph - DETX (187):

[0220] By constitutively expressing galP on the chromosome from the trc promoter the flux of carbon from glucose was increased into the pathway for the desired products, glycerol and 1,3-propanediol rather than into pathways to produce cell mass.

Claims Text - CLTX (1):

1. A method of increasing carbon flow into a metabolic pathway of a PTS.sup.-/Glu.sup.- bacterial host cell which was originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport comprising, a) modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a glucose assimilation protein in a PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a DNA construct comprising a promoter and DNA flanking sequences corresponding to upstream (5') regions of the glucose assimilation protein; b) allowing integration of the DNA construct to restore a Glu+ phenotype; and c) culturing the transformed host cell under suitable culture conditions, wherein the carbon flow into a metabolic pathway of the transformed host cell is increased compared to the carbon flow into the same metabolic pathway in a corresponding PTS bacterial host cell cultured under essentially the same culture conditions.

Claims Text - CLTX (22):

22. A method of increasing carbon flow into a metabolic pathway of a PTS.sup.-/Glu.sup.- bacterial host cell originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport comprising, a) modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a galactose permease in a PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a first DNA construct comprising a promoter and DNA flanking sequences corresponding to upstream (5') regions of the galactose permease; b) modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a glucokinase in the PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a second DNA construct comprising a promoter and DNA flanking sequences corresponding to upstream (5') regions of the glucokinase; c) allowing integration of the first and the second DNA constructs, wherein the first DNA construct replaces an endogenous promoter of the nucleic acid encoding the galactose permease and the second DNA construct replaces an endogenous promoter of the nucleic acid encoding the glucokinase wherein both the galactose permease and the glucokinase are expressed in the host cell and wherein said expression results in an increase in carbon flow into a metabolic pathway of the transformed host cell compared to carbon flow into the same metabolic pathway in a corresponding unaltered PTS.sup.-/Glu.sup.- bacterial cell.

Claims Text - CLTX (26):

26. A method of restoring a Glu+ phenotype to a PTS.sup.-/Glu.sup.- bacterial host cell which was originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport comprising a) modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a glucose transporter in a

PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a first DNA construct comprising a promoter and DNA flanking sequences corresponding to upstream (5') regions of the glucose transporter; b) allowing integration of the first DNA construct, wherein the first DNA construct replaces an endogenous promoter of the nucleic acid encoding the glucose transporter; and c) allowing expression of the glucose transporter, wherein said expression restores a Glu+ phenotype to the PTS.sup.-/Glu.sup.- host cell.

Claims Text - CLTX (34):

34. A method of increasing phosphoenolpyruvate (PEP) availability in a bacterial host cell comprising, a) selecting a bacterial host cell having a PTS.sup.-/Glu.sup.- phenotype, wherein the bacterial host was originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport; b) modifying an endogenous chromosomal regulatory sequence of the selected bacterial host cell comprising transforming said selected bacterial host cell with a DNA construct comprising a promoter, wherein said DNA construct is chromosomally integrated into the selected bacterial host cell replacing an endogenous promoter which is operably linked to a nucleic acid encoding a glucose assimilation protein; c) culturing the transformed bacterial host cell under suitable conditions; and d) allowing expression of the glucose assimilation protein to obtain an altered host cell having a PTS.sup.-/Glu.sup.+ phenotype, wherein the PEP availability is increased compared to the PEP availability in a corresponding unaltered PTS bacterial host cell cultured under essentially the same culture conditions.

Claims Text - CLTX (41):

41. A method for increasing the growth rate of a PTS.sup.-/Glu.sup.- bacterial host cell originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport comprising, a) modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a galactose permease in a PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a first DNA construct comprising an exogenous promoter and DNA flanking sequences corresponding to (5') upstream region of the galactose permease; b) modifying an endogenous regulatory region which is operably linked to a nucleic acid encoding a glucokinase in the PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a second DNA construct comprising an exogenous promoter and DNA flanking sequences corresponding to upstream (5') regions of the glucokinase; c) allowing integration of the first and the second DNA constructs, wherein the first DNA construct replaces the endogenous promoter of the nucleic acid encoding the galactose permease and the second DNA construct replaces the endogenous promoter of the nucleic acid encoding the glucokinase d) culturing the transformed bacterial host cell under suitable conditions; and e) allowing expression of the galactose permease and the glucokinase from the modified regulatory regions to obtain an altered bacterial cell having an increase specific growth rate compared to the specific growth rate of a corresponding unaltered PTS bacterial host cell cultured under essentially the same culture conditions.

PGPUB-DOCUMENT-NUMBER: 20050079482

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050079482 A1

TITLE: Method for redesign of microbial production systems

PUBLICATION-DATE: April 14, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Maranas, Costas D.	Port Matilda	PA	US	
Burgard, Anthony P.	State College	PA	US	
Pharkya, Priti	State College	PA	US	

APPL-NO: 10/ 929091

DATE FILED: August 26, 2004

RELATED-US-APPL-DATA:

child 10929091 A1 20040826

parent continuation-in-part-of 10616659 20030709 US PENDING

non-provisional-of-provisional 60395763 20020710 US

non-provisional-of-provisional 60417511 20021009 US

non-provisional-of-provisional 60444933 20030203 US

US-CL-CURRENT: 435/4, 702/19

ABSTRACT:

A computer-assisted method for identifying functionalities to add to an organism-specific metabolic network to enable a desired biotransformation in a host includes accessing reactions from a universal database to provide stoichiometric balance, identifying at least one stoichiometrically balanced pathway at least partially based on the reactions and a substrate to minimize a number of non-native functionalities in the production host, and incorporating the at least one stoichiometrically balanced pathway into the host to provide the desired biotransformation. A representation of the metabolic network as modified can be stored.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 10/616,659, filed Jul. 9, 2003 which is a conversion of: U.S. patent application Ser. No. 60/395,763, filed Jul. 10, 2002; U.S. patent application Ser. No. 60/417,511, filed Oct. 9, 2002; and U.S. patent application Ser. No. 60/444,933, filed Feb. 3, 2003, each of which is herein incorporated by reference in its entirety.

----- KWIC -----

#### Detail Description Paragraph - DETX (70):

[0093] is a minimum level of biomass production. The vector .nu. includes both internal and transport reactions. The forward (i.e., positive) direction of transport fluxes corresponds to the uptake of a particular metabolite, whereas the reverse (i.e., negative) direction corresponds to metabolite secretion. The uptake of glucose through the phosphotransferase system and glucokinase are denoted by .nu..sub.pts and .nu..sub.glk, respectively. Transport fluxes for metabolites that can only be secreted from the network are members of M.sub.secr.sub.--.s- ub.only. Note also that the complete set of reactions M is subdivided into reversible M.sub.rev and irreversible M.sub.irrev reactions. The cellular objective is often assumed to be a drain of biosynthetic precursors in the ratios required for biomass formation (Neidhardt and Curtiss, 1996). The fluxes are reported per 1 gDW.multidot.hr such that biomass formation is expressed as g biomass produced/gDW.multidot.hr or 1/hr.

#### Detail Description Paragraph - DETX (88):

[0109] Which reactions, if any, that could be removed from the E. coli K-12 stoichiometric model (Edwards & Palsson, 2000) so as the remaining network produces succinate or lactate whenever biomass maximization is a good descriptor of flux allocation were identified. A prespecified amount of glucose (10 mmol/gDW.multidot.hr), along with unconstrained uptake routes for inorganic phosphate, oxygen, sulfate, and ammonia are provided to fuel the metabolic network. The optimization step could opt for or against the phosphotransferase system, glucokinase, or both mechanisms for the uptake of glucose. Secretion routes for acetate, carbon dioxide, ethanol, formate, lactate and succinate are also enabled. Note that because the glucose uptake rate is fixed, the biomass and product yields are essentially equivalent to the rates of biomass and product production, respectively. In all cases, the OptKnock procedure eliminated the oxygen uptake reaction pointing at anaerobic growth conditions consistent with current succinate (Zeikus et al., 1999) and lactate (Datta et al., 1995) fermentative production strategies.

#### Detail Description Paragraph - DETX (90):

[0111] A less intuitive strategy was identified for mutant C which focused on inactivating two PEP consuming reactions rather than eliminating competing byproduct (i.e., ethanol, formate, and lactate) production mechanisms. First, the phosphotransferase system was disabled requiring the network to rely exclusively on glucokinase for the uptake of glucose. Next, pyruvate kinase was removed leaving PEP carboxykinase as the only central metabolic reaction capable of draining the significant amount of PEP supplied by glycolysis. This strategy, assuming that the maximum biomass yield could be attained, resulted in a succinate yield approaching 88% of the theoretical maximum. In addition, there was significant succinate production for every attainable biomass yield, while the maximum theoretical yield of succinate is the same as that for the wild-type strain.

#### Detail Description Table CWU - DETL (1):

1TABLE I Biomass and chemical yields for various gene knockout strategies identified by OptKnock. The reactions and corresponding enzymes for each knockout strategy are listed. The maximum biomass and corresponding chemical yields are provided on a basis of 10 mmol/hr glucose fed and 1 gDW of cells. The rightmost column provides the chemical yields for the same basis assuming a minimal redistribution of metabolic fluxes from the wild-type (undeleted) E. coli network (MOMA assumption). For the 1,3-propanediol case, glycerol secretion was disabled for both knockout strategies. max .nu..sub.biomass min .SIGMA.(84.sub.0 - .nu.).sup.2 Succinate Biomass Succinate Succinate ID Knockouts Enzyme (1/hr) (mmol/hr) (mmol/hr) Wild "Complete network" 0.38 0.12 0 A 1 COA + PYR ACCOA + FOR Pyruvate formate lyase 0.31 10.70 1.65 2

NADH + PYR LAC + NAD Lactate dehydrogenase B 1 COA + PYR ACCOA + FOR Pyruvate  
 formate lyase 0.31 10.70 4.79 2 NADH + PYR LAC + NAD Lactate dehydrogenase 3  
 ACCOA + 2 NADH COA + ETH + 2 NAD Acetaldehyde dehydrogenase C 1 ADP + PEP ATP  
 + PYR Pyruvate kinase 0.16 15.15 6.21 2 ACTP + ADP AC + ATP or Acetate  
 kinase ACCOA + Pi ACTP + COA Phosphotransacetylase 3 GLC + PEP G6P + PYR  
Phosphotransferase system max .nu..sub.biomass min .SIGMA.(84.sub.0 -  
 .nu.).sup.2 Lactate Biomass Lactate Lactate ID Knockouts Enzyme (1/hr)  
 (mmol/hr) (mmol/hr) Wild "Complete network" 0.38 0 0 A 1 ACTP + ADP AC +  
 ATP or Acetate kinase 0.28 10.46 5.58 ACCOA + Pi ACTP + COA  
 Phosphotransacetylase 2 ACCOA + 2 NADH COA + ETH + 2 NAD Acetaldehyde  
 dehydrogenase B 1 ACTP + ADP AC + ATP or Acetate kinase 0.13 18.00 0.19  
 ACCOA + Pi ACTP + COA Phosphotransacetylase 2 ATP + F6P ADP + FDP or  
 Phosphofructokinase FDP T3P1 + T3P2 Fructose-1,6-bisphosphatate aldolase C 1  
 ACTP + ADP AC + ATP or Acetate kinase 0.12 18.13 10.53 ACCOA + Pi ACTP + COA  
 Phosphotransacetylase 2 ATP + F6P ADP + FDP or Phosphofructokinase FDP T3P1  
 + T3P2 Fructose-1,6-bisphosphatate aldolase 3 ACCOA + 2 NADH COA + ETH + 2  
 NAD Acetaldehyde dehydrogenase 4 GLC + ATP G6P + PEP Glucokinase max  
 .nu..sub.biomass min .SIGMA.(84.sub.0 - .nu.).sup.2 1,3-Propanediol Biomass  
 1,3-PD 1,3-PD ID Knockouts Enzyme (1/hr) (mmol/hr) (mmol/hr) Wild "Complete  
 network" 1.06 0 0 A 1 FDP F6P + Pi or Fructose-1,6-bisphosphatase 0.21 9.66  
 8.66 FDP T3P1 + T3P2 Fructose-1,6-bisphosphatate aldolase 2 13PDG + ADP 3PG +  
 ATP or Phosphoglycerate kinase NAD + Pi + T3P1 13PDG + NADH  
 Glyceraldehyde-3-phosphate dehydrogenase 3 GL + NAD GLAL + NADH Aldehyde  
 dehydrogenase B 1 T3P1 T3P2 Triosphosphate isomerase 0.29 9.67 9.54 2 G6P +  
 NADP D6PGL + NADPH or Glucose 6-phosphate-1-dehydrogenase D6PGL D6PGC  
 6-Phosphogluconolactonase 3 DR5P ACAL + T3P1 Deoxyribose-phosphate aldolase  
 4 GL + NAD GLAL + NADH Aldehyde dehydrogenase



PGPUB-DOCUMENT-NUMBER: 20040261147

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040261147 A1

TITLE: High level production of arbutin in green plants and microbes

PUBLICATION-DATE: December 23, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Meyer, Knut	Wilmington	DE	US	
Viitanen, Paul V.	West Chester	PA	US	
Flint, Dennis	Newark	DE	US	

APPL-NO: 10/ 462162

DATE FILED: June 16, 2003

US-CL-CURRENT: 800/278, 435/468 , 435/471 , 435/488

ABSTRACT:

This invention relates to methods and materials to produce hydroquinone glucoside in genetically modified green plants and microorganisms.

----- KWIC -----

Detail Description Paragraph - DETX (71):

[0092] All co-factors, co-enzymes and co-substrates required for these pathways (such as FAD, NADH, O.sub.2, and UDPG) are present in the E. coli cytoplasm. E. coli strains with elevated levels of chorismate resulting from increased flux of carbon into the shikimate pathway have been disclosed (Berry et al., Trends Biotech, 14(7):250-256 (1996); Bongaerts et al., Metabolic Engineering, 3(4):289-300 (2001); Tatarko and Romeo T., Curr. Microbiol., 43(1):26-32 (2001); U.S. Pat. No. 6,210,937 B1; U.S. Pat. No. 5,776,736 A; and WO 73484 A1) and can be used to produce arbutin from glucose using the molecular tools described below.

Detail Description Paragraph - DETX (108):

[0129] Some degree of improvement has been achieved in this area by including in the chloroplast targeting sequence not only the transit peptide and the scissile bond, but also a small portion of the mature N-terminus of the transit peptide donor. Indeed, this approach has worked both in vivo and in vitro ((Van den Broeck et al., supra; Schreier et al., supra; Wasmann et al., supra; EP 0189707; U.S. Pat. No. 5,728,925; and U.S. Pat. No. 5,717,084)) for another bacterial protein, namely, neomycin phosphotransferase II (NPT-II). Thus, a chimeric protein consisting of the transit peptide of the Rubisco small subunit precursor plus the first 22 residues of mature Rubisco fused to the N-terminus of NPT-II was taken up by chloroplasts much better than a similar construct that only contained the transit peptide and scissile bond. However, this strategy is not foolproof as it is still associated with a high degree of unpredictability that is inextricably linked to the passenger protein. This is most readily seen in the literature attempts to target CPL to chloroplasts. For example, Sommer et al. (Plant Cell Physiol., 39(11):1240-1244 (1998))

describe an analogous artificial fusion protein comprising the CPL gene product fused at its N-terminus to the transit peptide and first 21 amino acid residues of the Rubisco small subunit (e.g., "TP21 UbiC"). This modification was undertaken to improve chloroplast uptake and processing, but the cells that contained the original construct, TP-UbiC, unexpectedly had much higher levels of both CPL enzyme activity and pHBA glucosides. Thus, application of the Wasmann et al. (supra) teaching had a detrimental effect when applied with a different protein.

Detail Description Paragraph - DETX (147):

[0167] The molecular identification and isolation of the pHBA 1-hydroxylase gene described by Applicants also enables arbutin production in microbial systems such as *E. coli* (described in detail in Examples 7 and 8). The pHBA 1-hydroxylase gene is expressed in *E. coli* cells in combination with a chorismate pyruvate-lyase gene and a suitable glucosyltransferase gene (Examples 6 and 8). Expressing these three enzymes in *E. coli* provides a route to arbutin from a cheap, fermentable carbon source, such as glucose, by creating a three-step pathway from chorismate to arbutin (FIG. 1). Those skilled in the art will recognize that all cofactors, coenzymes and co-substrates required for this pathway such as FAD, NADH, O.sub.2, and UDP-glucose (UDPG) are present in the *E. coli* cytoplasm. Moreover *E. coli* strains with elevated levels of chorismate resulting from increased flux of carbon into the shikimate pathway have been disclosed (Berry et al., Trends Biotech., 14(7):250-256 (1996); Bongaerts et al., Metabolic Engineering, 3(4):289-300 (2001); Tatarko and Romeo, Current Microbiology, 43(1):26-32 (2001); U.S. Pat. No. 6,210,937; US 5776736; and WO 73484 A1) and can be used to produce arbutin from glucose using the molecular tools described below.

PGPUB-DOCUMENT-NUMBER: 20040209337

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040209337 A1

TITLE: Synthesis of 1,2,3,4-tetrahydroxybenzenes from  
biomass-derived carbon

PUBLICATION-DATE: October 21, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Frost, John W.	Okemos	MI	US	
Hansen, Chad A.	East Lansing	MI	US	

APPL-NO: 10/ 838551

DATE FILED: May 4, 2004

RELATED-US-APPL-DATA:

child 10838551 A1 20040504

parent division-of 09937243 20020507 US GRANTED

parent-patent 6750049 US

child 09937243 20020507 US

parent a-371-of-international PCT/US00/06808 20000316 WO PENDING

child 09937243 20020507 US

parent continuation-of 09274732 19990323 US ABANDONED

US-CL-CURRENT: 435/156, 568/763

ABSTRACT:

A bioengineered synthesis scheme for the production of 1,2,3,4-tetrahydroxybenzene from a carbon source is provided. Methods of producing 1,2,3,4-tetrahydroxybenzene acid from a carbon source based on the synthesis scheme are also provided. Methods are also provided for converting 1,2,3,4-tetrahydroxybenzene to 1,2,3-trihydroxybenzene by catalytic hydrogenation.

RELATED APPLICATIONS

[0001] The present application is a divisional of U.S. application Ser. No. 09/937,243, filed Sep. 21, 2001, which is a national phase continuation of PCT international publication WO 00/56911 filed Mar. 16, 2000, which is a Continuation-in-Part of U.S. application Ser. No. 09/274,732 filed Mar. 23, 1999, which is hereby expressly incorporated by reference.

----- KWIC -----

Detail Description Paragraph - DETX (8):

[0024] In one embodiment, a recombinant *E. coli* microbe is employed in the methods of the present invention. In a preferred embodiment, the *E. coli* comprises a non-functional *serA* locus. This recombinant *E. coli*, designated, JWF1, may further comprise a plasmid carrying an *INO1* gene insert and a *serA* gene insert. The *INO1* gene encodes myo-inositol-1-phosphate synthase which converts glucose-6-phosphate to myo-inositol-1-phosphate. In a preferred embodiment, the *INO1* gene is from *Saccharomyces cerevisiae*. Overexpression of myo-inositol-1-phosphate synthase will increase carbon flow into the myo-inositol pathway. This recombinant microbe is capable of converting glucose to myo-inositol.

Detail Description Paragraph - DETX (10):

[0026] In a preferred embodiment, the recombinant *E. coli* comprises plasmid pAD1.88A carrying an *INO1* gene insert and a *serA* gene insert. As described above, the *INO1* gene insert encodes myo-inositol-1-phosphate synthase which converts glucose-6-phosphate to myo-inositol-1-phosphate, thus increasing the carbon flow into the myo-inositol pathway. Due to a mutation in the *E. coli* genomic *serA* locus required for L-serine biosynthesis, growth in minimal salts medium and plasmid maintenance follows from expression of plasmid-localized *serA*. The *serA* insert thus allows microbial growth in minimal salts medium, distinguishing the microbes containing the plasmid from non-plasmid containing microbes.

Detail Description Paragraph - DETX (26):

[0040] Synthesis of myo-inositol by *E. coli* JWF1/pAD1.88A begins with D-glucose uptake and conversion to D-glucose-6-phosphate catalyzed by the *E. coli* phosphotransferase system (Postma, P. W. et al., In *Escherichia coli* and *Salmonella*, 2nd ed., Neidhardt, F. C. et al., Eds., ASM: Washington, Vol. 1, p. 1149 (1996)) where phosphoenolpyruvate is the source of the transferred phosphoryl group. D-Glucose-6-phosphate then undergoes cyclization to myo-inositol 1-phosphate catalyzed by myo-inositol-1-phosphate synthase. This enzyme activity, which results from expression of the *Saccharomyces cerevisiae* *INO1* gene (Dean-Johnson, M. et al., *J. Biol. Chem.* 264:1274 (1989)) on plasmid pAD1.88A, varied significantly (0.022, 0.043, 0.018, and 0.009  $\mu\text{mol/min/mg}$  at 18 h, 30 h, 42 h, and 54 h, respectively) over the course of the fermentation.

PGPUB-DOCUMENT-NUMBER: 20040203093

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040203093 A1

TITLE: NUCLEOTIDE SEQUENCE OF THE HAEMOPHILUS INFLUENZAE RD  
GENOME, FRAGMENTS THEREOF, AND USES THEREOF

PUBLICATION-DATE: October 14, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fleischmann, Robert D.	Gaithersburg	MD	US	
Adams, Mark D.	Rockville	MD	US	
White, Owen	Gaithersburg	MD	US	
Smith, Hamilton O.	Reisterstown	MD	US	
Venter, J. Craig	Queenstown	MD	US	

APPL-NO: 10/ 158865

DATE FILED: June 3, 2002

RELATED-US-APPL-DATA:

child 10158865 A1 20020603

parent division-of 09557884 20000425 US GRANTED

parent-patent 6506581 US

child 09557884 20000425 US

parent continuation-of 08476102 19950607 US GRANTED

parent-patent 6355450 US

child 08476102 19950607 US

parent continuation-in-part-of 08426787 19950421 US ABANDONED

US-CL-CURRENT: 435/69.1, 435/320.1, 435/325, 435/6, 536/23.2, 702/20

ABSTRACT:

The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.

----- KWIC -----

Detail Description Paragraph - DETX (204):

[0230] In order to survive as a free living organism, *H. influenzae* must produce energy in the form of ATP via fermentation and/or electron transport. As a facultative anaerobe, *H. influenzae* Rd is known to ferment glucose, fructose, galactose, ribose, xylose and fucose (Dorocicz et al., J. Bacteriol. 175:7142 (1993)). The genes identified in Table 1(a) indicate that transport systems are available for the uptake of these sugars via the phosphoenolpyruvate-phosphotransferase system (PTS), and via non-PTS mechanisms. Genes that specify the common phosphate-carriers Enzyme I and Hpr (ptsI and ptsH) of the PTS system were identified as well as the glucose specific crr gene. The ptsH, ptsI, and crr genes constitute the pts operon. We have not however identified the gene encoding membrane-bound glucose specific Enzyme II. The latter enzyme is required for transport of glucose by the PTS system. A complete FITS system for fructose was identified.

Detail Description Table CWU - DETL (10):

HI1389 1480494 1480988 ferritin like protein (rsgA) [*Escherichia coli*] 57.3 73.8 164 HI0363 385804 384887 iron(III) dicitrate transport ATP-binding protein FECE [*Escherichia coli*] 35.9 56.4 220 HI1274 1347324 1347861 iron(III) dicitrate transport system permease protein (fecD) [*Escherichia coli*] 64.0 255 HI1037 1099321 1100265 magnesium and cobalt transport protein (corA) [*Escherichia coli*] 70.3 84.8 316 HI0097 103798 104679 major ferric iron binding protein precursor (fbp) [*Neisseria gonorrhoeae*] 69.7 82.3 293 HI1051 1114308 1114635 mercuric transport protein (merT) [*Pseudomonas aeruginosa*] 25.0 55.2 99 HI1052 1114651 1114926 mercury scavenger protein (merP) [*Pseudomonas fluorescens*] 29.3 45.7 91 HI0294 327396 327193 mercury scavenger protein (merP) [*Pseudomonas fluorescens*] 32.8 67.2 67 HI1531 1594953 1594219 molybdate-binding periplasmic protein precursor (modB) [*Azotobacter vinelandii*] HI0226 254880 253681 NA(+)/H(+) antiporter 1 (nhaA) [*Escherichia coli*] 52.6 74.6 380 HI0429 448992 450557 Na<sup>+</sup>/H<sup>+</sup> antiporter (nhaB) [*Escherichia coli*] 70.6 87.5 501 HI1110 1171933 1170530 Na<sup>+</sup>/H<sup>+</sup> antiporter (nhaC) [*Bacillus firmus*] 37.5 62.0 382 HI0098 104899 106317 periplasmic-binding-protein-dependent iron transport protein (sfuB) 38.1 59.5 457 [*Serratia marcescens*] HI1479 1558763 1558167 periplasmic-binding-protein-dependent iron transport protein (sfuC) 39.9 58.0 197 [*Serratia marcescens*] HI0913 964424 966276 potassium efflux system (kefC) [*Escherichia coli*] 40.9 65.7 594 HI0292 326934 324769 potassium/copper-transportING ATPase A (copA) [*Enterococcus faecalis*] 42.9 64.4 723 HI1355 1429787 1428276 sodium/proline symporter (proline permease) (putP) [*Escherichia coli*] 62.8 79.1 489 HI0252 283326 282517 tonB protein (tonB) [*Haemophilus influenzae*] 96.2 98.5 261 HI0627 664922 666362 TRK system potassium uptake protein (trkA) [*Escherichia coli*] 65.8 83.4 458 Carbohydrates, organic alcohols & acids HI0020 22097 20661 2-oxoglutarate/malate translocator (SODiT1) [*Spinacia oleracea*] 35.8 59.6 452 HI0824 872894 873940 D-galactose-binding periplasmic protein (mglB) [*Escherichia coli*] 67.6 81.2 329 HI1113 1176024 1174516 D-xylose transport ATP-binding protein (xylG) [*Escherichia coli*] 71.5 85.8 501 HI1114 1177073 1176078 D-xylose-binding periplasmic protein (rbsB) [*Escherichia coli*] 76.0 88.4 328 HI1718 1785024 1783300 enzyme I (ptsI) [*Salmonella typhimurium*] 70.2 84.3 574 HI0182 194818 193967 formate transporter (formate channel) [*Escherichia coli*] 53.2 73.4 263 HI0450 471781 470285 fructose-permease IIA/FPR component (fruB) [*Escherichia coli*] 51.5 68.3 374 HI0448 469337 467670 fructose-permease IIBC component (fruA) [*Escherichia coli*] 57.2 72.2 552 HI0614 643282 642851 fucose operon protein (fucU) [*Escherichia coli*] 66.3 80.0 94 HI0692 733673 734464 glpF protein (glpF) [*Escherichia coli*] 73.6 87.2 258 HI1019 1080518 1081194 glpF protein (glpF) [*Escherichia coli*] 30.6 54.6 208 HI1017 1078404 1079867 gluconate permease (gntP) [*Bacillus subtilis*] 29.1 56.4 442 HI1717 1783237 1782740 glucose phosphotransferase enzyme III-glc (crr) [*Escherichia coli*] 73.2 83.3 169 HI0688 729474 730914 glycerol-3-phosphatase transporter (glpT) [*Escherichia coli*] 64.5 78.9 445

HI0504 517869 519347 high affinity ribose transport protein (rbsA)  
 [Escherichia coli] 71.1 85.4 494 HI0505 519363 520331 high affinity ribose  
 transport protein (rbsC) [Escherichia coli] 68.0 86.5 303 HI0503 517436  
 517852 high affinity ribose transport protein (rbsD) [Escherichia coli] 59.0  
 78.4 139 HI0612 642139 640856 L-fucose permease (fucP) [Escherichia coli]  
 35.6 57.9 413 HI1221 1288578 1286983 L-lactate permease (lctP) [Escherichia  
 coli] 30.2 53.9 532 HI1735 1802527 1801757 lactam utilization protein (lamB)  
 [Emencella nidulans] 41.3 60.3 130 HI0825 874009 875526 mglA protein (mglA)  
 [Escherichia coli] 73.9 84.6 506 HI0826 875546 876553 mglC protein (mglC)  
 [Escherichia coli] 79.2 90.2 336 HI0506 520354 521229 periplasmic  
 ribose-binding protein (rbsB) [Escherichia coli] 73.9 86.6 291 HI1719 1785361  
 1785107 phosphohistidinoprotein- -hexose phosphotransferase (ptsH)  
 [Escherichia coli] 77.6 88.2 85 HI0830 878480 878773 potassium channel  
 homolog (kch) [Escherichia coli] 67.7 80.2 96 HI0154 170140 168807 putative  
 aspartate transport protein (dcuA) [Escherichia coli] 46.4 69.9 436 HI0748  
 803856 805175 putative aspartate transport protein (dcuA) [Escherichia coli]  
 42.6 70.1 435 HI1112 1174509 1173385 nbose transport permease protein (xylH)  
 [Escherichia coli] 69.8 84.1 371 HI1696 1759373 1760743 sodium- and  
 chloride-dependent GABA transporter [Homo sapiens] 29.3 52.6 471 HI0738  
 790926 789403 sodium-dependent noradrenaline transporter [Homo sapiens] 31.1  
 54.2 523 Nucleosides, purines & pyrimidines HI1089 1151815 1151024  
 ribonucleotide transport ATP-binding protein (mkl) [Mycobacterium leprae] 42.2  
 61.5 244 HI1230 1296319 1295078 uracil permease (ursA) [Escherichia coli]  
 37.2 61.6 400 Anions HI1104 1164213 1165028 cysteine synthetase (cysZ)  
 [Escherichia coli] 53.7 76.3 190 HI1697 1761825 1760773 hydrophilic  
 membrane-bound protein (modC) [Escherichia coli] 55.9 74.5 263 HI1698 1762501  
 1761815 hydrophobic membrane-bound protein (modB) [Escherichia coli] 65.9 84.8  
 223 HI1384 1477430 1476585 integral membrane protein (pstA) [Escherichia  
 coli] 59.6 77.6 272 HI0356 380045 380764 nitrate transporter ATPase component  
 (nasD) [Klebsiella pneumoniae] 34.9 57.8 254 HI1383 1475710 1476584 peripheral  
 membrane protein B (pstB) [Escherichia coli] 77.0 86.8 256 HI1385 1478379  
 1477435 peripheral membrane protein C (pstC) [Escherichia coli] 57.3 78.7 300  
 HI1386 1479246 1478473 periplasmic phosphate-binding protein (pstS)  
 [Escherichia coli] 49.8 67.7 256 HI1387 1479247 1479929 periplasmic  
 phosphate-binding protein (pstS) [Escherichia coli] 63.8 75.4 69 HI1610  
 1669474 1670733 phosphate permease(YBR296C) [Saccharomyces cerevisiae] 35.6  
 60.0 551 Other HI0060 62564 60804 ATP dependent translocator homolog (msbA)  
 [Haemophilus influenzae] 100.0 100.0 458 HI0623 653683 662010 ATP-binding  
 protein (abc)

PGPUB-DOCUMENT-NUMBER: 20040152159

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040152159 A1

TITLE: Materials and methods for the efficient production of acetate and other products

PUBLICATION-DATE: August 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Causey, Thomas B.	Gainesville	FL	US	
Ingram, Lonnie O'Neal	Gainesville	FL	US	
Zhou, Shengde	Gainesville	FL	US	
Shanmugam, Keelnathan T.	Gainesville	FL	US	

APPL-NO: 10/ 703812

DATE FILED: November 6, 2003

RELATED-US-APPL-DATA:

non-provisional-of-provisional 60424372 20021106 US

US-CL-CURRENT: 435/69.1, 435/252.3

ABSTRACT:

The subject invention provides materials and methods wherein unique and advantageous combinations of gene mutations are used to direct carbon flow from sugars to a single product. The techniques of the subject invention can be used to obtain products from native pathways as well as from recombinant pathways. In preferred embodiments, the subject invention provides new materials and methods for the efficient production of acetate and pyruvic acid.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application Serial No. 60/424,372, filed Nov. 6, 2002.

----- KWIC -----

Detail Description Paragraph - DETX (23):

[0061] Genetically modified E. coli W3110 was developed to produce acetic acid as the primary product from glucose during aerobic growth using only mineral salts as nutrients. The resulting biocatalyst (TC36) contains multiple chromosomal alterations (FIG. 1) that direct carbon flow to acetate and minimize carbon loss to cell mass, CO<sub>2</sub>, and alternative products. Strain TC36 is devoid of plasmids and antibiotic resistance genes, both potential advantages for commercial use. The subject invention provides an additional derivative of Escherichia coli W3110 as a new biocatalyst for the production of homo-acetate. Acetate production by this new strain (TC36) approaches the theoretical maximum of two acetate per glucose due to the disruption of oxidative phosphorylation.



Detail Description Paragraph - DETX (24):

[0062] Chromosomal deletions were used instead of point mutations to maximize stability. All antibiotic resistance genes and auxotrophic requirements were eliminated to permit growth in simple mineral salts medium. During oxidative metabolism, up to half of the substrate carbon can be converted to roughly equal amounts of cell mass and CO<sub>2</sub> (Contiero, J., C. Beatty, S. Kumar, C. L. DeSanti, W. R. Strohl, and A. Wolfe, 2000 "Effects of mutations in acetate metabolism on high-cell-density growth of *Escherichia coli*" J. Ind. Microbiol. 24:421-430; Neidhardt, F. C., J. L. Ingraham, and M. Schaechter, 1990 "Physiology of the bacterial cell: A molecular approach" Sinauer Associates, Inc., Sunderland, Mass.; Varma, A., B. W. Boesch, and B. O. Palsson, 1993 "Stoichiometric interpretation of *Escherichia coli* glucose catabolism under various oxygenation rates" Appl. Environ. Microbiol. 59:2465-2473) with minimal carbon flow into alternative products, such as acetate.

Detail Description Paragraph - DETX (28):

[0066] With additional mutations in fermentation pathways, further metabolism of pyruvate was limited primarily to small biosynthetic needs and conversion to acetyl-CoA by the pyruvate dehydrogenase complex. Although pyruvate dehydrogenase is activated by low NADH, acetyl-CoA production may be limited by the availability of free CoA (note pyruvate accumulation in TC36 broth between 9 h and 15 h; FIG. 4C). Resulting rises in pyruvate pools would serve as an allosteric activator of phosphotransferase (Suzuki, T., 1969 "Phosphotransacetylase of *Escherichia coli* B, activation by pyruvate and inhibition by NADH and certain nucleotides" Biochim. Biophys. Acta 191:559-569), the first committed step for acetate production from acetyl-CoA. Gratuitous ATP hydrolysis by F<sub>1</sub>-ATPase should ensure the availability of ADP for the final step in acetate production catalyzed by acetate kinase (FIG. 1). Excess pyruvate can also be directly oxidized to acetate by pyruvate oxidase (poxB), an enzyme that is induced during the latter stages of growth and by environmental stress (Chang, Y.-Y., A.-Y. Wang, and J. E. Cronan, Jr., 1994 "Expression of *Escherichia coli* pyruvate oxidase (PoxB) depends on the sigma factor encoded by the rpoS (katF) gene" Mol. Microbiol. 11:1019-1028). This enzyme may also contribute to acetate production by TC36.

Detail Description Paragraph - DETX (83):

[0114] Pyruvate levels in the broth of TC36 increased (16 mM at 12 h) during the transition stage (FIG. 4C). Although this pyruvate was subsequently metabolized, the excretion of pyruvate indicates that glucose uptake and glycolysis per se may not be limiting for acetate production. Because of the various mutations in TC36, metabolism of pyruvate is limited primarily to small biosynthetic needs and conversion to acetyl-CoA by the pyruvate dehydrogenase complex (FIG. 1). Although pyruvate dehydrogenase is activated by low NADH, acetyl-CoA production may be limited by the availability of free CoA. Resulting rises in pyruvate pools (FIG. 4C), would serve as an allosteric activator of phosphotransferase (Suzuki, T., 1969 "Phosphotransacetylase of *Escherichia coli* B, activation by pyruvate and inhibition by NADH and certain nucleotides" Biochim. Biophys. Acta 191:559-569), since phosphotransferase (pta) is the first committed step for acetate production from acetyl-CoA (FIG. 1). Gratuitous ATP hydrolysis by F<sub>1</sub>-ATPase (FIG. 1C) should ensure the availability of ADP for the final step in acetate production catalyzed by acetate kinase (ackA) (FIG. 1). Excess pyruvate can also be directly oxidized to acetate by pyruvate oxidase (poxB), an enzyme that is induced during the latter stages of growth and by environmental stress (Chang, Y.-Y., A.-Y. Wang, and J. E. Cronan, Jr., 1994 "Expression of *Escherichia coli* pyruvate oxidase (PoxB) depends on the sigma factor encoded by the rpoS (katF) gene" Mol. Microbiol. 11:1019-1028). Thus, pyruvate oxidase (poxB) may also contribute to acetate production by TC36.



PGPUB-DOCUMENT-NUMBER: 20040093641

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040093641 A1

TITLE: Regulating metabolism by modifying the level of  
trehalose-6-phosphate

PUBLICATION-DATE: May 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Goddijn, Oscar Johannes Maria	Ln Leider		NL	
Pen, Jan	Js Leiden	NL		
Smeekens, Josephus Christianus Maria	Ae Driebergen		NL	

APPL-NO: 10/ 682456

DATE FILED: October 9, 2003

RELATED-US-APPL-DATA:

child 10682456 A1 20031009

parent division-of 09171937 19990428 US ABANDONED

child 09171937 19990428 US

parent a-371-of-international PCT/EP97/02497 19970502 WO UNKNOWN

FOREIGN-APPL-PRIORITY-DATA:

COUNTRY	APPL-NO	DOC-ID	APPL-DATE
NL	EP96201225-8	1996NL-EP96201225-8	May 3, 1996
NL	EP96202128.3	1996NL-EP96202128.3	July 26, 1996
NL	EP96202395.8	1996NL-EP96202395.8	August 29, 1996

US-CL-CURRENT: 800/284, 435/468

ABSTRACT:

Method for the inhibition of carbon flow in the glycolytic direction in a cell by increasing the intracellular availability of trehalose-6-phosphate.

----- KWIC -----

Abstract Paragraph - ABTX (1):

Method for the inhibition of carbon flow in the glycolytic direction in a cell by increasing the intracellular availability of trehalose-6-phosphate.

Summary of Invention Paragraph - BSTX (14):

[0012] It has now been found that modification of the development and/or composition of cells, tissue and organs in vivo is possible by introducing the enzyme trehalose-6-phosphate synthase (TPS) and/or trehalose-6-phosphatase phosphate (TPP) thereby inducing a change in metabolic pathways of the saccharide trehalose-6-phosphate (T-6-P) resulting in an alteration of the

intracellular availability of T-6-P. Introduction of TPS thereby inducing an increase in the intracellular concentration of T-6-P causes inhibition of carbon flow in the glycolytic direction, stimulation of the photosynthesis, inhibition of growth stimulation of sink-related activity and an increase in storage of resources. Introduction of TPP thereby introducing a decrease in the intracellular concentration of T-6-P causes stimulation of carbon flow in the glycolytic direction, increase in biomass and a decrease in photosynthetic activity.

#### Brief Description of Drawings Paragraph - DRTX

(2):

[0030] FIG. 1. Schematic representation of plasmid pVDH275 harbouring the neomycin-phosphotransferase gene (NPTII) flanked by the 35S cauliflower mosaic virus promoter (P35S) and terminator (T35S) as a selectable marker; an expression cassette comprising the pea plastocyanin promoter (pPC<sub>pea</sub>) and the nopaline synthase terminator (T<sub>nos</sub>); right (RB) and left (LB) T-DNA border sequences and a bacterial kanamycin resistance (Kan<sup>R</sup>) marker gene.

#### Detail Description Paragraph - DETX (14):

[0078] Generation of the "plenty" signal by decreasing the intracellular concentration of trehalose-6-phosphate through expression of the enzyme TPP (or inhibition of the enzyme TPS) will signal all cell systems to increase glycolytic carbon flow and inhibit photosynthesis. This is nicely shown in the experimental part, where, for instance in Experiment 2 transgenic tobacco plants are described in which the enzyme TPP is expressed having increased leaf size, increased branching and a reduction of the amount of chlorophyll.

#### Detail Description Paragraph - DETX (51):

[0115] To select or screen for transformed cells, it is preferred to include a marker gene linked to the plant expressible gene according to the invention to be transferred to a plant cell. The choice of a suitable marker gene in plant transformation is well within the scope of the average skilled worker; some examples of routinely used marker genes are the neomycin phosphotransferase genes conferring resistance to kanamycin (EP-B 131 623), the glutathion-S-transferase gene from rat liver conferring resistance to glutathione derived herbicides (EP-A 256 223), glutamine synthetase conferring upon overexpression resistance to glutamine synthetase inhibitors such as phosphinothricin (WO 87/05327), the acetyl transferase gene from *Streptomyces viridochromogenes* conferring resistance to the selective agent phosphinothricin (EP-A 275 957), the gene encoding a 5-enolshikimate-3-phosphate synthase (EPSPS) conferring tolerance to N-phosphonomethylglycine, the bar gene conferring resistance against Bialaphos (e.g. WO 91/02071) and the like. The actual choice of the marker is not crucial as long as it is functional (i.e. selective) in combination with the plant cells of choice.

#### Claims Text - CLTX (3):

3. Method for the inhibition of carbon flow in the glycolytic direction in a cell by increasing the intracellular availability of trehalose-6-phosphate.

PGPUB-DOCUMENT-NUMBER: 20040073976

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040073976 A1

TITLE: Expression of fructose 1,6 bisphosphate aldolase in  
transgenic plants

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Barry, Gerard F.	St. Louis	MO	US	
Cheikh, Nordine	Manchester	MO	US	
Kishore, Ganesh M.	Creve Coeur	MO	US	

APPL-NO: 10/ 705430

DATE FILED: November 11, 2003

RELATED-US-APPL-DATA:

child 10705430 A1 20031111

parent continuation-of 10164204 20020606 US GRANTED

parent-patent 6663906 US

child 10164204 20020606 US

parent division-of 09098219 19980616 US GRANTED

parent-patent 6441277 US

non-provisional-of-provisional 60049955 19970617 US

US-CL-CURRENT: 800/284, 435/189 , 435/320.1 , 435/419 , 536/23.2

ABSTRACT:

Fructose-1,6-bisphosphate aldolase (FDA) is an enzyme reversibly catalyzing the reaction converting triosephosphate into fructose-1,6-bisphosphate. In the leaf, this enzyme is located in the chloroplast (starch synthesis) and the cytosol (sucrose biosynthesis). Transgenic plants were generated that express the E. coli fda gene in the chloroplast to improve plant yield by increasing leaf starch biosynthetic ability in particular and sucrose production in general. Leaves from plants expressing the fda transgene showed a significantly higher starch accumulation, as compared to control plants expressing the null vector, particularly early in the photoperiod, but had lower leaf sucrose. Transgenic plants also had a significantly higher root mass. Furthermore, transgenic potatoes expressing fda exhibited improved uniformity of solids.

[0001] This application is based on U.S. Provisional Application Serial No. 60/049,995, filed Jun. 17, 1997.

----- KWIC -----

Summary of Invention Paragraph - BSTX (26):

[0024] First, increasing the expression of the FDA enzyme in the chloroplast would increase the flow of carbon through the Calvin Cycle and increase atmospheric carbon assimilation during early photoperiod. This would result in an increase in photosynthetic efficiency and an increase in chloroplast starch production (a leaf carbon storage form degraded during periods when photosynthesis is low or absent). Both of these responses would lead to an increase in sucrose production by the leaf and a net increase in carbon export during a given photoperiod. This increase in source capacity is a desirable trait in crop plants and would lead to increased plant growth, storage ability, yield, vigor, and stress tolerance.

Summary of Invention Paragraph - BSTX (28):

[0026] Third, expression of FDA in sink tissues can show several desirable traits, such as increased amino acid and/or fatty acid pools via increases in carbon flux through glycolysis (and thus pyruvate levels) in seeds or other sinks and increased starch levels as result of increased production of glucose 6-phosphate in seeds, roots, stems, and tubers where starch is a major storage nonstructural carbohydrate (reverse glycolysis). This increase in sink strength is a desirable trait in crop plants and would lead to increased plant growth, storage ability, yield, vigor, and stress tolerance.

Detail Description Paragraph - DETX (2):

[0038] This invention is directed to a method for producing plant cells and plants demonstrating an increased or improved growth and development, yield, quality, starch storage uniformity, vigor, and/or stress tolerance. The method utilizes a DNA sequence encoding an fda (fructose 1,6 bisphosphate aldolase) gene integrated in the cellular genome of a plant as the result of genetic engineering and causes expression of the FDA enzyme in the transgenic plant so produced. Plants that overexpress the FDA enzyme exhibit increased carbon flow through the Calvin Cycle and increased atmospheric carbon assimilation during early photoperiod resulting in an increase in photosynthetic efficiency and an increase in starch production. Thus, such plants exhibit higher levels of sucrose production by the leaf and the ability to achieve a net increase in carbon export during a given photoperiod. This increase in source capacity leads to increased plant growth that in turn generates greater biomass and/or increases the size of the sink and ultimately providing greater yields of the transgenic plant. This greater biomass or increased sink size may be evidenced in different ways or plant parts depending on the particular plant species or growing conditions of the plant overexpressing the FDA enzyme. Thus, increased size resulting from overexpression of FDA may be seen in the seed, fruit, stem, leaf, tuber, bulb or other plant part depending upon the plant species and its dominant sink during a particular growth phase and upon the environmental effects caused by certain growing conditions, e.g. drought, temperature or other stresses. Transgenic plants overexpressing FDA may therefore have increased carbon assimilation, export and storage in plant source and sink organs, which results in growth, yield, and uniformity and quality improvements.

Detail Description Paragraph - DETX (3):

[0039] Plants overexpressing FDA may also exhibit desirable quality traits such as increased production of starch, oils and/or proteins depending upon the plant species overexpressing the FDA. Thus, overexpression of FDA in a particular plant species may affect or alter the direction of the carbon flux thereby directing metabolite utilization and storage either to starch

production, protein production or oil production via the role of FDA in the glycolysis and gluconeogenesis metabolic pathways.

Detail Description Paragraph - DETX (36):

[0066] A recombinant DNA molecule of the invention typically includes a selectable marker so that transformed cells can be easily identified and selected from non-transformed cells. Examples of such include, but are not limited to, a neomycin phosphotransferase (nptII) gene (Potrykus et al., 1985), which confers kanamycin resistance. Cells expressing the nptII gene can be selected using an appropriate antibiotic such as kanamycin or G418. Other commonly used selectable markers include the bar gene, which confers bialaphos resistance; a mutant EPSP synthase gene (Hinchee et al., 1988), which confers glyphosate resistance; a nitrilase gene, which confers resistance to bromoxynil (Stalker et al., 1988); a mutant acetolactate synthase gene (ALS), which confers imidazolinone or sulphonylurea resistance (European Patent Application 154,204, 1985); and a methotrexate resistant DHFR gene (Thillet et al., 1988).

Detail Description Paragraph - DETX (88):

[0115] This increase in sucrose export by fda-expressing leaves is an illustration of an increase in source capacity, very likely due to an increased carbon flow through the Calvin Cycle (in response to increased triose-P utilization) and thus an increase in net carbon utilization by the leaf. As seen in Table 2, the increase in sucrose loading in the phloem correlates with the level of fda expression.

Detail Description Paragraph - DETX (95):

[0121] For the cytosolic expression of the fda gene in corn plants, a construct was made in which the fda gene sequence was fused to the backbone of a vector containing the enhanced CaMV 35S promoter (e35S; Kay et al., 1987), the HSP70 intron (U.S. Pat. No. 5,593,874), and the NOS3' polyadenylation sequence (Fraley et al., 1983). This created a NotI cassette [P-e35S/HSP70 intron/fda/NOS3'] that was cloned into the NotI site of pMON30460, a monocot transformation vector, to form the plant transformation vector pMON13925, as shown in FIG. 5. pMON30460 contains an expression cassette for the selectable marker neomycin phosphotransferase typell gene (nptII) [P-35S/NPTII/NOS3'] and a unique NotI site for cloning the gene of interest. The final vector (pMON13925) was constructed so that the gene of interest and the selectable marker gene were cloned in the same orientation. A vector fragment containing the expression cassettes for these gene sequences could be excised from the bacterial selector (Kan) and ori, gel purified, and used for plant transformation.

Detail Description Paragraph - DETX (99):

[0125] Transgenic maize plants transformed with the vectors pMON13925 (described above) or pMON17590 (described above) were produced using microprojectile bombardment, a procedure well-known to the art (Fromm, 1990; Gordon-Kamm et al., 1990; Walters et al., 1992). Embryogenic callus initiated from immature maize embryos was used as a target tissue. Plasmid DNA at 1 mg/mL in TE buffer was precipitated onto M10 tungsten particles using a calcium chloride/spermidine procedure, essentially as described by Klein et al. (1988). In addition to the gene of interest, the plasmids also contained the neomycin phosphotransferase II gene (nptII) driven by the 35S promoter from Cauliflower Mosaic Virus. The embryogenic callus target tissue was pretreated on culture medium osmotically buffered with 0.2M mannitol plus 0.2M sorbitol for approximately four hours prior to bombardment (Vain et al., 1993). Tissue was bombarded two times with the DNA-coated tungsten particles using the gunpowder version of the BioRad Particle Delivery System (PDS) 1000 device. Approximately 16 hours following bombardment, the tissue was subcultured onto a medium of the same composition except that it contained no mannitol or

sorbitol, and it contained an appropriate aminoglycoside antibiotic, such as G418", to select for those cells that contained and expressed the 35S/nptII gene. Actively growing tissue sectors were transferred to fresh selective medium approximately every 3 weeks. About 3 months after bombardment, plants were regenerated from surviving embryogenic callus essentially as described by Duncan and Widholm (1988).

Detail Description Paragraph - DETX (114):

[0139] A second potato transformation vector was constructed by cloning the NotI cassette [P-FMV/CTP2/fda/NOS3'] (described earlier) into the unique NotI site of pMON23616. pMON23616 is a potato transformation vector containing the nopaline-type T-DNA right border region (Fraley et al., 1985), an expression cassette for the neomycin phosphotransferase typell gene [P-35S/NPTII/NOS3'] (selectable marker), a unique NotI site for cloning the gene expression cassette of interest, and the T-DNA left border region (Barker et al., 1983). Cloning of the NotI cassette [P-FMV/CTP2/fda/NOS3'] (described earlier) into the NotI site of pMON23616 results in the potato transformation vector pMON17581, as shown in FIG. 8. The vector pMON17581 was constructed such that the gene of interest and the selectable marker gene were transcribed in the same direction.



PGPUB-DOCUMENT-NUMBER: 20040019931

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040019931 A1

TITLE: Methods and compositions for modifying oil and protein  
content in plants

PUBLICATION-DATE: January 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tarczynski, Mitchell C.	West Des Moines	IA	US	
Li, Changjiang	Urbandale	IA	US	

APPL-NO: 09/ 930906

DATE FILED: August 16, 2001

RELATED-US-APPL-DATA:

non-provisional-of-provisional 60226142 20000818 US

US-CL-CURRENT: 800/281, 435/194 , 435/320.1 , 435/419 , 435/69.1 , 536/23.2

ABSTRACT:

Compositions and methods for altering pyruvate synthesis in plants are provided. The compositions and methods find use in increasing the oil or protein content of plant tissues, particularly seeds. Novel isolated nucleotide molecules encoding cytosolic and plastidic pyruvate kinases are provided. The methods involve introducing into a plant nucleotide sequences encoding enzymes that alter pyruvate synthesis. Additionally provided are isolated pyruvate kinases and transformed plants, plant tissues, plant cells, and seeds thereof.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 60/226,142, filed Aug. 18, 2000, which is hereby incorporated herein in its entirety by reference.

----- KWIC -----

Summary of Invention Paragraph - BSTX (24):

[0021] If desired, one or more additional nucleotide constructs may be introduced into the plant. Such additional nucleotide constructs can comprise, for example, at least a portion of a nucleotide sequence of an enzyme, or other protein, that is capable of affecting the synthesis of pyruvate in the cytosol. If expression of the nucleotide sequence is desired, the nucleotide construct can additionally comprise an operably linked promoter. The invention does not depend on a particular nucleotide sequence. Any nucleotide sequence originating from a gene or transcript that encodes an enzyme or protein that is capable of increasing or decreasing the synthesis and/or level of pyruvate in the cytosol can be employed. Typically, such an enzyme or protein is capable of altering the amount of PEP that is available in the cytosol for the

formation of pyruvate. If a decreased level or activity of such an enzyme or protein is desired, the methods of the invention may additionally comprise anti-sense suppression, co-suppression, or chimeraplasty.

Summary of Invention Paragraph - BSTX (29):

[0026] Methods are provided for altering the metabolism of pyruvate in plastids. The methods find use in increasing the synthesis of fatty acids and/or oil in a plant, or part thereof. In particular, the methods find use in the production of improved cultivars of crop plants having seeds with increased levels of oil. By increasing the flux of carbon toward oil biosynthesis, increased levels of oil, fatty acids, oil precursors, and specialty molecules that are synthesized from oil precursors can be achieved in a plant, or part thereof. The methods involve introducing into a plant at least one nucleotide construct comprising at least a portion of a nucleotide sequence encoding a pyruvate kinase or an NADP.sup.+ -dependent malic enzyme. In some embodiments of the invention, both a pyruvate kinase nucleotide sequence and a NADP.sup.+ -dependent malic enzyme nucleotide sequence are introduced into the plant. Such nucleotide sequences can be introduced into the plant as a single nucleotide molecule comprising both the pyruvate kinase and a NADP.sup.+ -dependent malic enzyme nucleotide sequences. Alternatively, the pyruvate kinase and a NADP.sup.+ -dependent malic enzyme nucleotide sequences can be introduced into the plant on two separate nucleotide molecules.

Summary of Invention Paragraph - BSTX (33):

[0030] If desired, one or more additional nucleotide constructs may be introduced into the plant. Such additional nucleotide constructs can comprise, for example, at least a portion of a nucleotide sequence encoding an enzyme, or other protein, that is capable of affecting the synthesis or the level of pyruvate in the plastid. If expression of the nucleotide sequence is desired, the nucleotide construct can additionally comprise an operably linked promoter. The invention does not depend on a particular nucleotide sequence. Any nucleotide sequence that encodes an enzyme, or protein, that is capable of increasing or decreasing the synthesis of pyruvate in the cytosol can be employed. Typically, such an enzyme or protein is capable of altering the amount of PEP, malate, or both that is available for the formation of pyruvate within the plastid. Such an enzyme can be localized in any compartment or organelle of the cell, including, but not limited to, the cytosol, plastids, mitochondria, and vacuoles. If a decreased level or activity of such an enzyme or protein is desired, the methods of the invention may additionally comprise anti-sense suppression, co-suppression, chimeraplasty, and dominant-negative strategies.

Summary of Invention Paragraph - BSTX (38):

[0035] To reduce or eliminate the conversion of malate to pyruvate in mitochondria, the plant can be transformed with a nucleotide construct comprising at least a portion of an NAD.sup.+ -dependent malic enzyme nucleotide sequence. Malate that is formed in the cytosol, instead of entering the chloroplast, can enter the mitochondria where it can be decarboxylated to form pyruvate, which can then be converted into acetyl-CoA. Acetyl-CoA can then enter the TCA cycle. Reducing or eliminating the decarboxylation of malate in plant mitochondria by antisense suppression of mitochondrial NAD.sup.+ -dependent malic enzyme is known to increase the flux of carbon to plastids in plant storage tissues. See WO 98/23757, herein incorporated by reference.

Summary of Invention Paragraph - BSTX (40):

[0037] While the methods of the present invention do not depend on a particular biological mechanism for increasing the oil or other desired product, it is recognized the methods of the present invention can lead to a

disruption in the metabolism of the plant leading to an increased flux of carbon flux to the plastids. This increased carbon flux may be the result of an increased rate of transport of malate from the cytosol to the plastids. Other cytosolic metabolites may, however, contribute to the increased flux of carbon to the plastid. Such metabolites include, but are not limited to, 3-phosphoglyceric acid and dihydroxyacetone phosphate.

Summary of Invention Paragraph - BSTX (89):

[0086] Root-preferred promoters are known and can be selected from the many available from the literature or isolated de novo from various compatible species. See, for example, Hire et al. (1992) *Plant Mol. Biol.* 20(2): 207-218 (soybean root-preferred glutamine synthetase gene); Keller and Baumgartner (1991) *Plant Cell* 3(10):1051-1061 (root-preferred control element in the GRP 1.8 gene of French bean); Sanger et al. (1990) *Plant Mol. Biol.* 14(3):433-443 (root-preferred promoter of the mannopine synthase (MAS) gene of *Agrobacterium tumefaciens*); and Miao et al. (1991) *Plant Cell* 3(1):11-22 (full-length cDNA clone encoding cytosolic glutamine synthetase (GS), which is expressed in roots and root nodules of soybean). See also Bogusz et al. (1990) *Plant Cell* 2(7):633-641, where two root-preferred promoters isolated from hemoglobin genes from the nitrogen-fixing nonlegume *Parasponia andersonii* and the related non-nitrogen-fixing nonlegume *Trema tomentosa* are described. The promoters of these genes were linked to a .beta.-glucuronidase reporter gene and introduced into both the nonlegume *Nicotiana tabacum* and the legume *Lotus corniculatus*, and in both instances root-preferred promoter activity was preserved. Leach and Aoyagi (1991) describe their analysis of the promoters of the highly expressed rolC and rolD root-inducing genes of *Agrobacterium rhizogenes* (see *Plant Science (Limerick)* 79(1):69-76). They concluded that enhancer and tissue-preferred DNA determinants are dissociated in those promoters. Teeri et al. (1989) used gene fusion to lacZ to show that the *Agrobacterium* T-DNA gene encoding octopine synthase is especially active in the epidermis of the root tip and that the TR2' gene is root specific in the intact plant and stimulated by wounding in leaf tissue, an especially desirable combination of characteristics for use with an insecticidal or larvicidal gene (see *EMBO J.* 8(2):343-350). The TR1' gene, fused to nptII (neomycin phosphotransferase II) showed similar characteristics. Additional root-preferred promoters include the VfENOD-GRP3 gene promoter (Kuster et al. (1995) *Plant Mol. Biol.* 29(4):759-772); and rolB promoter (Capana et al. (1994) *Plant Mol. Biol.* 25(4):681-691. See also U.S. Pat. Nos. 5,837,876; 5,750,386; 5,633,363; 5,459,252; 5,401,836; 5,110,732; and 5,023,179.

Summary of Invention Paragraph - BSTX (91):

[0088] Generally, the expression cassette will comprise a selectable marker gene for the selection of transformed cells. Selectable marker genes are utilized for the selection of transformed cells or tissues. Marker genes include genes encoding antibiotic resistance, such as those encoding neomycin phosphotransferase II (NEO) and hygromycin phosphotransferase (HPT), as well as genes conferring resistance to herbicidal compounds, such as glufosinate ammonium, bromoxynil, imidazolinones, and 2,4-dichlorophenoxyacetate (2,4-D). See generally, Yarranton (1992) *Curr. Opin. Biotech.* 3:506-511; Christopherson et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:6314-6318; Yao et al. (1992) *Cell* 71:63-72; Reznikoff (1992) *Mol. Microbiol.* 6:2419-2422; Barkley et al. (1980) in *The Operon*, pp. 177-220; Hu et al. (1987) *Cell* 48:555-566; Brown et al. (1987) *Cell* 49:603-612; Figge et al. (1988) *Cell* 52:713-722; Deuschle et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:5400-5404; Fuerst et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:2549-2553; Deuschle et al. (1990) *Science* 248:480-483; Gossen (1993) Ph.D. Thesis, University of Heidelberg; Reines et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:1917-1921; Labow et al. (1990) *Mol. Cell. Biol.* 10:3343-3356; Zambretti et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:3952-3956; Baim et al (1991) *Proc. Natl.*

Acad. Sci. USA 88:5072-5076; Wyborski et al. (1991) Nucleic Acids Res. 19:4647-4653; Hillenand-Wissman (1989) Topics Mol. Struc. Biol. 10:143-162; Degenkolb et al. (1991) Antimicrob. Agents Chemother. 35:1591-1595; Kleinschmidt et al. (1988) Biochemistry 27:1094-1104; Bonin (1993) Ph.D. Thesis, University of Heidelberg; Gossen et al. (1992) Proc. Natl. Acad Sci USA 89:5547-5551; Oliva et al. (1992) Antimicrob. Agents Chemother. 36:913-919; Hlavka et al. (1985) Handbook of Experimental Pharmacology, Vol. 78 (Springer-Verlag, Berlin); Gill et al. (1988) Nature 334:721-724. Such disclosures are herein incorporated by reference.

Detail Description Paragraph - DETX (28):

[0124] A selectable marker gene that can be used to facilitate soybean transformation is a transgene composed of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) Nature 313:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 (from E. coli; Gritz et al. (1983) Gene 25:179-188), and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of Agrobacterium tumefaciens. The expression cassette comprising the pyruvate kinase or malic enzyme nucleotide sequence operably linked to a seed-preferred promoter can be isolated as a restriction fragment. This fragment can then be inserted into a unique restriction site of the vector carrying the marker gene.

PGPUB-DOCUMENT-NUMBER: 20040018503

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040018503 A1

TITLE: Nucleotide sequence of the haemophilus influenza Rd  
genome, fragments thereof, and uses thereof

PUBLICATION-DATE: January 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fleischmann, Robert D.	Gaithersburg	MD	US	
Adams, Mark D.	Rockville	MD	US	
White, Owen	Rockville	MD	US	
Smith, Hamilton O.	Reisterstown	MD	US	
Venter, J. Craig	Queenstown	MD	US	

APPL-NO: 10/ 329670

DATE FILED: December 27, 2002

RELATED-US-APPL-DATA:

child 10329670 A1 20021227

parent division-of 09643990 20000823 US GRANTED

parent-patent 6528289 US

child 09643990 20000823 US

parent continuation-of 08487429 19950607 US GRANTED

parent-patent 6468765 US

child 08487429 19950607 US

parent continuation-in-part-of 08426787 19950421 US ABANDONED

US-CL-CURRENT: 435/6, 435/252.3, 435/320.1, 435/69.3, 530/350, 530/388.4  
, 536/23.7

ABSTRACT:

The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO: 1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique NotI restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a divisional of and claims priority under 35 U.S.C. .sctn. 120 to U.S. application Ser. No. 09/643,990, filed Aug. 23, 2000, which is a continuation of and claims priority under 35 U.S.C. .sctn. 120 to U.S. application Ser. No. 08/487,429, filed Jun. 7, 1995, which is a continuation-in-part of and claims priority under 35 U.S.C. .sctn. 120 to U.S. application Ser. No. 08/426,787, filed Apr. 21, 1995, which is hereby incorporated by reference in its entirety.

----- KWIC -----

Detail Description Paragraph - DETX (206):

[0242] In order to survive as a free living organism, *H. influenzae* must produce energy in the form of ATP via fermentation and/or electron transport. As a facultative anaerobe, *H. influenzae* Rd is known to ferment glucose, fructose, galactose, ribose, xylose and fucose (Dorocicz et al., J. Bacteriol. 175:7142 (1993)). The genes identified in Table 1(a) indicate that transport systems are available for the uptake of these sugars via the phosphoenolpyruvate-phosphotransferase system (PTS), and via non-PTS mechanisms. Genes that specify the common phosphate-carriers Enzyme I and Hpr (ptsI and ptsH) of the PTS system were identified as well as the glucose specific crr gene. The ptsH, ptsI, and crr genes constitute the pts operon. We have not however identified the gene encoding membrane-bound glucose specific Enzyme II. The latter enzyme is required for transport of glucose by the PTS system. A complete PTS system for fructose was identified.

Detail Description Table CWU - DETL (10):

HI1275 1347862 1348650 ferric enterobactin transport ATP-binding protein (fepC) [*Escherichia coli*] 29.4 51.3 238 HI1475 1555193 1554435 ferric enterobactin transport ATP-binding protein (fepC) [*Escherichia coli*] 33.2 54.8 220 HI1471 1549654 1551853 ferrichrome-iron receptor (fhuA) [*Escherichia coli*] 26.4 48.9 710 HI1388 1479930 1480475 ferritin like protein (rsgA) [*Escherichia coli*] 57.4 79.0 162 HI1389 1480494 1480988 ferritin like protein (rsgA) [*Escherichia coli*] 57.3 73.8 164 HI0363 385804 384887 iron(III) dicitrate transport ATP-binding protein FECE [*Escherichia coli*] 35.9 56.4 220 HI1274 1347324 1347861 iron(III) dicitrate transport system permease protein (fecD) [*Escherichia coli*] 36.0 64.0 255 HI1037 1099321 1100265 magnesium and cobalt transport protein (corA) [*Escherichia coli*] 70.3 84.8 316 HI0097 103798 104679 major ferric iron binding protein precursor (fbp) [*Neisseria gonorrhoeae*] 69.7 82.3 293 HI1051 1114308 1114635 mercuric transport protein (merT) [*Pseudomonas aeruginosa*] 25.0 55.2 99 HI1052 1114651 1114926 mercury scavenger protein (merP) [*Pseudomonas fluorescens*] 29.3 45.7 91 HI0294 327396 327193 mercury scavenger protein (merP) [*Pseudomonas fluorescens*] 32.8 67.2 67 HI1531 1594953 1594219 molybdate-binding periplasmic protein precursor (modB) [*Azotobacter vinelandii*] HI0226 254880 253681 NA(+)/H(+) antiporter 1 (rhaA) [*Escherichia coli*] 52.6 74.6 380 HI0429 448992 450557 Na<sup>+</sup>/H<sup>+</sup> antiporter (nhaB) [*Escherichia coli*] 70.6 87.5 501 HI1110 1171933 1170530 Na<sup>+</sup>/H<sup>+</sup> antiporter (nhaC) [*Bacillus firmus*] 37.5 62.0 382 HI0098 104899 106317 periplasmic-binding-protein-dependent iron transport protein (stuB) 38.1 59.5 457 [*Serratia marcescens*] HI1479 1558763 1558167 periplasmic-binding-protein-dependent iron transport protein (sfuC) 39.9 58.0 197 [*Serratia marcescens*] HI0913 964424 966276 potassium efflux system (kelC) [*Escherichia coli*] 40.9 65.7 594 HI0292 326934 324769 potassium/copper-transportING ATPase A (copA) [*Enterococcus faecalis*] 42.9 64.4 723 HI1355 1429787 1428276 sodium/proline symporter (proline permease) (putP) [*Escherichia coli*] 62.8 79.1 489 HI0252 283326 282517 tonB protein (tonB) [*Haemophilus influenzae*] 96.2 98.5 261 HI0627 664922 666362 TRK system potassium uptake protein (trkA) [*Escherichia coli*] 65.8 83.4 458 Carbohydrates, organic alcohols & acids HI0020 22097 20661

2-oxoglutarate/malate translocator (SODiT1) [*Spinacia oleracea*] 35.8 59.6 452  
 HI0824 872894 873940 D-galactose-binding periplasmic protein (mglB)  
 [*Escherichia coli*] 67.6 81.2 329 HI1113 1176024 1174516 D-xylose transport  
 ATP-binding protein (xylG) [*Escherichia coli*] 71.5 85.8 501 HI1114 1177073  
 1176078 D-xylose-binding periplasmic protein (rbsB) [*Escherichia coli*] 76.0  
 88.4 328 HI1718 1785024 1783300 enzyme I (ptsI) [*Salmonella typhimurium*] 70.2  
 84.3 574 HI0182 194818 193967 formate transporter (formate channel)  
 [*Escherichia coli*] 53.2 73.4 263 HI0450 471781 470285 fructose-permease  
 IIA/FPR component (fruB) [*Escherichia coli*] 51.5 68.3 374 HI0448 469337  
 467670 fructose-permease IIBC component (truA) [*Escherichia coli*] 57.2 72.2  
 552 HI0614 643282 642851 fucose operon protein (fucu) [*Escherichia coli*] 66.3  
 80.0 94 HI0692 733673 734484 glpF protein (glpF) [*Escherichia coli*] 73.6 87.2  
 258 HI1019 1080518 1081194 glpF protein (glpP) [*Escherichia coli*] 30.6 54.6  
 208 HI1017 1078404 1079867 gluconate permease (gntP) [*Bacillus subtilis*] 29.1  
 56.4 442 HI1717 1783237 1782740 glucose phosphotransferase enzyme III-glc  
 (crr) [*Escherichia coli*] 73.2 83.3 169 HI0688 729474 730914  
 glycerol-3-phosphatase transporter (glpT) [*Escherichia coli*] 64.5 78.9 445  
 HI0504 517869 519347 high affinity ribose transport protein (rbsA)  
 [*Escherichia coli*] 71.1 85.4 494 HI0505 519363 520331 high affinity ribose  
 transport protein (rbsC) [*Escherichia coli*] 68.0 86.5 303 HI0503 517436  
 517852 high affinity ribose transport protein (rbsD) [*Escherichia coli*] 59.0  
 78.4 139 HI0612 542139 640856 L-fucose permease (fucP) [*Escherichia coli*]  
 35.6 57.9 413 HI1221 1288578 1286983 L-lactate permease (lctP) [*Escherichia*  
*coli*] 30.2 53.9 532 HI1735 1802527 1801757 lactam utilization protein (lamB)  
 [*Emerella nidulans*] 41.3 60.3 130 HI0825 874009 875526 mglA protein (mglA)  
 [*Escherichia coli*] 73.9 84.6 506 HI0826 875546 876553 mglC protein (mglC)  
 [*Escherichia coli*] 79.2 90.2 336 HI0506 520354 521229 periplasmic  
 ribose-binding protein (rbsB) [*Escherichia coli*] 73.9 86.6 291 HI1719 1785361  
 1785107 phosphohistidinoprotein- -hexose phosphotransferase (ptsH)  
 [*Escherichia coli*] 77.6 88.2 85 HI0830 878480 878773 potassium channel  
 homolog (kch) [*Escherichia coli*] 67.7 80.2 96 HI0154 170140 168807 putative  
 aspartate transport protein (dcuA) [*Escherichia coli*] 46.4 69.9 436 HI0748  
 803856 805175 putative aspartate transport protein (dcuA) [*Escherichia coli*]  
 42.6 70.1 435 HI1112 1174509 1173385 ribose transport permease protein (xylH)  
 [*Escherichia coli*] 69.8 84.1 371 HI1696 1759373 1760743 sodium- and  
 chloride-dependent GABA transporter [*Homo sapiens*] 29.3 52.6 471 HI0738  
 790926 789403 sodium-dependent noradrenaline transporter [*Homo sapiens*] 31.1  
 54.2 523 Nucleosides, purines & pyrimidines HI1089 1151815 1151024  
 ribonucleotide transport ATP-binding protein (mkl) [*Mycobacterium leprae*] 42.2  
 61.5 244 HI1230 1296319 1295078 uracil permease (ursA) [*Escherichia coli*]  
 37.2 61.6 400 Anions HI1104 1164213 1165028 cysteine synthetase (cysZ)  
 [*Escherichia coli*] 53.7 76.3 190 HI1697 1761825 1760773 hydrophilic  
 membrane-bound protein (modC) [*Escherichia coli*] 55.9 74.5 263 HI1698 1762501  
 1761815 hydrophobic membrane-bound protein (modB) [*Escherichia coli*] 65.9 84.8  
 223 HI1384 1477430 1476585 integral membrane protein (patA) [*Escherichia*  
*coli*] 59.6 77.6 272 HI0356 380045 380764 nitrate transporter ATPase component  
 (nasD) [*Klebsiella pneumoniae*] 34.9 57.8 254 HI1383 1475710 1475584 peripheral  
 membrane protein B (pstB) [*Escherichia coli*] 77.0 86.8 256 HI1385 1478379  
 1477435 peripheral membrane protein C (pstC) [*Escherichia coli*] 57.3 78.7 300  
 HI1386 1479246 1478473 periplasmic phosphate-binding protein (pstS)  
 [*Escherichia coli*] 49.8 67.7 256 HI1387 1479247 1479929 periplasmic  
 phosphate-binding protein (pstS) [*Escherichia coli*] 63.8 75.4 69 HI1610  
 1669474 1670733 phosphate permease (YBR296C) [*Saccharomyces cerevisiae*] 35.6  
 60.0 551 Other HI0060 62564 60804 ATP dependent translocator homolog (msbA)  
 [*Haemophilus influenzae*] 100.0

PGPUB-DOCUMENT-NUMBER: 20040014118

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040014118 A1

TITLE: Detection of group a streptococcus

PUBLICATION-DATE: January 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Uhl, James R.	Rochester	MN	US	
Cockerill, Franklin R.	Rochester	MN	US	

APPL-NO: 10/ 465205

DATE FILED: June 19, 2003

RELATED-US-APPL-DATA:

child 10465205 A1 20030619

parent continuation-of 10081923 20020220 US GRANTED

parent-patent 6593093 US

US-CL-CURRENT: 435/6, 435/91.2

ABSTRACT:

The invention provides methods to detect Group A Streptococcus (GAS) in biological samples using real-time PCR. Primers and probes for the detection of GAS are provided by the invention. Articles of manufacture containing such primers and probes for detecting GAS are further provided by the invention.

----- KWIC -----

Detail Description Paragraph - DETX (7):

[0021] A metabolic pathway chart showing the phosphoenolpyruvate:phosphotransferase system is available at <http://www.genome.ad.jp/kegg/pathway/eco/eco02060.html>. Briefly, the phosphoenolpyruvate:phosphotransferase system (pep:pts or pts) is composed of two enzymes, HPr and enzyme I (or EI) encoded by the ptsH and ptsI genes, respectively. Enzyme I is autophosphorylated by phosphoenolpyruvate. Phosphorylated EI then catalyzes the phosphorylation of HPr in the membrane. HPr phosphorylates a sugar-specific enzyme that is translocated across the membrane. Thus, E1 and HPr are necessary for sugar translocation. The phosphotransferase system is reviewed by, for example, Postma et al. (1993, Microbiol. Rev., 57:543-94) and the pts operon is reviewed by, for example, Vadeboncoeur et al. (2000, J. Mol. Microbiol. Biotechnol., 2:483-90).

Detail Description Paragraph - DETX (8):

[0022] The invention provides methods to detect GAS by amplifying, for example, GAS nucleic acid molecules corresponding to a portion of the ptsI gene encoding enzyme I (EI) of the phosphoenolpyruvate:sugar phosphotransferase system. GAS nucleic acid molecules other than those exemplified herein (e.g.,



other than ptsI) also can be used to detect GAS in a sample and are known to those of skill in the art. Nucleic acid sequences encoding GAS ptsI have been described (see, for example, Ferretti et al., 2001, Proc. Natl. Acad. Sci. USA, 98:4658-63; and GenBank Accession Nos. NC 002737, and AE004092). Specifically, primers and probes to amplify and detect GAS ptsI nucleic acid molecules are provided by the invention.

PGPUB-DOCUMENT-NUMBER: 20040009466

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040009466 A1

TITLE: Method for determining gene knockouts

PUBLICATION-DATE: January 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Maranas, Costas D.	Port Matilda	PA	US	
Burgard, Anthony P.	State College	PA	US	
Pharkya, Priti	State College	PA	US	

APPL-NO: 10/ 616659

DATE FILED: July 9, 2003

RELATED-US-APPL-DATA:

non-provisional-of-provisional 60395763 20020710 US

non-provisional-of-provisional 60417511 20021009 US

non-provisional-of-provisional 60444933 20030203 US

US-CL-CURRENT: 435/4, 435/6, 702/20

ABSTRACT:

A method for determining candidates for gene deletions and additions using a model of a metabolic network associated with an organism, the model includes a plurality of metabolic reactions defining metabolite relationships, the method includes selecting a bioengineering objective for the organism, selecting at least one cellular objective, forming an optimization problem that couples the at least one cellular objective with the bioengineering objective, and solving the optimization problem to yield at least one candidate.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is based on U.S. Patent Application Serial No. 60/395,763, filed Jul. 10, 2002; U.S. Patent Application Serial No. 60/417,511, filed Oct. 9, 2002, and U.S. Patent Application Serial No. 60/444,933, filed Feb. 3, 2003, each of which is herein incorporated by reference in its entirety.

----- KWIC -----

Detail Description Paragraph - DETX (12):

[0029] is a minimum level of biomass production. The vector  $v$  includes both internal and transport reactions. The forward (i.e., positive) direction of transport fluxes corresponds to the uptake of a particular metabolite, whereas the reverse (i.e., negative) direction corresponds to metabolite secretion. The uptake of glucose through the phosphotransferase system and glucokinase are denoted by  $v_{\text{sub.pts}}$  and  $v_{\text{sub.glk}}$ , respectively. Transport fluxes for

metabolites that can only be secreted from the network are members of .sub.secr.sub..sub.--.sub.onl- y. Note also that the complete set of reactions is subdivided into reversible .sub.rev and irreversible .sub.irrev reactions. The cellular objective is often assumed to be a drain of biosynthetic precursors in the ratios required for biomass formation (Neidhardt and Curtiss, 1996). The fluxes are reported per 1 gDW.multidot.hr such that biomass formation is expressed as g biomass produced/gDW.multidot.hr or 1/hr.

#### Detail Description Paragraph - DETX (31):

[0046] Which reactions, if any, that could be removed from the E. coli K-12 stoichiometric model (Edwards and Palsson, 2000) so as the remaining network produces succinate or lactate whenever biomass maximization is a good descriptor of flux allocation were identified. A prespecified amount of glucose (10 mmol/gDW.multidot.hr), along with unconstrained uptake routes for inorganic phosphate, oxygen, sulfate, and ammonia are provided to fuel the metabolic network. The optimization step could opt for or against the phosphotransferase system, glucokinase, or both mechanisms for the uptake of glucose. Secretion routes for acetate, carbon dioxide, ethanol, formate, lactate and succinate are also enabled. Note that because the glucose uptake rate is fixed, the biomass and product yields are essentially equivalent to the rates of biomass and product production, respectively. In all cases, the OptKnock procedure eliminated the oxygen uptake reaction pointing at anaerobic growth conditions consistent with current succinate (Zeikus et al., 1999) and lactate (Datta et al., 1995) fermentative production strategies.

#### Detail Description Paragraph - DETX (33):

[0048] A less intuitive strategy was identified for mutant C which focused on inactivating two PEP consuming reactions rather than eliminating competing byproduct (i.e., ethanol, formate, and lactate) production mechanisms. First, the phosphotransferase system was disabled requiring the network to rely exclusively on glucokinase for the uptake of glucose. Next, pyruvate kinase was removed leaving PEP carboxykinase as the only central metabolic reaction capable of draining the significant amount of PEP supplied by glycolysis. This strategy, assuming that the maximum biomass yield could be attained, resulted in a succinate yield approaching 88% of the theoretical maximum. In addition, FIG. 3A revealed significant succinate production for every attainable biomass yield, while the maximum theoretical yield of succinate is the same as that for the wild-type strain.

#### Detail Description Table CWU - DETL (1):

1 Succinate max v.sub.biomass min .SIGMA.(v.sub.0 - v).sup.2 Biomass	
Succinate	ID Knockouts Enzyme (1/hr) (mmol/hr) (mmol/hr) Wild "Complete network"
0.38	0.12 0 A 1 COA + PYR .fwdarw. ACCOA + FOR Pyruvate formate lyase 0.31 10.70 1.65 2 NADH + PYR LAC + NAD Lactate dehydrogenase B 1 COA + PYR .fwdarw. ACCOA + FOR Pyruvate formate lyase 0.31 10.70 4.79 2 NADH + PYR LAC + NAD Lactate dehydrogenase 3 ACCOA + 2NADH COA + ETH + 2NAD Acetaldehyde dehydrogenase C 1 ADP + PEP .fwdarw. ATP + PYR Pyruvate kinase 0.16 15.15 6.21 2 ACTP + ADP AC + ATP or Acetate kinase ACCOA + Pi ACTP + COA Phosphotransacetylase 3 GLC + PEP .fwdarw. G6P + PYR <u>Phosphotransferase</u> system Lactate max v.sub.biomass min .SIGMA.(v.sub.0 - v).sup.2 Biomass
Lactate	ID Knockouts Enzyme (1/hr) (mmol/hr) (mmol/hr) Wild "Complete network"
0.38	0 0 A 1 ACTP + ADP AC + ATP or Acetate kinase 0.28 10.46 5.58 ACCOA + Pi ACTP + COA Phosphotransacetylase 2 ACCOA + 2NADH COA + ETH + 2NAD Acetaldehyde dehydrogenase B 1 ACTP + ADP AC + ATP or Acetate kinase 0.13 18.00 0.19 ACCOA + Pi ACTP + COA Phosphotransacetylase 2 ATP + F6P .fwdarw. ATP + FDP or Phosphofructokinase FDP T3P1 + T3P2 Fructose-1,6-bisphosphate aldolase C 1 ACTP + ADP AC + ATP or Acetate kinase 0.12 18.13 10.53 ACCOA + Pi ACTP + COA Phosphotransacetylase 2 ATP + F6P .fwdarw. ATP + FDP or Phosphofructokinase FDP T3P1 + T3P2 Fructose-1,6-bisphosphate aldolase 3

ACCOA + 2NADH COA + ETH + 2NAD Acetaldehyde dehydrogenase 4 GLC + ATP  
 .fwdarw. G6P + PEP Glucokinase 1,3-Propanediol max v.sub.biomass min  
 .SIGMA.(v.sub.0 - v).sup.2 Biomass 1,3-PD 1,3-PD ID Knockouts Enzyme (1/hr)  
 (mmol/hr) (mmol/hr) Wild "Complete network" 1.06 0 0 A 1 FDP .fwdarw. F6P +  
 Pi or Fructose-1,6-bisphosphatase 0.21 9.66 8.66 FDP T3P1 + T3P2  
 Fructose-1,6-bisphosphate aldolase 2 13PDG + ADP 3PG + ATP or  
 Phosphoglycerate kinase NAD + Pi + T3P1 13PDG + NADH  
 Glyceraldehyde-3-phosphate dehydrogenase 3 GL + NAD GLAL + NADH Aldehyde  
 dehydrogenase B 1 T3P1 T3P2 Triosphosphate isomerase 0.29 9.67 9.54 2 G6P +  
 NADP D6PGL + NADPH or Glucose 6-phosphate-1-dehydrogenase D6PGL .fwdarw.  
 D6PGC 6-Phosphogluconolactonase 3 DR5P .fwdarw. ACAL + T3P1  
 Deoxyribose-phosphate aldolase 4 GL + NAD GLAL + NADH Aldehyde dehydrogenase

Claims Text - CLTX (18):

17. The method of claim 1 wherein the bioengineering objective is  
 overproduction of succinate and at least one candidate is for gene deletion and  
 comprising genes coding for the enzymes pyruvate formate lyase, acetaldehyde  
 dehydrogenase, pyruvate kinase, FOF1-ATPase, NADH dehydrogenase I, fumarase,  
 D-Lactate dehydrogenase, pyridine nucleotide transhydrogenase,  
 phosphotransacetylase, acetate kinase, phosphotransferase, or combinations  
 thereof.

US-PAT-NO: 6846651

DOCUMENT-IDENTIFIER: US 6846651 B2

TITLE: Nucleotide sequence of the Haemophilus influenzae Rd genome, fragments thereof, and uses thereof

DATE-ISSUED: January 25, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fleischmann; Robert D.	Gaithersburg	MD	N/A	N/A
Adams; Mark D.	Rockville	MD	N/A	N/A
White; Owen	Gaithersburg	MD	N/A	N/A
Smith; Hamilton O.	Reistertown	MD	N/A	N/A
Venter; J. Craig	Queenstown	MD	N/A	N/A

APPL-NO: 10/ 158865

DATE FILED: June 3, 2002

PARENT-CASE:

This appln is a DIV of Ser. No. 09/557,884, filed Apr. 25, 2000, now U.S. Pat. No. 6,506,881 which is a con of Ser. No. 08/476,102 filed Jun. 7, 1995, now U.S. Pat. No. 6,355,450 which is a CIP of Ser. No. 08/426,787 filed Apr. 21, 1995, abandoned.

US-CL-CURRENT: 435/69.1, 435/252.3, 435/320.1, 536/23.7

ABSTRACT:

The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.

50 Claims, 47 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 47

----- KWIC -----

Detailed Description Text - DETX (203):

In order to survive as a free living organism, H. influenzae must produce energy in the form of ATP via fermentation and/or electron transport. As a facultative anaerobe, H. influenzae Rd is known to ferment glucose, fructose, galactose, ribose, xylose and fucose (Dorocicz et al., J. Bacteriol. 175:7142 (1993)). The genes identified in Table 1(a) indicate that transport systems are available for the uptake of these sugars via the

phosphoenolpyruvate-phosphotransferase system (PTS), and via non-PTS mechanisms. Genes that specify the common phosphate carriers Enzyme I and Hpr (ptsI and ptsH) of the PTS system were identified as well as the glucose specific crr gene. The ptsH, ptsI, and crr genes constitute the pts operon. We have not however identified the gene encoding membrane-bound glucose specific Enzyme II. The latter enzyme is required for transport of glucose by the PTS system. A complete FTS system for fructose was identified.

Detailed Description Paragraph Table - DETL (8):

influenzae) 96.2 98.5 261 HI0627 664922 666362 TRK system potassium uptake protein (trkA) (Escherichia coli) 85.8 83.4 458 Carbohydrates, organic alcohols & acids HI0020 22097 20661 2-oxoglutarate/malate translocator (SOD/T1) (Spinacia oleracea) 35.8 59.6 452 HI0824 872894 873940 D-galactose-binding periplasmic protein (mglB) (Escherichia coli) 67.6 81.2 329 HI1113 1176024 1174516 D-xylose transport ATP-binding protein (xylG) (Escherichia coli) 71.5 85.8 501 HI1114 1177073 1176076 D-xylose-binding periplasmic protein (rbsB) (Escherichia coli) 76.0 88.4 328 HI1718 1785024 1783300 enzyme 1 (ptsI) (Salmonella typhimurium) 70.2 84.3 574 HI0182 194818 193967 formate transporter (formate channel) (Escherichia coli) 53.2 73.4 263 HI0450 471781 470285 fructose-permease IIA/FPR component (fruB) (Escherichia coli) 51.5 68.3 374 HI0448 469337 467670 fructose-permease IIBC component (fruA) (Escherichia coli) 57.2 72.2 552 HI0614 643282 642851 fucose operon protein (fucU) (Escherichia coli) 66.3 80.0 94 HI0692 733673 734464 glpF protein (glpF) (Escherichia coli) 73.6 87.2 258 HI1019 1080518 1081194 glpF protein (glpF) (Escherichia coli) 30.6 54.6 208 HI1017 1078404 1079867 gluconate permease (gntP) (Bacillus subtilis) 29.1 56.4 442 HI1717 1783237 1782740 glucose phosphotransferase enzyme III-glc (crr) (Escherichia coli) 73.2 83.3 169 HI0688 729474 730914 glycerol-3-phosphatase transporter (glpT) (Escherichia coli) 64.5 78.9 445 HI0504 517869 519347 high affinity ribose transport protein (rbsA) (Escherichia coli) 71.1 85.4 494 HI0505 519363 520331 high affinity ribose transport protein (rbsC) (Escherichia coli) 68.0 86.5 303 HI0503 517436 517852 high affinity ribose transport protein (rbsD) (Escherichia coli) 59.0 78.4 139 HI0612 642139 640856 L-fucose permease (fucP) (Escherichia coli) 35.6 57.9 413 HI1221 1288578 1286983 L-lactate permease (lctP) (Escherichia coli) 30.2 53.9 532 HI1735 1802527 1801757 lactam utilization protein (lamB) (Emmericella nidulans) 41.3 60.3 130 HI0825 874009 875526 mglA protein (mglA) (Escherichia coli) 73.9 84.6 506 HI0826 875546 876553 mglC protein (mglC) (Escherichia coli) 79.2 90.2 336 HI0506 520354 521229 periplasmic ribose-binding protein (rbsB) (Escherichia coli) 73.9 86.6 291 HI1719 1785361 1785107 phosphohistidinoprotein-hexose phosphotransferase (ptsH) (Escherichia coli) 77.6 88.2 85 HI0830 878480 876773 potassium channel homolog (kch) (Escherichia coli) 67.7 80.2 96 HI0154 170140 168807 putative aspartate transport protein (dcuA) (Escherichia coli) 46.4 59.9 436 HI0748 803856 805175 putative aspartate transport protein (dcuA) (Escherichia coli) 42.6 70.1 435 HI1112 1174509 1173385 ribose transport permease protein (xylH) (Escherichia coli) 69.8 84.1 371 HI1696 1759373 1760743 sodium- and chloride-dependent GABA transporter (Homo sapiens) 29.3 52.6 471 HI0738 790926 789403 sodium-dependent noradrenaline transporter (Homo sapiens) 31.1 54.2 523 Nucleosides, purines & pyrimidines HI1089 1151815 1151024 ribonucleotide transport ATP-binding protein (mkl) (Mycobacterium leprae) 42.2 61.5 244 HI1230 1296319 1295078 uracil permease (uraA) (Escherichia coli) 37.2 61.6 400 Anions HI1104 1164213 1165028 cysteine synthetase (cysZ) (Escherichia coli) 53.7 76.3 190 HI1697 1761825 1760773 hydrophilic membrane-bound protein (modC) (Escherichia coli) 55.9 74.5 263 HI1698 1762501 1761815 hydrophobic membrane-bound protein (modB) (Escherichia coli) 65.9 84.8 223 HI1384 1477430 1476585 integral membrane protein (pstA) (Escherichia coli) 59.6 77.6 272 HI0358 380045 380764 nitrate transporter ATPase component (nasD) (Klebsiella pneumoniae) 34.9 57.8 254 HI1383 1475710 1476584 peripheral membrane protein B (pstB) (Escherichia coli) 77.0 86.8 256 HI1385 1478379

1477435 peripheral membrane protein C (pstC) (*Escherichia coli*) 57.3 78.7 300  
 HI1386 1479246 1478473 periplasmic phosphate-binding protein (pstS)  
 (*Escherichia coli*) 49.8 67.7 256 HI1387 1479247 1479929 periplasmic  
 phosphate-binding protein (pstS) (*Escherichia coli*) 63.8 75.4 89 HI1610  
 1669474 1670733 phosphate permease (YBR296C) (*Saccharomyces cerevisiae*) 35.6  
 60.0 551 Other HI0060 62564 60804 ATP dependent translocator homolog (msbA)  
 (*Haemophilus influenzae*) 100.0 100.0 458 HI0623 653683 662010 ATP-binding  
 protein (abc) (*Escherichia coli*) 74.0 86.5 200 HI1625 1686470 1686186 cystic  
 fibrosis transmembrane conductance regulator (*Bos taurus*) 35.3 60.8 233  
 HI0855 899042 900688 heme-binding lipoprotein (dppA) (*Haemophilus influenzae*)  
 98.9 99.3 547 HI0266 295639 298353 heme-hemopexin-binding protein (hxaA)  
 (*Haemophilus influenzae*) 82.1 89.5 928 HI1476 1556199 1555189 hemin permease  
 (hemU) (*Yersinia enterocolitica*) 36.1 62.7 325 HI0264 291684 293852 hemin  
 receptor precursor (hemR) (*Yersinia enterocolitica*) 28.5 45.9 578 HI1712  
 1779487 1777481 high-affinity choline transport protein (betT) (*Escherichia*  
*coli*) 34.7 61.6 653 HI0663 705327 703054 lactoferrin binding protein (lbpA)  
 (*Neisseria meningitidis*) 30.2 47.9 763 HI0610 637954 639336 Na<sup>+</sup>/sulfate  
 cotransporter (*Rattus norvegicus*) 34.4 57.8 562 HI0977 1032420 1033871  
 pantothenate permease (panF) (*Escherichia coli*) 60.2 77.9 478 HI0714 760739  
 757488 transferrin binding protein 1 precursor (tbp1) (*Neisseria meningitidis*)  
 29.9 48.6 894 HI0996 1059604 1056869 transferrin binding protein 1 precursor  
 (tbp1) (*Neisseria meningitidis*) 51.2 69.5 885 HI1220 1286725 1283987  
 transferrin binding protein 1 precursor (tbp1) (*Neisseria meningitidis*) 28.4  
 46.8 902 HI0997 1061509 1059635 transferrin binding protein 1 precursor  
 (tbp1) (*Neisseria meningitidis*) 39.9 54.7 692 HI0975 1029676 1030542  
 transferrin-binding protein (ttbA) (*Actinobacillus pleuropneumoniae*) 28.9 48.0  
 578 HI1571 1633105 1633993 transferrin-binding protein 1 (tbp1) (*Neisseria*  
*meningitidis*) 41.3 59.5 727 HI0837 676956 674098 transferrin-binding protein 1  
 (tbp2) (*Neisseria gonorrhoeae*) 31.6 51.7 828 HI0665 706622 708309 transport  
 ATP-binding protein (cydD) (*Escherichia coli*) 26.4 54.0 561 HI1160 1228897  
 1225140 transport ATP-binding protein (cydD) (*Escherichia coli*) 50.7 73.5 588  
 Cellular processes Chaperones HI0544 565037 565324 chaperonin (groES) (mopB)  
 (*Escherichia coli*) 87.5 94.8 96 HI0545 565350 566993 heat shock protein  
 (groEL) (mopA) (*Haemophilus ducreyi*) 89.8 94.9 547 HI1241 1310497 1311678  
 heat shock protein (dnaJ) (*Escherichia coli*) 68.0 82.5 376 HI0104 111572  
 109680 heat shock protein C62.5 (htpG) (*Escherichia coli*) 75.4 88.3 621  
 HI0375 396463 394607 hsc66 protein (hsc66) (*Escherichia coli*) 69.2 82.0 616  
 HI1240 1308539 1310443 hsp70 protein (dnaK) (*Escherichia coli*) 78.5 88.2 638  
 Cell division HI0771 831200 831853 cell division ATP-binding protein (tts)  
 (*Escherichia coli*) 64.1 78.3 216 HI1211 1275245 1274358 cell division  
 inhibitor (sulA) (*Vibrio cholerae*) 33.9 55.7 116 HI1145 1210058 1211332 cell  
 division protein (itsA) (*Escherichia coli*) 52.8 74.2 420 HI1338 1410017  
 1412129 cell division protein (itsH) (*Escherichia coli*) 75.2 87.8 624 HI1470  
 1549516 1548374 cell division protein (itsH) (*Escherichia coli*) 77.8 88.3 369  
 HI1337 1409390 1410016 cell division protein (itsJ) (*Escherichia coli*) 81.7  
 90.4 208 HI1134 1196901 1197221 cell division protein (itsL) (*Escherichia*  
*coli*) 36.6 60.4 101 HI1144 1209275 1210036 cell division protein (itsQ)  
 (*Escherichia coli*) 40.6 58.5 231 HI1140 1204467 1205648 cell division protein  
 (itsW) (*Escherichia coli*) 52.3 74.9 374 HI0770 829937 831178 cell division  
 protein (itsY) (*Escherichia coli*) 66.0 61.1 497 HI1146 1211419 1212681 cell  
 division protein (itsZ) (*Escherichia coli*) 67.2 83.1 306 HI1377 1465224  
 1469760 cell division protein (mukB) (*Escherichia coli*) 61.4 77.3 1455 HI1356  
 1429903 1431375 cytoplasmic axial filament protein (cefA) (*Escherichia coli*)  
 71.0 66.3 488 HI0772 831866 832795 ItsX protein (ItsX) (*Escherichia coli*)  
 43.5 69.9 292 HI1067 1128511 1129221 mukB suppressor protein (smba)  
 (*Escherichia coli*) 77.4 90.2 235 HI1135 1197237 1199067 penicillin-binding  
 protein 3 (ftsI) (*Escherichia coli*) 52.8 70.7 564 Protein, peptide secretion  
 HI0016 17278 15485 GTP-binding membrane protein (lepA) (*Escherichia coli*) 85.6  
 91.0 597 HI1472 1551915 1553681 colicin V secretion ATP-binding protein

(cvaB) (*Escherichia coli*) 29.9 56.0 373 HI1008 1070885 1071397 lipoprotein  
 signal peptidase (lspA) (*Escherichia coli*) 51.3 71.5 158 HI1648 1706947  
 1707753 peptide transport system ATP-binding protein SAPF (sapF) (*Escherichia coli*) 49.6 70.8 264 HI0718 764525 764842 preprotein translocase (secE)  
 (*Escherichia coli*) 40.6 62.3 106 HI0600 848438 849760 preprotein translocase  
 SECY subunit (secY) (*Escherichia coli*) 74.7 86.9 443 HI0241 269734 267887  
 protein-export membrane protein (secD) (*Escherichia coli*) 59.6 77.3 615  
 HI0240 267876 266902 protein-export membrane protein (secF) (*Escherichia coli*)  
 48.0 73.0 302 HI0447 466800 467135 protein-export membrane protein (secG)  
 (*Escherichia coli*) 58.9 81.3 110 HI0745 801965 801459 protein-export protein  
 (secB) (*Escherichia coli*) 56.2 80.8 145 HI0911 961135 963837 secA protein  
 (secA) (*Escherichia coli*) 88.0 81.7 896 HI0015 15473 14427 signal peptidase I  
 (lepB) (*Escherichia coli*) 46.3 65.1 319 HI0106 114073 112688 signal  
 recognition particle protein (54 homolog) (lfh) (*Escherichia coli*) 79.9 90.9  
 452 HI0715 761040 762335 trigger factor (tig) (*Escherichia coli*) 64.4 80.3  
 432 HI0298 330445 329758 type 4 prepilin-like protein specific leader  
 peptidase (hopD) (*Escherichia coli*) 27.2 49.0 208 HI0299 331661 330445 xcpS  
 protein (xcpS) (*Pseudomonas putida*) 29.2 56.7 398 Detoxification HI0930  
 985290 966813 KW20 catalase (hktE) (*Haemophilus influenzae*) 99.2 99.4 508  
 HI1090 1152892 1152248 superoxide dismutase (sodA) (*Haemophilus influenzae*)  
 99.0 99.5 209 HI1004 1065726 1067108 thiophene and furan oxidation protein  
 (thdF) (*Escherichia coli*) 73.8 85.4 451 Cell killing HI0303 334801 335697  
 hemolysin (tlyC) (*Serpulina hyodysenteriae*) 36.9 57.5 252 HI1664 1723070  
 1723648 hemolysin, 21 kDa (hly) (*Actinobacillus pleuropneumoniae*) 54.5 72.4  
 156 HI1376 1464493 1465221 killing protein (kicA) (*Escherichia coli*) 69.0  
 83.6 222 HI1375 1463019 1464443 killing protein suppressor (kicB)  
 (*Escherichia coli*) 66.9 83.0 440 HI1053 1116898 1115057 leukotoxin secretion  
 ATP-binding protein (lktB) (*Actinobacillus*) 34.2 55.1 512  
 actinomycetemcomitans) Transformation HI0436 456360 455674 com101A protein  
 (comF) (*Haemophilus influenzae*) 100.0 100.0 229 HI1010 1072519 1072854  
 competence locus E (comE1) (*Bacillus subtilis*) 46.7 70.0 59 HI0603 622277  
 622927 tfoX protein (tfoX) (*Haemophilus influenzae*) 99.5 99.5 217 HI0443  
 462729 463571 transformation gene cluster hypothetical protein (GB:M62809\_1)  
 (com) 100.0 100.0 281 (*Haemophilus influenzae*) HI0435 455595 455002  
 transformation gene cluster hypothetical protein (GB:M62809\_10) (com) 99.5  
 99.5 198 (*Haemophilus influenzae*) HI0442 460047 462638 transformation gene  
 cluster hypothetical protein (GB:M62809\_2) (com) 100.0 100.0 864 (*Haemophilus influenzae*)  
 HI0441 459948 459154 transformation gene cluster hypothetical  
 protein (GB:M62809\_3) (com) 100.0 100.0 265 (*Haemophilus influenzae*)



US-PAT-NO: 6833490

DOCUMENT-IDENTIFIER: US 6833490 B1

TITLE: Regulating metabolism by modifying the level of  
trehalose-6-phosphate

DATE-ISSUED: December 21, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Goddijn; Oscar Johannes Maria	Leider		N/A	N/A
Pen; Jan	Leiden	N/A	N/A	NL
Smeekens; Josephus	Driebergen		N/A	N/A
Christianus Maria				NL

APPL-NO: 09/ 171937

DATE FILED: April 28, 1999

FOREIGN-APPL-PRIORITY-DATA:

COUNTRY	APPL-NO	APPL-DATE
NL	96201225	May 3, 1996
NL	96202128	July 26, 1996
NL	96202395	August 29, 1996

PCT-DATA:

APPL-NO: PCT/EP97/02497  
DATE-FILED: May 2, 1997  
PUB-NO: WO97/42326  
PUB-DATE: Nov 13, 1997  
371-DATE: Apr 28, 1999  
102(E)-DATE: Apr 28, 1999

US-CL-CURRENT: 800/284, 435/101, 435/194, 435/468, 435/469, 800/278  
, 800/287, 800/288, 800/290, 800/294

ABSTRACT:

The invention involves decreasing the intracellular availability of trehalose-6-phosphate by plant cell transformation with a gene encoding trehalose-6-phosphate phosphatase from E. coli. Phenotypic effects of plant transformation with this gene include stimulation of glycolysis, cell or tissue growth, and metabolism; and inhibition of photosynthesis and bolting.

20 Claims, 51 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 42

----- KWIC -----

Brief Summary Text - BSTX (13):

It has now been found that modification of the development and/or composition of cells, tissue and organs in vivo is possible by introducing the

enzyme trehalose-6-phosphate synthase (TPS) and/or trehalose-6-phosphatase phosphate (TPP) thereby inducing a change in metabolic pathways of the saccharide trehalose-6-phosphate (T-6-P) resulting in an alteration of the intracellular availability of T-6-P. Introduction of TPS thereby inducing an increase in the intracellular concentration of T-6-P causes inhibition of carbon flow in the glycolytic direction, stimulation of the photosynthesis, inhibition of growth, stimulation of sink-related activity and an increase in storage of resources. Introduction of TPP thereby introducing a decrease in the intracellular concentration of T-6-P causes stimulation of carbon flow in the glycolytic direction, increase in biomass and a decrease in photosynthetic activity.

Drawing Description Text - DRTX (2):

FIG. 1. Schematic representation of plasmid pVDH275 harbouring the neomycin-phosphotransferase gene (NPTII) flanked by the 35S cauliflower mosaic virus promoter (P35S) and terminator (T35S) as a selectable marker; an expression cassette comprising the pea plastocyanin promoter (pPC<sub>pea</sub>) and the nopaline synthase terminator (Tnos); right (RB) and left (LB) T-DNA border sequences and a bacterial kanamycin resistance (KanR) marker gene.

Detailed Description Text - DETX (15):

Generation of the "plenty" signal by decreasing the intracellular concentration of trehalose-6-phosphate through expression of the enzyme TPP (or inhibition of the enzyme TPS) will signal all cell systems to increase glycolytic carbon flow and inhibit photosynthesis. This is nicely shown in the experimental part, where for instance in Experiment 2 transgenic tobacco plants are described in which the enzyme TPP is expressed having increased leaf size, increased branching and a reduction of the amount of chlorophyll. However, since the "plenty" signal is generated in the absence of sufficient supply of glucose, the pool of carbohydrates in the cell is rapidly depleted.

Detailed Description Text - DETX (50):

To select or screen for transformed cells, it is preferred to include a marker gene linked to the plant expressible gene according to the invention to be transferred to a plant cell. The choice of a suitable marker gene in plant transformation is well within the scope of the average skilled worker; some examples of routinely used marker genes are the neomycin phosphotransferase genes conferring resistance to kanamycin (EP-B 131 623), the glutathion-S-transferase gene from rat liver conferring resistance to glutathione derived herbicides (EP-A 256 223), glutamine synthetase conferring upon overexpression resistance to glutamine synthetase inhibitors such as phosphinothricin (WO 87/05327), the acetyl transferase gene from *Streptomyces viridochromogenes* conferring resistance to the selective agent phosphinothricin (EP-A 275 957), the gene encoding a 5-enolshikimate-3-phosphate synthase (EPSPS) conferring tolerance to N-phosphonomethylglycine, the bar gene conferring resistance against Bialaphos (e.g. WO 91/02071) and the like. The actual choice of the marker is not crucial as long as it is functional (i.e. selective) in combination with the plant cells of choice.

Other Reference Publication - OREF (26):

Hajirezaei, M. et al. "Transgenic potato plants with strongly decreased expression of pyrophosphate: fructose-6-phosphate phosphotransferase show no visible phenotype and only minor changes in metabolic fluxes in their tubers." Plant, vol. 192(1994),pp. 16-30.

US-PAT-NO: 6822142

DOCUMENT-IDENTIFIER: US 6822142 B2

TITLE: Transgenic plants containing altered levels of steroid compounds

DATE-ISSUED: November 23, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Karunanandaa; Balasulojini	St. Louis	MO	N/A	N/A
Post-Beittenmiller; Martha	St. Louis	MO	N/A	N/A
Venkatramesh; Mylavarapu	St. Louis	MO	N/A	N/A
Kishore; Ganesh M.	St. Louis	MO	N/A	N/A
Thorne; Gregory M.	St. Louis	MO	N/A	N/A
LeDeaux; John R.	St. Louis	MO	N/A	N/A

APPL-NO: 09/ 885723

DATE FILED: June 20, 2001

US-CL-CURRENT: 800/298, 435/320.1 , 435/419 , 536/23.6 , 800/278

ABSTRACT:

Disclosed are constructs comprising sequences encoding 3-hydroxy-3methylglutaryl-Coenzyme A reductase and at least one other sterol synthesis pathway enzyme. Also disclosed are methods for using such constructs to alter sterol production and content in cells, plants, seeds and storage organs of plants. Also provided are oils and compositions containing altered sterol levels produced by use of the disclosed constructs. Novel nucleotide sequences useful in the alteration of sterol production are also provided. Also provided are cells, plants, seeds and storage organs of plants comprising sequences encoding 3-hydroxy-3methylglutaryl-Coenzyme A reductase, at least one other sterol synthesis pathway enzyme and at least one tocopherol synthesis enzyme.

18 Claims, 78 Drawing figures

Exemplary Claim Number: 18

Number of Drawing Sheets: 78

----- KWIC -----

Drawing Description Text - DRTX (8):

FIG. 6 is a map showing the structure of construct pMON43818. pMON43818 is a recombinant binary vector carrying the gene encoding rubber hydroxymethyl glutaryl CoA reductase1 (HMGR1) in sense orientation driven by the soybean alpha' beta conglycinin promoter. P-NOS: nopaline synthase gene promoter; kan: coding region for neomycin phospho transferase protein to confer resistance to kanamycin; NOS 3': 3' termination end of nopaline synthase coding region; Soy Alpha' Beta Conglycinin: 7S alpha' beta conglycinin gene promoter from soybean; Rubber HMGR1 gene: coding sequence for HMGR1 gene from Hevea brasiliensis; E9 3': 3' end of pea rbcS E9 gene; Left border: octopine left border, sequence

essential for transfer of T-DNA into Agrobacterium; ori-V: plasmid origin of replication in Agrobacterium; rop: coding sequence for repressor of primer; Ori-322: origin of replication in E. coli; Spc/Str: coding region for Tn7 adenyltransferase (AAD(3'')) conferring resistance to spectinomycin and streptomycin; Right Border: right border sequence of T-DNA essential for integration into Agrobacterium.

Drawing Description Text - DRTX (9):

FIG. 7 is a map showing the structure of construct pMON43052. pMON43052 is a recombinant shuttle vector, carrying the cDNA fragment encoding the catalytic domain of Arabidopsis HMGR1 in sense orientation driven by the soybean alpha' beta conglycinin promoter. P-NOS: nopaline synthase gene promoter; kan: coding region for neomycin phosphotransferase protein to confer resistance to kanamycin; NOS 3': 3' termination end of nopaline synthase coding region; Soy Alpha' Beta Conglycinin: 7S alpha' beta conglycinin gene promoter from soybean; Arabidopsis HMGR catalytic domain: coding sequence for the catalytic domain of Arabidopsis HMGR1 protein; E9 3': 3' end of pea rbcS E9 gene; Left border: octopine left border, sequence essential for transfer of T-DNA into Agrobacterium; ori-V: plasmid origin of replication in Agrobacterium; rop: coding sequence for repressor of primer; Ori-322: origin of replication in E. coli; Spc/Str: coding region for Tn7 adenyltransferase (AAD(3'')) conferring resistance to spectinomycin and streptomycin; Right Border: right border sequence of T-DNA essential for integration into Agrobacterium.

Drawing Description Text - DRTX (10):

FIG. 8 is a map showing the structure of construct pMON51850. pMON51850 is a binary vector for Agrobacterium mediated transformation of soybean. P-NOS: nopaline synthase gene promoter; kan: coding region for neomycin phosphotransferase protein to confer resistance to kanamycin; NOS 3': 3' termination end of nopaline synthase coding region; Left border: octopine left border sequence essential for transfer of T-DNA into Agrobacterium; ori-v: plasmid origin of replication in Agrobacterium; rop: coding sequence for repressor of primer; ori-322: origin of replication in E. coli; Spc/Str: coding region for Tn7 adenyltransferase (AAD(3'')) conferring resistance to spectinomycin and streptomycin; Right Border: right border sequence of T-DNA essential for integration into Agrobacterium.

Drawing Description Text - DRTX (11):

FIG. 9 is a map showing the structure of construct pMON43057. pMON43057 is a recombinant binary vector for Agrobacterium mediated transformation of soybean, carrying the gene cassette for expressing catalytic domain of HMGR1 from Arabidopsis thaliana. The catalytic domain of the HMGR1 cDNA is driven by soybean 7S alpha' beta conglycinin promoter. P-NOS: nopaline synthase gene promoter; kan: coding region for neomycin phosphotransferase protein to confer resistance to kanamycin; NOS 3': 3' termination end of nopaline synthase coding region; Left border: octopine left border sequence essential for transfer of T-DNA into Agrobacterium; ori-V: plasmid origin of replication in Agrobacterium; rop: coding sequence for repressor of primer; ori-322: origin of replication in E. coli; Spc/Str: coding region for Tn7 adenyltransferase (AAD(3'')) conferring resistance to spectinomycin and streptomycin; Right Border: right border sequence essential for transfer of T-DNA into Agrobacterium; Soy Alpha' Beta Conglycinin: soybean 7S alpha' beta conglycinin gene promoter; Arabidopsis HMGR catalytic domain: coding sequence for Arabidopsis HMGR1 catalytic domain; E9 3': 3' end of pea rbcS E9 gene.

Drawing Description Text - DRTX (12):

FIG. 10 is a map showing the structure of construct pMON43058. pMON43058 is a recombinant binary vector for Agrobacterium-mediated soybean transformation, carrying gene expression cassettes for catalytic domain of HMGR1 from

Arabidopsis thaliana and SMTII from Arabidopsis thaliana. P-NOS: nopaline synthase gene promoter; kan: coding region for neomycin phosphotransferase protein to confer resistance to kanamycin; NOS 3': 3' termination end of nopaline synthase coding region; Left border: octopine left border sequence essential for transfer of T-DNA into Agrobacterium; ori-V: plasmid origin of replication in Agrobacterium; rop: coding sequence for repressor of primer; ori-322: origin of replication in E. coli; Spc/Str: coding region for Tn7 adenyltransferase (AAD(3")) conferring resistance to spectinomycin and streptomycin; Right Border: right border sequence essential for transfer of T-DNA into Agrobacterium; Soy Alpha' Beta Conglycinin: 7S alpha' beta conglycinin gene promoter from soybean; Arabidopsis HMGR catalytic domain: sequence encoding the catalytic domain of Arabidopsis HMGR1; E9 3': 3' end of pea rbcS E9 gene; Soy Alpha' Beta Conglycinin: soybean 7S alpha' beta conglycinin gene promoter; Arabidopsis SMT2: cDNA encoding sterol methyl transferase II enzyme from Arabidopsis thaliana (accession no: X89867); NOS 3': 3' termination end of nopaline synthase coding region.

#### Detailed Description Text - DETX (207):

In preferred embodiments, the vector used to express the polypeptide coding gene includes a selection marker that is effective in a plant cell, preferably a drug resistance selection marker. One preferred drug resistance marker is the gene whose expression results in kanamycin resistance; i.e., the chimeric gene containing the nopaline synthase promoter, Tn5 neomycin phosphotransferase II and nopaline synthase 3' nontranslated region described by Rogers et al., in Methods for Plant Molecular Biology, A. Weissbach and H. Weissbach eds., Academic Press Inc., San Diego, Calif. (1988).

#### Detailed Description Text - DETX (342):

Total sterols increased by 3.2- and 3.9-fold in the best performing plants (transgenic events 3 and 4). These two events also showed the highest increases of individual sterols. Campesterol increased by 2.7-fold, sitosterol by 3.4-fold, sitostanol by 3.2-fold and other sterols by 6.5-fold in event 3 while stigmasterol increased by 2.3-fold in event 4. The other sterols, which account for the highest increase in total sterols were pathway intermediates that included squalene, cycloartenol, 24-methylene cycloartenol, obtusifolol, isofucosterol, and stigmasta-7-enol. These pathway intermediates normally form minor constituents in the sterol composition of seeds. However, in the transgenic seeds, probably due to increased carbon flux through the pathway, they accumulate in significant amounts. This suggests additional control points for sterol biosynthesis in plants such as squalene epoxidase, C-24 sterol methyltransferase, and C-14 obtusifolol demethylase.

#### Detailed Description Text - DETX (353):

Six transgenic lines harboring pMON43058 produced 5.8- to 6-fold increase in total sterols and the rest of the 10 transgenic lines with the pMON43058 showed 3- to 5-fold increase in total sterols. The best performing transgenic lines showed about 2- to 3-fold increase in sitosterol and 4.5- to 6-fold increase in sitostanol levels. However, the campesterol accumulation was reduced by 50% in these lines. This was due to overexpression of the Arabidopsis SMTII enzyme which enhances the carbon flux towards the synthesis of 24-ethyl sterols thereby reducing the carbon flux through the pathway leading to the synthesis of 24-methyl sterols. As seen in pMON43057 transgenic lines, all of the transgenic lines harboring the pMON43058 also accumulated 50-60% of the total sterols in the form of pathway intermediates which are squalene, cycloartenol, 24-methylene cycloartenol, obtusifolol, isofucosterol, and stigmasta-7-enol. These pathway intermediates normally form minor constituents in the sterol composition of seeds. However, in the transgenic seeds, probably due to increased carbon flux through the pathway, they accumulate in significant amounts. The pathway intermediates accumulation is highly significant when the

truncated form of HMGR is overexpressed as compared to the full length form of HMGR suggesting that the overexpression of the truncated form of HMGR creates even greater increase in carbon flux through the pathway. This provides further evidence for additional control points for sterol biosynthesis in plants such as squalene epoxidase, sterol methyltransferase I, sterol C4-demethylase, obtusifolioside C14.alpha.-demethylase, sterol C5-desaturase, and sterol methyl transferase II.

US-PAT-NO: 6787683

DOCUMENT-IDENTIFIER: US 6787683 B1

\*\*See image for Certificate of Correction\*\*

TITLE: Phytyl/prenyltransferase nucleic acids, polypeptides and  
uses thereof

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Penna; Dean Della	Williamston	MI	N/A	N/A
Collakova; Eva	Lansing	MI	N/A	N/A
Coughlan; Sean J.	Hockessin	DE	N/A	N/A
Helentjaris; Timothy G.	Ankeny	IA	N/A	N/A

APPL-NO: 09/ 560761

DATE FILED: April 28, 2000

PARENT-CASE:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a CIP of U.S. patent application Ser. No. 09/307,460  
filed May 7, 1999, now abandoned which is hereby incorporated by reference.

US-CL-CURRENT: 800/281, 435/468 , 800/278

ABSTRACT:

The invention provides isolated nucleic acids and their encoded proteins that are involved in tocopherol or plastoquinone biosynthesis. The invention further provides recombinant expression cassettes, host cells, transgenic plants, and antibody compositions. The present invention provides methods and compositions relating to altering phytyl/prenyltransferase protein content and/or composition of plants.

3 Claims, 0 Drawing figures

Exemplary Claim Number: 1

----- KWIC -----

Brief Summary Text - BSTX (78):

The vector comprising the sequences from a polynucleotide of the present invention will typically comprise a marker gene which confers a selectable phenotype on plant cells. Usually, the selectable marker gene will encode antibiotic or herbicide resistance. Suitable genes include those coding for resistance to the antibiotic spectinomycin or streptomycin (e.g., the aada gene), the streptomycin phosphotransferase (SPT) gene coding for streptomycin resistance, the neomycin phosphotransferase (NPTII) gene encoding kanamycin or geneticin resistance, the hygromycin phosphotransferase (HPT) gene coding for hygromycin resistance.

Detailed Description Text - DETX (5):

To demonstrate that SLR1736 might be involved in tocopherol biosynthesis in *Synechocystis*, this gene was disrupted by insertion of the kanamycin expression cassette. The method of gene disruption by gene replacement technique has been previously described (Williams, 1988). The resulting mutant was named .DELTA.SLR1736. Before analyses, the mutant was sub-cultured at least 6 times by single colony section on kanamycin to select for the colonies containing only copies of the SLR1736 gene disrupted with the kanamycin resistance gene. The absence of wild type SLR1736 genes was confirmed by PCR. The lack of tocopherols in the mutant was shown by HPLC separation of lipid extracts from wild type and mutant *Synechocystis* on a normal-phase column using fluorescent detection (FLD). Levels of phyloquinone (vitamin K1) and plastoquinone seem to be unaffected in this mutant. This suggests that there are at least two separate prenyltransferase activities for tocopherol and plastoquinone synthesis in *Synechocystis* and we may be able to manipulate carbon flow through the pathway by altering gene expression of either. Phytylation/prenylation of homogentisic acid is the branch-point in tocopherol and plastoquinone synthesis, and therefore, most likely an important regulatory point of the pathway. As well as the prenylation activities, availability of different prenyl tails may also be crucial for the regulation of carbon flow through the pathway. This will become significant for manipulating tocopherol levels in higher plants.

Detailed Description Text - DETX (18):

The kanamycin resistance gene from the transposon Tn903 encoding aminoglycoside 3'-phosphotransferase was used to disrupt the wild type SLR1736 gene. Plasmid pUC4K (Pharmacia) was cut with EcoRI to release the kanamycin resistance expression cassette. Since SLR1736 has a unique MfeI site about 200 bp from the beginning of the gene, plasmid KS-1736 #5 was digested with MfeI (NEB). MfeI leaves 5'-cohesive ends compatible with EcoRI so that no other molecular manipulations are necessary. The two DNA fragments were purified from agarose gels as described above and ligated using T4 DNA ligase (Gibco BRL) as recommended by the manufacturer. Competent *E. coli* DH5.alpha. cells were transformed with the ligation reaction and transformants selected on LB plates containing 50 mg of kanamycin per liter of media. Plasmids were purified and subjected to restriction analysis. Two plasmids having opposite orientation of the kanamycin cassette were chosen for *Synechocystis* transformation. The two constructs were designated as KS.DELTA.1736-KAN-F and B, respectively, to indicate the orientation of the kanamycin resistance gene in respect to the SLR1736 gene.

Detailed Description Text - DETX (93):

A selectable marker gene which can be used to facilitate soybean transformation is a chimeric gene composed of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 (from *E. coli*; Gritz et al. (1983) *Gene* 25:179-188) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*. The seed expression cassette comprising the phaseolin 5' region, the fragment encoding the instant polypeptides and the phaseolin 3' region can be isolated as a restriction fragment. this fragment can then be inserted into a unique restriction site of the vector carrying the marker gene.



US-PAT-NO: 6750049

DOCUMENT-IDENTIFIER: US 6750049 B1

TITLE: Synthesis of 1,2,3,4-tetrahydroxybenzenes and  
1,2,3-trihydroxybenzenes using myo-inositol-1-phosphate  
synthase and myo-inositol 2-dehydrogenase

DATE-ISSUED: June 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Frost; John W.	Okemos	MI	N/A	N/A
Hansen; Chad A.	East Lansing	MI	N/A	N/A

APPL-NO: 09/ 937243

DATE FILED: May 7, 2002

PARENT-CASE:

RELATED APPLICATIONS

The present invention is a continuation-in-part of U.S. Ser. No.  
09/274,732, filed Mar. 23, 1999, now abandoned which is hereby expressly  
incorporated by reference.

PCT-DATA:

APPL-NO: PCT/US00/06808

DATE-FILED: March 16, 2000

PUB-NO: WO00/56911

PUB-DATE: Sep 28, 2000

371-DATE:

102(E)-DATE:

US-CL-CURRENT: 435/158, 435/190 , 435/233 , 435/252.3 , 435/252.33  
, 435/252.4

ABSTRACT:

A bioengineered synthesis scheme for the production of  
1,2,3,4-tetrahydroxybenzene from a carbon source is provided. Methods of  
producing 1,2,3,4-tetrahydroxybenzene from a carbon source based on the  
synthesis scheme are also provided. Methods are also provided for converting  
1,2,3,4-tetrahydroxybenzene to 1,2,3-trihydroxybenzene by catalytic  
hydrogenation.

41 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

----- KWIC -----

Detailed Description Text - DETX (8):

In one embodiment, a recombinant *E. coli* microbe is employed in the methods of the present invention. In a preferred embodiment, the *E. coli* comprises a non-functional *serA* locus. This recombinant *E. coli*, designated, JWF1, may further comprise a plasmid carrying an *INO1* gene insert and a *serA* gene insert. The *INO1* gene encodes myo-inositol-1-phosphate synthase which converts glucose-6-phosphate to myo-inositol-1-phosphate. In a preferred embodiment, the *INO1* gene is from *Saccharomyces cerevisiae*. Overexpression of myo-inositol-1-phosphate synthase will increase carbon flow into the myo-inositol pathway. This recombinant microbe is capable of converting glucose to myo-inositol.

Detailed Description Text - DETX (10):

In a preferred embodiment, the recombinant *E. coli* comprises plasmid pAD1.88A carrying an *INO1* gene insert and a *serA* gene insert. As described above, the *INO1* gene insert encodes myo-inositol-1-phosphate synthase which converts glucose-6-phosphate to myo-inositol-1-phosphate, thus increasing the carbon flow into the myo-inositol pathway. Due to a mutation in the *E. coli* genomic *serA* locus required for L-serine biosynthesis, growth in minimal salts medium and plasmid maintenance follows from expression of plasmid-localized *serA*. The *serA* insert thus allows microbial growth in minimal salts medium, distinguishing the microbes containing the plasmid from non-plasmid containing microbes.

Detailed Description Text - DETX (26):

Synthesis of myo-inositol by *E. coli* JWF1/pAD1.88A begins with D-glucose uptake and conversion to D-glucose-6-phosphate catalyzed by the *E. coli* phosphotransferase system (Postma, P. W. et al., In *Escherichia coli* and *Salmonella*, 2nd ed., Neidhardt, F. C. et al., Eds., ASM: Washington, Vol. 1, p. 1149 (1996)) where phosphoenolpyruvate is the source of the transferred phosphoryl group. D-Glucose-6-phosphate then undergoes cyclization to myo-inositol 1-phosphate catalyzed by myo-inositol-1-phosphate synthase. This enzyme activity, which results from expression of the *Saccharomyces cerevisiae* *INO1* gene (Dean-Johnson, M. et al., *J. Biol. Chem.* 264:1274-1279 (1989)) on plasmid pAD1.88A, varied significantly (0.022, 0.043, 0.018, and 0.009  $\mu\text{mol/min/mg}$  at 18 h, 30 h, 42 h, and 54 h, respectively) over the course of the fermentation.

US-PAT-NO: 6716474

DOCUMENT-IDENTIFIER: US 6716474 B2

TITLE: Expression of fructose 1,6 bisphosphate aldolase in transgenic plants

DATE-ISSUED: April 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barry; Gerard F.	St. Louis	MO	N/A	N/A
Cheikh; Nordine	Manchester	MO	N/A	N/A
Kishore; Ganesh M.	Creve Coeur	MO	N/A	N/A

APPL-NO: 09/ 923109

DATE FILED: August 6, 2001

PARENT-CASE:

This application is a divisional application Ser. No. 09/098,219 filed Jun. 16, 1998, now U.S. Pat. No. 6,441,277, which is based on U.S. Provisional application Serial No. 60/049,995, filed Jun. 17, 1997.

US-CL-CURRENT: 426/637

ABSTRACT:

Fructose-1,6-bisphosphate aldolase (FDA) is an enzyme reversibly catalyzing the reaction converting triosephosphate into fructose-1,6-bisphosphate. In the leaf, this enzyme is located in the chloroplast (starch synthesis) and the cytosol (sucrose biosynthesis). Transgenic plants were generated that express the E. coli fda gene in the chloroplast to improve plant yield by increasing leaf starch biosynthetic ability in particular and sucrose production in general. Leaves from plants expressing the fda transgene showed a significantly higher starch accumulation, as compared to control plants expressing the null vector, particularly early in the photoperiod, but had lower leaf sucrose. Transgenic plants also had a significantly higher root mass. Furthermore, transgenic potatoes expressing fda exhibited improved uniformity of solids.

2 Claims, 12 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

----- KWIC -----

Brief Summary Text - BSTX (17):

First, increasing the expression of the FDA enzyme in the chloroplast would increase the flow of carbon through the Calvin Cycle and increase atmospheric carbon assimilation during early photoperiod. This would result in an increase in photosynthetic efficiency and an increase in chloroplast starch production (a leaf carbon storage form degraded during periods when photosynthesis is low

or absent). Both of these responses would lead to an increase in sucrose production by the leaf and a net increase in carbon export during a given photoperiod. This increase in source capacity is a desirable trait in crop plants and would lead to increased plant growth, storage ability, yield, vigor, and stress tolerance.

Brief Summary Text - BSTX (19):

Third, expression of FDA in sink tissues can show several desirable traits, such as increased amino acid and/or fatty acid pools via increases in carbon flux through glycolysis (and thus pyruvate levels) in seeds or other sinks and increased starch levels as result of increased production of glucose 6-phosphate in seeds, roots, stems, and tubers where starch is a major storage nonstructural carbohydrate (reverse glycolysis). This increase in sink strength is a desirable trait in crop plants and would lead to increased plant growth, storage ability, yield, vigor, and stress tolerance.

Detailed Description Text - DETX (2):

This invention is directed to a method for producing plant cells and plants demonstrating an increased or improved growth and development, yield, quality, starch storage uniformity, vigor, and/or stress tolerance. The method utilizes a DNA sequence encoding an *fda* (fructose 1,6 bisphosphate aldolase) gene integrated in the cellular genome of a plant as the result of genetic engineering and causes expression of the FDA enzyme in the transgenic plant so produced. Plants that overexpress the FDA enzyme exhibit increased carbon flow through the Calvin Cycle and increased atmospheric carbon assimilation during early photoperiod resulting in an increase in photosynthetic efficiency and an increase in starch production. Thus, such plants exhibit higher levels of sucrose production by the leaf and the ability to achieve a net increase in carbon export during a given photoperiod. This increase in source capacity leads to increased plant growth that in turn generates greater biomass and/or increases the size of the sink and ultimately providing greater yields of the transgenic plant. This greater biomass or increased sink size may be evidenced in different ways or plant parts depending on the particular plant species or growing conditions of the plant overexpressing the FDA enzyme. Thus, increased size resulting from overexpression of FDA may be seen in the seed, fruit, stem, leaf, tuber, bulb or other plant part depending upon the plant species and its dominant sink during a particular growth phase and upon the environmental effects caused by certain growing conditions, e.g. drought, temperature or other stresses. Transgenic plants overexpressing FDA may therefore have increased carbon assimilation, export and storage in plant source and sink organs, which results in growth, yield, and uniformity and quality improvements.

Detailed Description Text - DETX (3):

Plants overexpressing FDA may also exhibit desirable quality traits such as increased production of starch, oils and/or proteins depending upon the plant species overexpressing the FDA. Thus, overexpression of FDA in a particular plant species may affect or alter the direction of the carbon flux thereby directing metabolite utilization and storage either to starch production, protein production or oil production via the role of FDA in the glycolysis and gluconeogenesis metabolic pathways.

Detailed Description Text - DETX (36):

A recombinant DNA molecule of the invention typically includes a selectable marker so that transformed cells can be easily identified and selected from non-transformed cells. Examples of such include, but are not limited to, a neomycin phosphotransferase (*nptII*) gene (Potrykus et al., 1985), which confers kanamycin resistance. Cells expressing the *nptII* gene can be selected using an appropriate antibiotic such as kanamycin or G418. Other commonly used

selectable markers include the bar gene, which confers bialaphos resistance; a mutant EPSP synthase gene (Hinchee et al., 1988), which confers glyphosate resistance; a nitrilase gene, which confers resistance to bromoxynil (Stalker et al., 1988); a mutant acetolactate synthase gene (ALS), which confers imidazolinone or sulphonylurea resistance (European Patent Application 154,204, 1985); and a methotrexate resistant DHFR gene (Thillet et al., 1988).

Detailed Description Text - DETX (88):

This increase in sucrose export by *fda*-expressing leaves is an illustration of an increase in source capacity, very likely due to an increased carbon flow through the Calvin Cycle (in response to increased triose-P utilization) and thus an increase in net carbon utilization by the leaf. As seen in Table 2, the increase in sucrose loading in the phloem correlates with the level of *fda* expression.

Detailed Description Text - DETX (94):

For the cytosolic expression of the *fda* gene in corn plants, a construct was made in which the *fda* gene sequence was fused to the backbone of a vector containing the enhanced CaMV 35S promoter (e35S; Kay et al., 1987), the HSP70 intron (U.S. Pat. No. 5,593,874), and the NOS3' polyadenylation sequence (Fraley et al., 1983). This created a NotI cassette [P-e35S/HSP70 intron/*fda*/NOS3'] that was cloned into the NotI site of pMON30460, a monocot transformation vector, to form the plant transformation vector pMON13925, as shown in FIG. 5. pMON30460 contains an expression cassette for the selectable marker neomycin phosphotransferase typell gene (*nptII*) [P-35S/NPTII/NOS3'] and a unique NotI site for cloning the gene of interest. The final vector (pMON13925) was constructed so that the gene of interest and the selectable marker gene were cloned in the same orientation. A vector fragment containing the expression cassettes for these gene sequences could be excised from the bacterial selector (Kan) and ori, gel purified, and used for plant transformation.

Detailed Description Text - DETX (98):

Transgenic maize plants transformed with the vectors pMON13925 (described above) or pMON17590 (described above) were produced using microprojectile bombardment, a procedure well-known to the art (Fromm, 1990; Gordon-Kamm et al., 1990; Walters et al., 1992). Embryogenic callus initiated from immature maize embryos was used as a target tissue. Plasmid DNA at 1 mg/mL in TE buffer was precipitated onto M10 tungsten particles using a calcium chloride/spermidine procedure, essentially as described by Klein et al. (1988). In addition to the gene of interest, the plasmids also contained the neomycin phosphotransferase II gene (*nptII*) driven by the 35S promoter from Cauliflower Mosaic Virus. The embryogenic callus target tissue was pretreated on culture medium osmotically buffered with 0.2M mannitol plus 0.2M sorbitol for approximately four hours prior to bombardment (Vain et al., 1993). Tissue was bombarded two times with the DNA-coated tungsten particles using the gunpowder version of the BioRad Particle Delivery System (PDS) 1000 device. Approximately 16 hours following bombardment, the tissue was subcultured onto a medium of the same composition except that it contained no mannitol or sorbitol, and it contained an appropriate aminoglycoside antibiotic, such as G418", to select for those cells that contained and expressed the 35S/*nptII* gene. Actively growing tissue sectors were transferred to fresh selective medium approximately every 3 weeks. About 3 months after bombardment, plants were regenerated from surviving embryogenic callus essentially as described by Duncan and Widholm (1988).

Detailed Description Text - DETX (113):

A second potato transformation vector was constructed by cloning the NotI cassette [P-FMV/CTP2/*fda*/NOS3'] (described earlier) into the unique NotI site

of pMON23616. pMON23616 is a potato transformation vector containing the nopaline-type T-DNA right border region (Fraley et al., 1985), an expression cassette for the neomycin ~~phosphotransferase~~ typell gene [P-35S/NPTII/NOS3'] (selectable marker), a unique NotI site for cloning the gene expression cassette of interest, and the T-DNA left border region (Barker et al., 1983). Cloning of the NotI cassette [P-FMV/CTP2/fda/NOS3'] (described earlier) into the NotI site of pMON23616 results in the potato transformation vector pMON17581, as shown in FIG. 8. The vector pMON 17581 was constructed such that the gene of interest and the selectable marker gene were transcribed in the same direction.

US-PAT-NO: 6682918

DOCUMENT-IDENTIFIER: US 6682918 B1

TITLE: Bacterial sucrose synthase compositions and methods of use

DATE-ISSUED: January 27, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Haselkorn; Robert	Chicago	IL	N/A	N/A
Buikema; William J.	Richton Park	IL	N/A	N/A
Bauer; Christopher C.	Houston	TX	N/A	N/A

APPL-NO: 08/ 684005

DATE FILED: July 19, 1996

US-CL-CURRENT: 435/193

ABSTRACT:

The present invention provides isolated and purified polynucleotides that encode bacterial polypeptides that participate in the utilization of sucrose. Isolated bacterial sucrose synthase compositions and methods of use are provided. Processes for altering sucrose synthase activity, altering the starch and/or sucrose content of bacterial and/or plant cells, methods of identifying sucrose synthase-encoding nucleic acid segments, and compositions comprising sucrose synthase peptides and antibodies are also disclosed.

48 Claims, 6 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

----- KWIC -----

Detailed Description Text - DETX (32):

In preferred embodiments, the vector used to express the polypeptide includes a selection marker that is effective in a plant cell, preferably a drug resistance selection marker. One preferred drug resistance marker is the gene whose expression results in kanamycin (Kan) resistance; i.e., the chimeric gene containing the nopaline synthase promoter, Tn5 neomycin phosphotransferase II (nptII) and nopaline synthase 3' nontranslated region described (Rogers et al., 1988).

Detailed Description Text - DETX (177):

An alternate plant transformation protocol utilizes the biolistic mechanism, whereby tungsten beads are coated with DNA and used to bombard plant tissue. In this protocol, the sucA gene may be engineered with specific plant promoter and processing sequences and cloned into a vector containing either a chimeric uidA gene encoding .beta.-glucuronidase or a chimeric kan gene encoding neomycin phosphotransferase, such as pFF19G or pFF19K (Maliga, 1995). This DNA is grown in E. coli and used to coat tungsten particles. The particles are

loaded into a biolistic gun, such as the PDS-1000/He (DuPont) and used to bombard plant tissues, such as embryos, protoplasts or leaves. The plant tissue may then be cultured on selective media and the resultant plant shoots regenerated on appropriate media.

Detailed Description Text - DETX (190):

The inventors contemplate that transformation of plants with the *Anabaena* sucA gene appropriately expressed via tissue-specific promoters is useful in the preparation of cultivars with improved features such as enhanced starch production in potato tubers and seed grains. The *Anabaena* sucA gene may be fused to specific promoters or promoter elements that will allow expression of sucrose synthase in a whole plant, tissue-specific, or subcellular compartment-specific manner. Many useful promoters and promoter elements are known that are suitable. One such promoter would be the patatin promoter that is active mainly in potato tubers (Bevan et al., 1986). The fusion of the *Anabaena* sucA gene to the patatin promoter and expression in plants may permit an increase in the expression of sucrose synthase activity in the tuber, possibly resulting in an increase in net carbon flow into the tuber and increased starch synthesis.



Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	5111	carbon near2 (flux or flow)	US-PGPUB; USPAT	OR	OFF	2005/05/13 15:33
L2	374	1 near4 (modif\$8 or alter\$8 or increas\$8)	US-PGPUB; USPAT	OR	OFF	2005/05/13 15:33
L3	233	(phosphoenol adj pyruvate or pep or phosphoenolpyruvate or phospho adj enol adj pyruvate) near4 (suppl\$4 or availab\$8)	US-PGPUB; USPAT	OR	OFF	2005/05/13 15:34
L4	11	2 and 3	US-PGPUB; USPAT	OR	OFF	2005/05/13 15:34
L5	8702	phosphotransferase\$1 or phospho adj transferase\$1	US-PGPUB; USPAT	OR	OFF	2005/05/13 15:51
L6	58	(2 or 3) and 5	US-PGPUB; USPAT	ADJ	OFF	2005/05/13 15:51
L7	43	(2 or 3) same (aromatic or shikimate)	US-PGPUB; USPAT	OR	OFF	2005/05/13 16:07

PGPUB-DOCUMENT-NUMBER: 20050079617

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050079617 A1

TITLE: Glucose transport mutants for production of biomaterial

PUBLICATION-DATE: April 14, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cervin, Marguerite A.	Redwood City	CA	US	
Soucaille, Philippe	Deyme	CA	FR	
Valle, Fernando	Burlingame	CA	US	
Whited, Gregory M.	Belmont		US	

APPL-NO: 10/ 728337

DATE FILED: December 3, 2003

FOREIGN-APPL-PRIORITY-DATA:

COUNTRY	APPL-NO	DOC-ID	APPL-DATE
WO	PCT/US03/31544	2003WO-PCT/US03/31544	October 3, 2003

US-CL-CURRENT: 435/471

ABSTRACT:

A method is disclosed for restoring a Glu.sup.+ phenotype to a PTS.sup.-/Glu.sup.- bacterial cell which was originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport. Bacterial cells comprising the Glu.sup.+ phenotype have modified endogenous chromosomal regulatory regions which are operably linked to polynucleotides encoding galactose permeases and glucokinases.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to application PCT/US03/31544, filed Oct. 3, 2003, U.S. Provisional Application 60/416,166 filed Oct. 4, 2002 and U.S. Provisional Application 60/374,931 filed Oct. 4, 2002, which are hereby incorporated by reference.

----- KWIC -----

Summary of Invention Paragraph - BSTX (19):

[0017] In a first aspect, the invention pertains to a method of increasing carbon flow into a metabolic pathway of a PTS.sup.-/Glu.sup.- bacterial host cell which was originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport which comprises a) modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a glucose assimilation protein in a PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a DNA construct comprising a promoter and DNA flanking sequences corresponding to upstream (5') regions of the glucose assimilation protein; b) allowing integration of the DNA construct to restore a Glu+ phenotype; and c) culturing the transformed host cell under suitable culture conditions, wherein the carbon flow into a

metabolic pathway of the transformed host cell is increased compared to the carbon flow into the same metabolic pathway in a corresponding PTS bacterial host cell cultured under essentially the same culture conditions. In one embodiment of the method the promoter is a non-host cell promoter or a modified endogenous promoter. In a second embodiment the glucose assimilation protein is a glucose transporter, preferably a galactose permease obtained from E. coli or a glucose transporter having at least 80% sequence identity thereto. In a third embodiment the glucose assimilation protein is a phosphorylating protein, preferably a glucokinase obtained from E. coli or a glucokinase having at least 80% sequence identity thereto. In a fourth embodiment of the method the bacterial host cell is selected from the group consisting of E. coli cells, Bacillus cells and Pantoea cells. In a fifth embodiment, the PTS.sup.-/Glu.sup.- host cell is obtained from a PTS cell by deletion of one or more genes selected from the group consisting of ptsI, ptsH and crr. In a sixth embodiment, the PTS.sup.-/Glu.sup.+ host cell is transformed with a polynucleotide encoding a protein selected from the group consisting of a transketolase, a transaldolase, a phosphoenolpyruvate synthase, DAHP synthase, DHQ synthase, DHQ dehydratase, shikimate dehydrogenase, shikimate kinase EPSP synthase and chorismate synthase.

#### Summary of Invention Paragraph - BSTX (22):

[0020] In a fourth aspect, the invention pertains to a method of increasing carbon flow into a metabolic pathway of a PTS.sup.-/Glu.sup.- bacterial host cell originally capable of utilizing a phosphotransferase transport system (PTS) for carbohydrate transport which comprises a) modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a galactose permease in a PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a first DNA construct comprising a promoter and DNA flanking sequences corresponding to upstream (5') regions of the galactose permease; b) modifying an endogenous chromosomal regulatory region which is operably linked to a nucleic acid encoding a glucokinase in the PTS.sup.-/Glu.sup.- host cell by transforming the PTS.sup.-/Glu.sup.- host cell with a second DNA construct comprising a promoter and DNA flanking sequences corresponding to upstream (5') regions of the glucokinase; c) allowing integration of the first and the second DNA constructs, wherein the first DNA construct replaces an endogenous promoter of the nucleic acid encoding the galactose permease and the second DNA construct replaces an endogenous promoter of the nucleic acid encoding the glucokinase wherein both the galactose permease and the glucokinase are expressed in the host cell and wherein said expression results in an increase in carbon flow into a metabolic pathway of the transformed host cell compared to carbon flow into the same metabolic pathway in the corresponding unaltered PTS.sup.-/Glu.sup.- bacterial cell. In one embodiment the metabolic pathway is the common aromatic pathway. In a second embodiment the method further comprises transforming the PTS.sup.-/Glu.sup.- host cell with a polynucleotide encoding a protein selected from the group consisting of a transketolase, a transaldolase and a phosphoenolpyruvate synthase.

#### Brief Description of Drawings Paragraph - DRTX

(3):

[0027] The following abbreviations are used in the figure and throughout the disclosure: PEP=phosphoenolpyruvate; DAHP=3-deoxy-D-arabino-heptulosonate 7-phosphate; DHQ=3-dehydroquinate; DHS=3-dehydroshikimate; SHK=shikimate; S3P=shikimate 3-phosphate; EPSP=5-enolpyruvyl shikimate 3-phosphate; PHE=phenylalanine; TYR=tyrosine; TRP=tryptophan; Pyk=pyruvate kinase, which is encoded by the gene pyk; and Ppc=PEP carboxylase, which is encoded by the gene ppc. Further, the following genes are illustrated for the common aromatic pathway: aroB which encodes DHQ synthase; aroD which encodes DHQ dehydratase; aroE which encodes shikimate dehydrogenase; aroL and aroK which encode

shikimate kinase; aroA which encodes EPSP synthase and aroC which encodes chorismate synthase. While not specifically illustrated, one skilled in the art is aware that aroG, aroF and aroH encode the three isozymes of DAHP synthase which catalyzes the conversion of Erythrose-4P (E4P) and PEP to DAHP in E. coli. FIG. 1B illustrates the varied compounds, the production of which, may be enhanced by an increase in carbon flux and PEP availability according to the methods encompassed by the invention.

Detail Description Paragraph - DETX (124):

[0162] It should be noted that as the host cell is cultured in conditions which create an increase in carbon flow into the aromatic pathway, it may be necessary to identify and overcome rate-limiting steps in the pathway. This methodology is available to the artisan, see, for example, U.S. Pat. Nos. 5,168,056 and 5,776,736.

Detail Description Paragraph - DETX (127):

[0165] In addition to increasing the carbon flux through the aromatic pathway, the following genes may be overexpressed in PTS.sup.-/Glu.sup.+ cells according to the invention: pps which encodes PEP synthase in E. coli (see U.S. Pat. No. 5,985,617) and talA which encodes transaldolase (Iida et al. (1993) J. Bacterial. 175:5375-5383). Further any gene encoding an enzyme that catalyzes reactions within the common aromatic pathway (for example, DAHP synthase (aroF, aroG, aroH), DHQ synthase (aroB), DHQ dehydratase (aroD), shikimate dehydrogenase (aroE), shikimate kinase (aroL, aroK), EPSP synthase (aroA) and chorismate synthase (aroC) may be amplified in the PTS.sup.-/Glu.sup.+ cells encompassed by the present invention.

Detail Description Paragraph - DETX (135):

[0173] Thus, having provided a PTS.sup.-/Glu.sup.+ strain which conserves PEP resulting in an increase in carbon flux into a metabolic pathway, such as the aromatic amino acid pathway, glycolysis, the TCA cycle, and the pentose phosphate pathway, by redirecting PEP and PEP precursors, the inventors have provided a host system which can be utilized for enhanced production of desired compounds in comparison to the production of the same compounds in a corresponding PTS host cell.

PGPUB-DOCUMENT-NUMBER: 20040261147

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040261147 A1

TITLE: High level production of arbutin in green plants and microbes

PUBLICATION-DATE: December 23, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Meyer, Knut	Wilmington	DE	US	
Viitanen, Paul V.	West Chester	PA	US	
Flint, Dennis	Newark	DE	US	

APPL-NO: 10/ 462162

DATE FILED: June 16, 2003

US-CL-CURRENT: 800/278, 435/468 , 435/471 , 435/488

ABSTRACT:

This invention relates to methods and materials to produce hydroquinone glucoside in genetically modified green plants and microorganisms.

----- KWIC -----

Detail Description Paragraph - DETX (71):

[0092] All co-factors, co-enzymes and co-substrates required for these pathways (such as FAD, NADH, O.sub.2, and UDPG) are present in the E. coli cytoplasm. E. coli strains with elevated levels of chorismate resulting from increased flux of carbon into the shikimate pathway have been disclosed (Berry et al., Trends Biotech, 14(7):250-256 (1996); Bongaerts et al., Metabolic Engineering, 3(4):289-300 (2001); Tatarko and Romeo T., Curr. Microbiol., 43(1):26-32 (2001); U.S. Pat. No. 6,210,937 B1; U.S. Pat. No. 5,776,736 A; and WO 73484 A1) and can be used to produce arbutin from glucose using the molecular tools described below.

Detail Description Paragraph - DETX (147):

[0167] The molecular identification and isolation of the pHBA 1-hydroxylase gene described by Applicants also enables arbutin production in microbial systems such as E. coli (described in detail in Examples 7 and 8). The pHBA 1-hydroxylase gene is expressed in E. coli cells in combination with a chorismate pyruvate-lyase gene and a suitable glucosyltransferase gene (Examples 6 and 8). Expressing these three enzymes in E. coli provides a route to arbutin from a cheap, fermentable carbon source, such as glucose, by creating a three-step pathway from chorismate to arbutin (FIG. 1). Those skilled in the art will recognize that all cofactors, coenzymes and co-substrates required for this pathway such as FAD, NADH, O.sub.2, and UDP-glucose (UDPG) are present in the E. coli cytoplasm. Moreover E. coli strains with elevated levels of chorismate resulting from increased flux of carbon into the shikimate pathway have been disclosed (Berry et al., Trends Biotech., 14(7):250-256 (1996); Bongaerts et al., Metabolic Engineering, 3(4):289-300 (2001); Tatarko and Romeo, Current Microbiology, 43(1):26-32

(2001); U.S. Pat. No. 6,210,937; US 5776736; and WO 73484 A1) and can be used to produce arbutin from glucose using the molecular tools described below.

US-PAT-NO: 6794164

DOCUMENT-IDENTIFIER: US 6794164 B2

TITLE: Process for the isolation of polyhydroxy cyclic  
carboxylic acids

DATE-ISSUED: September 21, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Malmberg; Mats	Lund	N/A	N/A	SE
Westrup; Brita	Lund	N/A	N/A	SE

APPL-NO: 10/ 041865

DATE FILED: January 7, 2002

US-CL-CURRENT: 435/136, 424/94.1 , 562/125 , 562/507 , 562/510

ABSTRACT:

This invention is directed to the use of crystallization acids, such as acetic, lactic and propionic acids, to obtain high purity polyhydroxyl cyclic carboxylic acids (PCCA) from low purity aqueous solutions. The preferred PCCA is shikimic acid and the preferred crystallization acid is acetic acid. The method according to the invention is particularly applicable to the isolation of shikimic acid from a fermentation broth.

16 Claims, 0 Drawing figures

Exemplary Claim Number: 1

----- KWIC -----

Detailed Description Text - DETX (14):

Yet another source of shikimic acid upon which the present invention can be conducted is obtained from fermentations wherein the carbon flow is increased into the shikimate pathway by combining metabolic manipulations during the fermentation. Further enhancement of the production of shikimic acid can be achieved through nutrient limitation. For example, the growth of microorganisms can be limited by limiting the cells' availability of aromatic amino acids (no exogenous source of aromatic amino acids exist in the growth medium). Alternatively, or in combination with the other techniques, shikimic acid production can be enhanced by feeding inorganic phosphate to the microorganisms at a growth limiting rate.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:23:28 ON 13 MAY 2005

=> fil .bec

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILES 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS,  
ESBIOBASE, BIOTECHNO, WPIDS' ENTERED AT 16:23:35 ON 13 MAY 2005  
ALL COPYRIGHTS AND RESTRICTIONS APPLY. SEE HELP USAGETERMS FOR DETAILS.

11 FILES IN THE FILE LIST

=> s carbon(2a) (flux or flow)

FILE 'MEDLINE'

211552 CARBON

26515 FLUX

351840 FLOW

L1 834 CARBON(2A) (FLUX OR FLOW)

FILE 'SCISEARCH'

353976 CARBON

135682 FLUX

590741 FLOW

L2 3109 CARBON(2A) (FLUX OR FLOW)

FILE 'LIFESCI'

48047 CARBON

10791 FLUX

50360 FLOW

L3 1108 CARBON(2A) (FLUX OR FLOW)

FILE 'BIOTECHDS'

12023 CARBON

1682 FLUX

13895 FLOW

L4 235 CARBON(2A) (FLUX OR FLOW)

FILE 'BIOSIS'

258149 CARBON

47579 FLUX

363374 FLOW

L5 3395 CARBON(2A) (FLUX OR FLOW)

FILE 'EMBASE'

155509 CARBON

28512 FLUX

357323 FLOW

L6 860 CARBON(2A) (FLUX OR FLOW)

FILE 'HCAPLUS'

1118225 CARBON

240791 FLUX

786811 FLOW

L7 5491 CARBON(2A) (FLUX OR FLOW)

FILE 'NTIS'

70746 CARBON

36645 FLUX

166050 FLOW

L8 265 CARBON(2A) (FLUX OR FLOW)



```

FILE 'ESBIOBASE'
    64940 CARBON
    18659 FLUX
    98559 FLOW
L9      1298 CARBON(2A) (FLUX OR FLOW)

FILE 'BIOTECHNO'
    37961 CARBON
    7514 FLUX
    51787 FLOW
L10     541 CARBON(2A) (FLUX OR FLOW)

FILE 'WPIDS'
    343161 CARBON
    76396 FLUX
    743793 FLOW
L11     1341 CARBON(2A) (FLUX OR FLOW)

TOTAL FOR ALL FILES
L12     18477 CARBON(2A) (FLUX OR FLOW)

=> s l12(6a)(modif? or alter? or increas?)
FILE 'MEDLINE'
    379490 MODIF?
    663608 ALTER?
    1993446 INCREAS?
L13     102 L1 (6A) (MODIF? OR ALTER? OR INCREAS?)

FILE 'SCISEARCH'
    506078 MODIF?
    664601 ALTER?
    2041515 INCREAS?
L14     208 L2 (6A) (MODIF? OR ALTER? OR INCREAS?)

FILE 'LIFESCI'
    95034 MODIF?
    177896 ALTER?
    501087 INCREAS?
L15     108 L3 (6A) (MODIF? OR ALTER? OR INCREAS?)

FILE 'BIOTECHDS'
    34573 MODIF?
    26976 ALTER?
    65234 INCREAS?
L16     46 L4 (6A) (MODIF? OR ALTER? OR INCREAS?)

FILE 'BIOSIS'
    374593 MODIF?
    662880 ALTER?
    2110652 INCREAS?
L17     200 L5 (6A) (MODIF? OR ALTER? OR INCREAS?)

FILE 'EMBASE'
    339040 MODIF?
    622098 ALTER?
    1865543 INCREAS?
L18     94 L6 (6A) (MODIF? OR ALTER? OR INCREAS?)

FILE 'HCAPLUS'
    914660 MODIF?
    837999 ALTER?
    3827700 INCREAS?
L19     232 L7 (6A) (MODIF? OR ALTER? OR INCREAS?)

```

FILE 'NTIS'

96792 MODIF?  
90985 ALTER?  
183123 INCREAS?

L20 9 L8 (6A) (MODIF? OR ALTER? OR INCREAS?)

FILE 'ESBIOBASE'

145943 MODIF?  
236575 ALTER?  
720067 INCREAS?

L21 119 L9 (6A) (MODIF? OR ALTER? OR INCREAS?)

FILE 'BIOTECHNO'

86734 MODIF?  
148127 ALTER?  
383544 INCREAS?

L22 69 L10 (6A) (MODIF? OR ALTER? OR INCREAS?)

FILE 'WPIDS'

269188 MODIF?  
431842 ALTER?  
1239303 INCREAS?

L23 57 L11 (6A) (MODIF? OR ALTER? OR INCREAS?)

TOTAL FOR ALL FILES

L24 1244 L12 (6A) (MODIF? OR ALTER? OR INCREAS?)

=> s phosphoenolpyruvate or (phospho enol or phosphoenol) (w)pyruvate or pep

FILE 'MEDLINE'

6819 PHOSPHOENOLPYRUVATE  
4911 PHOSPHO  
1189 ENOL  
70 PHOSPHO ENOL  
(PHOSPHO (W) ENOL)  
246 PHOSPHOENOL  
25213 PYRUVATE  
283 (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
3336 PEP

L25 9513 PHOSPHOENOLPYRUVATE OR (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
OR PEP

FILE 'SCISEARCH'

6460 PHOSPHOENOLPYRUVATE  
4384 PHOSPHO  
8134 ENOL  
78 PHOSPHO ENOL  
(PHOSPHO (W) ENOL)  
240 PHOSPHOENOL  
20485 PYRUVATE  
298 (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
3296 PEP

L26 9225 PHOSPHOENOLPYRUVATE OR (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
OR PEP

FILE 'LIFESCI'

2287 PHOSPHOENOLPYRUVATE  
1637 "PHOSPHO"  
256 "ENOL"  
25 PHOSPHO ENOL  
( "PHOSPHO" (W) "ENOL" )  
119 PHOSPHOENOL  
6259 PYRUVATE  
132 (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
1012 PEP

L27 2971 PHOSPHOENOLPYRUVATE OR (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
OR PEP

FILE 'BIOTECHDS'

503 PHOSPHOENOLPYRUVATE  
253 PHOSPHO  
170 ENOL  
6 PHOSPHO ENOL  
(PHOSPHO (W) ENOL)  
131 PHOSPHOENOL  
2127 PYRUVATE  
133 (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
258 PEP

L28 769 PHOSPHOENOLPYRUVATE OR (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
OR PEP

FILE 'BIOSIS'

8490 PHOSPHOENOLPYRUVATE  
58187 PHOSPHO  
2208 ENOL  
167 PHOSPHO ENOL  
(PHOSPHO (W) ENOL)  
3680 PHOSPHOENOL  
36636 PYRUVATE  
3779 (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
4068 PEP

L29 12909 PHOSPHOENOLPYRUVATE OR (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
OR PEP

FILE 'EMBASE'

4617 PHOSPHOENOLPYRUVATE  
3903 "PHOSPHO"  
2177 "ENOL"  
48 PHOSPHO ENOL  
( "PHOSPHO" (W) "ENOL" )  
189 PHOSPHOENOL  
20745 PYRUVATE  
218 (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
2893 PEP

L30 7008 PHOSPHOENOLPYRUVATE OR (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
OR PEP

FILE 'HCAPLUS'

11382 PHOSPHOENOLPYRUVATE  
9949 PHOSPHO  
22228 ENOL  
67 PHOSPHO ENOL  
(PHOSPHO (W) ENOL)  
728 PHOSPHOENOL  
49364 PYRUVATE  
702 (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
6683 PEP

L31 16639 PHOSPHOENOLPYRUVATE OR (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
OR PEP

FILE 'NTIS'

37 PHOSPHOENOLPYRUVATE  
58 PHOSPHO  
77 ENOL  
0 PHOSPHO ENOL  
(PHOSPHO (W) ENOL)  
5 PHOSPHOENOL  
306 PYRUVATE  
3 (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE

1354 PEP  
L32 1386 PHOSPHOENOLPYRUVATE OR (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
OR PEP

FILE 'ESBIOBASE'

2206 PHOSPHOENOLPYRUVATE  
2662 PHOSPHO  
517 ENOL  
29 PHOSPHO ENOL  
(PHOSPHO(W) ENOL)  
93 PHOSPHOENOL  
6677 PYRUVATE  
119 (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
1161 PEP  
L33 3039 PHOSPHOENOLPYRUVATE OR (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
OR PEP

FILE 'BIOTECHNO'

2544 PHOSPHOENOLPYRUVATE  
1717 PHOSPHO  
192 ENOL  
21 PHOSPHO ENOL  
(PHOSPHO(W) ENOL)  
82 PHOSPHOENOL  
6527 PYRUVATE  
96 (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
819 PEP  
L34 3075 PHOSPHOENOLPYRUVATE OR (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
OR PEP

FILE 'WPIDS'

255 PHOSPHOENOLPYRUVATE  
3629 PHOSPHO  
1803 ENOL  
79 PHOSPHO ENOL  
(PHOSPHO(W) ENOL)  
199 PHOSPHOENOL  
2047 PYRUVATE  
205 (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
448 PEP  
L35 799 PHOSPHOENOLPYRUVATE OR (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
OR PEP

TOTAL FOR ALL FILES

L36 67333 PHOSPHOENOLPYRUVATE OR (PHOSPHO ENOL OR PHOSPHOENOL) (W) PYRUVATE  
OR PEP

=> s l36(4a) (suppl#### or availab?)

FILE 'MEDLINE'

365570 SUPPL####  
353142 AVAILAB?  
L37 45 L25(4A) (SUPPL#### OR AVAILAB?)

FILE 'SCISEARCH'

123739 SUPPL####  
395727 AVAILAB?  
L38 53 L26(4A) (SUPPL#### OR AVAILAB?)

FILE 'LIFESCI'

23230 SUPPL####  
92976 AVAILAB?  
L39 27 L27(4A) (SUPPL#### OR AVAILAB?)

FILE 'BIOTECHDS'

```

        7569 SUPPL####
        9223 AVAILAB?
L40      15 L28(4A) (SUPPL#### OR AVAILAB?)

FILE 'BIOSIS'
        119608 SUPPL####
        300652 AVAILAB?
L41      42 L29(4A) (SUPPL#### OR AVAILAB?)

FILE 'EMBASE'
        81881 SUPPL####
        310156 AVAILAB?
L42      35 L30(4A) (SUPPL#### OR AVAILAB?)

FILE 'HCAPLUS'
        294096 SUPPL####
        433899 AVAILAB?
L43      72 L31(4A) (SUPPL#### OR AVAILAB?)

FILE 'NTIS'
        86949 SUPPL####
        169372 AVAILAB?
L44      16 L32(4A) (SUPPL#### OR AVAILAB?)

FILE 'ESBIOBASE'
        30675 SUPPL####
        118451 AVAILAB?
L45      21 L33(4A) (SUPPL#### OR AVAILAB?)

FILE 'BIOTECHNO'
        14397 SUPPL####
        58426 AVAILAB?
L46      17 L34(4A) (SUPPL#### OR AVAILAB?)

FILE 'WPIDS'
        1044324 SUPPL####
        114346 AVAILAB?
L47      8 L35(4A) (SUPPL#### OR AVAILAB?)

TOTAL FOR ALL FILES
L48      351 L36(4A) (SUPPL#### OR AVAILAB?)

=> s phosphotransferase# or phospho transferase#
FILE 'MEDLINE'
        20187 PHOSPHOTRANSFERASE#
        4911 PHOSPHO
        54262 TRANSFERASE#
        16 PHOSPHO TRANSFERASE#
           (PHOSPHO(W) TRANSFERASE#)
L49      20195 PHOSPHOTRANSFERASE# OR PHOSPHO TRANSFERASE#

FILE 'SCISEARCH'
        5021 PHOSPHOTRANSFERASE#
        4384 PHOSPHO
        42554 TRANSFERASE#
        18 PHOSPHO TRANSFERASE#
           (PHOSPHO(W) TRANSFERASE#)
L50      5033 PHOSPHOTRANSFERASE# OR PHOSPHO TRANSFERASE#

FILE 'LIFESCI'
        2999 PHOSPHOTRANSFERASE#
        1637 "PHOSPHO"
        13552 TRANSFERASE#
        9 PHOSPHO TRANSFERASE#

```

```

                ("PHOSPHO" (W) TRANSFERASE#)
L51      3004 PHOSPHOTRANSFERASE# OR PHOSPHO TRANSFERASE#

FILE 'BIOTECHDS'
    2097 PHOSPHOTRANSFERASE#
    253 PHOSPHO
    3455 TRANSFERASE#
    2 PHOSPHO TRANSFERASE#
      (PHOSPHO (W) TRANSFERASE#)
L52      2098 PHOSPHOTRANSFERASE# OR PHOSPHO TRANSFERASE#

FILE 'BIOSIS'
    6687 PHOSPHOTRANSFERASE#
    58187 PHOSPHO
    74049 TRANSFERASE#
    1758 PHOSPHO TRANSFERASE#
      (PHOSPHO (W) TRANSFERASE#)
L53      7582 PHOSPHOTRANSFERASE# OR PHOSPHO TRANSFERASE#

FILE 'EMBASE'
    12241 PHOSPHOTRANSFERASE#
    3903 "PHOSPHO"
    38606 TRANSFERASE#
    9 PHOSPHO TRANSFERASE#
      ("PHOSPHO" (W) TRANSFERASE#)
L54      12246 PHOSPHOTRANSFERASE# OR PHOSPHO TRANSFERASE#

FILE 'HCAPLUS'
    8085 PHOSPHOTRANSFERASE#
    9949 PHOSPHO
    50074 TRANSFERASE#
    15 PHOSPHO TRANSFERASE#
      (PHOSPHO (W) TRANSFERASE#)
L55      8096 PHOSPHOTRANSFERASE# OR PHOSPHO TRANSFERASE#

FILE 'NTIS'
    131 PHOSPHOTRANSFERASE#
    58 PHOSPHO
    1278 TRANSFERASE#
    0 PHOSPHO TRANSFERASE#
      (PHOSPHO (W) TRANSFERASE#)
L56      131 PHOSPHOTRANSFERASE# OR PHOSPHO TRANSFERASE#

FILE 'ESBIOBASE'
    3639 PHOSPHOTRANSFERASE#
    2662 PHOSPHO
    32718 TRANSFERASE#
    9 PHOSPHO TRANSFERASE#
      (PHOSPHO (W) TRANSFERASE#)
L57      3644 PHOSPHOTRANSFERASE# OR PHOSPHO TRANSFERASE#

FILE 'BIOTECHNO'
    7016 PHOSPHOTRANSFERASE#
    1717 PHOSPHO
    16723 TRANSFERASE#
    6 PHOSPHO TRANSFERASE#
      (PHOSPHO (W) TRANSFERASE#)
L58      7018 PHOSPHOTRANSFERASE# OR PHOSPHO TRANSFERASE#

FILE 'WPIDS'
    351 PHOSPHOTRANSFERASE#
    3629 PHOSPHO
    5247 TRANSFERASE#
    14 PHOSPHO TRANSFERASE#

```

```

                (PHOSPHO(W)TRANSFERASE#)
L59          356 PHOSPHOTRANSFERASE# OR PHOSPHO TRANSFERASE#

TOTAL FOR ALL FILES
L60          69403 PHOSPHOTRANSFERASE# OR PHOSPHO TRANSFERASE#

=> s 112 and 160
FILE 'MEDLINE'
L61          25 L1 AND L49

FILE 'SCISEARCH'
L62          33 L2 AND L50

FILE 'LIFESCI'
L63          12 L3 AND L51

FILE 'BIOTECHDS'
L64          7 L4 AND L52

FILE 'BIOSIS'
L65          18 L5 AND L53

FILE 'EMBASE'
L66          13 L6 AND L54

FILE 'HCAPLUS'
L67          21 L7 AND L55

FILE 'NTIS'
L68          1 L8 AND L56

FILE 'ESBIOBASE'
L69          16 L9 AND L57

FILE 'BIOTECHNO'
L70          14 L10 AND L58

FILE 'WPIDS'
L71          2 L11 AND L59

TOTAL FOR ALL FILES
L72          162 L12 AND L60

=> s 160(8a)(delet? or inactivat?)
FILE 'MEDLINE'
      136235 DELET?
      106731 INACTIVAT?
L73      106 L49(8A) (DELET? OR INACTIVAT?)

FILE 'SCISEARCH'
      118498 DELET?
      90881 INACTIVAT?
L74      65 L50(8A) (DELET? OR INACTIVAT?)

FILE 'LIFESCI'
      59379 DELET?
      40828 INACTIVAT?
L75      76 L51(8A) (DELET? OR INACTIVAT?)

FILE 'BIOTECHDS'
      14166 DELET?
      8291 INACTIVAT?
L76      47 L52(8A) (DELET? OR INACTIVAT?)

```

FILE 'BIOSIS'  
128579 DELET?  
113806 INACTIVAT?  
L77 114 L53(8A) (DELET? OR INACTIVAT?)

FILE 'EMBASE'  
114134 DELET?  
93104 INACTIVAT?  
L78 75 L54(8A) (DELET? OR INACTIVAT?)

FILE 'HCAPLUS'  
129189 DELET?  
143397 INACTIVAT?  
L79 163 L55(8A) (DELET? OR INACTIVAT?)

FILE 'NTIS'  
4498 DELET?  
2164 INACTIVAT?  
L80 0 L56(8A) (DELET? OR INACTIVAT?)

FILE 'ESBIOBASE'  
64611 DELET?  
41847 INACTIVAT?  
L81 30 L57(8A) (DELET? OR INACTIVAT?)

FILE 'BIOTECHNO'  
73821 DELET?  
40724 INACTIVAT?  
L82 58 L58(8A) (DELET? OR INACTIVAT?)

FILE 'WPIDS'  
29569 DELET?  
12585 INACTIVAT?  
L83 6 L59(8A) (DELET? OR INACTIVAT?)

TOTAL FOR ALL FILES  
L84 740 L60(8A) (DELET? OR INACTIVAT?)

=> s l84 and transport?

FILE 'MEDLINE'  
296421 TRANSPORT?  
L85 11 L73 AND TRANSPORT?

FILE 'SCISEARCH'  
443238 TRANSPORT?  
L86 9 L74 AND TRANSPORT?

FILE 'LIFESCI'  
72351 TRANSPORT?  
L87 8 L75 AND TRANSPORT?

FILE 'BIOTECHDS'  
6416 TRANSPORT?  
L88 5 L76 AND TRANSPORT?

FILE 'BIOSIS'  
2677074 TRANSPORT?  
L89 15 L77 AND TRANSPORT?

FILE 'EMBASE'  
299979 TRANSPORT?  
L90 13 L78 AND TRANSPORT?

FILE 'HCAPLUS'



```

727010 TRANSPORT?
L91      24 L79 AND TRANSPORT?

FILE 'NTIS'
      139160 TRANSPORT?
L92      0 L80 AND TRANSPORT?

FILE 'ESBIOBASE'
      200631 TRANSPORT?
L93      8 L81 AND TRANSPORT?

FILE 'BIOTECHNO'
      85418 TRANSPORT?
L94      9 L82 AND TRANSPORT?

FILE 'WPIDS'
      292993 TRANSPORT?
L95      1 L83 AND TRANSPORT?

TOTAL FOR ALL FILES
L96      103 L84 AND TRANSPORT?

=> s l60 and glucose
FILE 'MEDLINE'
      266672 GLUCOSE
L97      2512 L49 AND GLUCOSE

FILE 'SCISEARCH'
      192558 GLUCOSE
L98      928 L50 AND GLUCOSE

FILE 'LIFESCI'
      42406 GLUCOSE
L99      557 L51 AND GLUCOSE

FILE 'BIOTECHDS'
      31108 GLUCOSE
L100     138 L52 AND GLUCOSE

FILE 'BIOSIS'
      273610 GLUCOSE
L101     1252 L53 AND GLUCOSE

FILE 'EMBASE'
      223080 GLUCOSE
L102     1131 L54 AND GLUCOSE

FILE 'HCAPLUS'
      382557 GLUCOSE
L103     1511 L55 AND GLUCOSE

FILE 'NTIS'
      2876 GLUCOSE
L104     9 L56 AND GLUCOSE

FILE 'ESBIOBASE'
      65106 GLUCOSE
L105     492 L57 AND GLUCOSE

FILE 'BIOTECHNO'
      43289 GLUCOSE
L106     676 L58 AND GLUCOSE

FILE 'WPIDS'

```

32982 GLUCOSE  
L107 56 L59 AND GLUCOSE

TOTAL FOR ALL FILES  
L108 9262 L60 AND GLUCOSE

=> s 184 and 1108  
FILE 'MEDLINE'  
L109 14 L73 AND L97

FILE 'SCISEARCH'  
L110 10 L74 AND L98

FILE 'LIFESCI'  
L111 9 L75 AND L99

FILE 'BIOTECHDS'  
L112 7 L76 AND L100

FILE 'BIOSIS'  
L113 16 L77 AND L101

FILE 'EMBASE'  
L114 14 L78 AND L102

FILE 'HCAPLUS'  
L115 27 L79 AND L103

FILE 'NTIS'  
L116 0 L80 AND L104

FILE 'ESBIOBASE'  
L117 6 L81 AND L105

FILE 'BIOTECHNO'  
L118 9 L82 AND L106

FILE 'WPIDS'  
L119 2 L83 AND L107

TOTAL FOR ALL FILES  
L120 114 L84 AND L108

=> s 1108 and transport  
FILE 'MEDLINE'  
254687 TRANSPORT  
L121 741 L97 AND TRANSPORT

FILE 'SCISEARCH'  
381436 TRANSPORT  
L122 414 L98 AND TRANSPORT

FILE 'LIFESCI'  
56425 TRANSPORT  
L123 226 L99 AND TRANSPORT

FILE 'BIOTECHDS'  
4481 TRANSPORT  
L124 43 L100 AND TRANSPORT

FILE 'BIOSIS'  
2631403 TRANSPORT  
L125 458 L101 AND TRANSPORT

FILE 'EMBASE'  
267785 TRANSPORT  
L126 493 L102 AND TRANSPORT

FILE 'HCAPLUS'  
650334 TRANSPORT  
L127 641 L103 AND TRANSPORT

FILE 'NTIS'  
79193 TRANSPORT  
L128 3 L104 AND TRANSPORT

FILE 'ESBIOBASE'  
181970 TRANSPORT  
L129 244 L105 AND TRANSPORT

FILE 'BIOTECHNO'  
74784 TRANSPORT  
L130 315 L106 AND TRANSPORT

FILE 'WPIDS'  
193572 TRANSPORT  
L131 27 L107 AND TRANSPORT

TOTAL FOR ALL FILES  
L132 3605 L108 AND TRANSPORT

=> s l132 and l36

FILE 'MEDLINE'  
L133 403 L121 AND L25

FILE 'SCISEARCH'  
L134 279 L122 AND L26

FILE 'LIFESCI'  
L135 160 L123 AND L27

FILE 'BIOTECHDS'  
L136 35 L124 AND L28

FILE 'BIOSIS'  
L137 293 L125 AND L29

FILE 'EMBASE'  
L138 284 L126 AND L30

FILE 'HCAPLUS'  
L139 468 L127 AND L31

FILE 'NTIS'  
L140 3 L128 AND L32

FILE 'ESBIOBASE'  
L141 134 L129 AND L33

FILE 'BIOTECHNO'  
L142 194 L130 AND L34

FILE 'WPIDS'  
L143 25 L131 AND L35

TOTAL FOR ALL FILES  
L144 2278 L132 AND L36

```

=> s l144 and mut/q
FILE 'MEDLINE'
L145      252 L133 AND MUT/Q

FILE 'SCISEARCH'
L146      170 L134 AND MUT/Q

FILE 'LIFESCI'
L147      88 L135 AND MUT/Q

FILE 'BIOTECHDS'
L148      24 L136 AND MUT/Q

FILE 'BIOSIS'
L149      168 L137 AND MUT/Q

FILE 'EMBASE'
L150      162 L138 AND MUT/Q

FILE 'HCAPLUS'
L151      254 L139 AND MUT/Q

FILE 'NTIS'
L152      2 L140 AND MUT/Q

FILE 'ESBIOBASE'
L153      85 L141 AND MUT/Q

FILE 'BIOTECHNO'
L154      119 L142 AND MUT/Q

FILE 'WPIDS'
L155      6 L143 AND MUT/Q

TOTAL FOR ALL FILES
L156      1330 L144 AND MUT/Q

=> s l156 and (aromatic or shikimate)
FILE 'MEDLINE'
      33045 AROMATIC
      460 SHIKIMATE
L157      5 L145 AND (AROMATIC OR SHIKIMATE)

FILE 'SCISEARCH'
      102529 AROMATIC
      951 SHIKIMATE
L158      5 L146 AND (AROMATIC OR SHIKIMATE)

FILE 'LIFESCI'
      14691 AROMATIC
      306 SHIKIMATE
L159      2 L147 AND (AROMATIC OR SHIKIMATE)

FILE 'BIOTECHDS'
      5433 AROMATIC
      127 SHIKIMATE
L160      4 L148 AND (AROMATIC OR SHIKIMATE)

FILE 'BIOSIS'
      50696 AROMATIC
      1243 SHIKIMATE
L161      2 L149 AND (AROMATIC OR SHIKIMATE)

FILE 'EMBASE'

```

49121 AROMATIC  
345 SHIKIMATE  
L162 3 L150 AND (AROMATIC OR SHIKIMATE)

FILE 'HCAPLUS'  
220110 AROMATIC  
298279 AROM  
416075 AROMATIC  
(AROMATIC OR AROM)  
1906 SHIKIMATE  
L163 10 L151 AND (AROMATIC OR SHIKIMATE)

FILE 'NTIS'  
11413 AROMATIC  
8 SHIKIMATE  
L164 0 L152 AND (AROMATIC OR SHIKIMATE)

FILE 'ESBIOBASE'  
18251 AROMATIC  
347 SHIKIMATE  
L165 3 L153 AND (AROMATIC OR SHIKIMATE)

FILE 'BIOTECHNO'  
12919 AROMATIC  
232 SHIKIMATE  
L166 2 L154 AND (AROMATIC OR SHIKIMATE)

FILE 'WPIDS'  
185875 AROMATIC  
1766 AROM  
187038 AROMATIC  
(AROMATIC OR AROM)  
69 SHIKIMATE  
L167 5 L155 AND (AROMATIC OR SHIKIMATE)

TOTAL FOR ALL FILES  
L168 41 L156 AND (AROMATIC OR SHIKIMATE)

=> s 124 and 136

FILE 'MEDLINE'  
L169 9 L13 AND L25

FILE 'SCISEARCH'  
L170 15 L14 AND L26

FILE 'LIFESCI'  
L171 10 L15 AND L27

FILE 'BIOTECHDS'  
L172 8 L16 AND L28

FILE 'BIOSIS'  
L173 19 L17 AND L29

FILE 'EMBASE'  
L174 8 L18 AND L30

FILE 'HCAPLUS'  
L175 26 L19 AND L31

FILE 'NTIS'  
L176 0 L20 AND L32

FILE 'ESBIOBASE'

L177 10 L21 AND L33

FILE 'BIOTECHNO'

L178 9 L22 AND L34

FILE 'WPIDS'

L179 4 L23 AND L35

TOTAL FOR ALL FILES

L180 118 L24 AND L36

=> s l24 and glucose

FILE 'MEDLINE'

266672 GLUCOSE

L181 39 L13 AND GLUCOSE

FILE 'SCISEARCH'

192558 GLUCOSE

L182 39 L14 AND GLUCOSE

FILE 'LIFESCI'

42406 GLUCOSE

L183 25 L15 AND GLUCOSE

FILE 'BIOTECHDS'

31108 GLUCOSE

L184 21 L16 AND GLUCOSE

FILE 'BIOSIS'

273610 GLUCOSE

L185 40 L17 AND GLUCOSE

FILE 'EMBASE'

223080 GLUCOSE

L186 40 L18 AND GLUCOSE

FILE 'HCAPLUS'

382557 GLUCOSE

L187 54 L19 AND GLUCOSE

FILE 'NTIS'

2876 GLUCOSE

L188 0 L20 AND GLUCOSE

FILE 'ESBIOBASE'

65106 GLUCOSE

L189 28 L21 AND GLUCOSE

FILE 'BIOTECHNO'

43289 GLUCOSE

L190 30 L22 AND GLUCOSE

FILE 'WPIDS'

32982 GLUCOSE

L191 8 L23 AND GLUCOSE

TOTAL FOR ALL FILES

L192 324 L24 AND GLUCOSE

=> s (l48 or l72 or l96 or l120 or l156 or l168 or l180 or l192)

FILE 'MEDLINE'

L193 368 (L37 OR L61 OR L85 OR L109 OR L145 OR L157 OR L169 OR L181)

FILE 'SCISEARCH'

L194 301 (L38 OR L62 OR L86 OR L110 OR L146 OR L158 OR L170 OR L182)  
 FILE 'LIFESCI'  
 L195 164 (L39 OR L63 OR L87 OR L111 OR L147 OR L159 OR L171 OR L183)  
 FILE 'BIOTECHDS'  
 L196 65 (L40 OR L64 OR L88 OR L112 OR L148 OR L160 OR L172 OR L184)  
 FILE 'BIOSIS'  
 L197 290 (L41 OR L65 OR L89 OR L113 OR L149 OR L161 OR L173 OR L185)  
 FILE 'EMBASE'  
 L198 259 (L42 OR L66 OR L90 OR L114 OR L150 OR L162 OR L174 OR L186)  
 FILE 'HCAPLUS'  
 L199 430 (L43 OR L67 OR L91 OR L115 OR L151 OR L163 OR L175 OR L187)  
 FILE 'NTIS'  
 L200 19 (L44 OR L68 OR L92 OR L116 OR L152 OR L164 OR L176 OR L188)  
 FILE 'ESBIOBASE'  
 L201 155 (L45 OR L69 OR L93 OR L117 OR L153 OR L165 OR L177 OR L189)  
 FILE 'BIOTECHNO'  
 L202 187 (L46 OR L70 OR L94 OR L118 OR L154 OR L166 OR L178 OR L190)  
 FILE 'WPIDS'  
 L203 19 (L47 OR L71 OR L95 OR L119 OR L155 OR L167 OR L179 OR L191)  
 TOTAL FOR ALL FILES  
 L204 2257 (L48 OR L72 OR L96 OR L120 OR L156 OR L168 OR L180 OR L192)  
 => s l204 and py=<1995 range=2003,  
 FILE 'MEDLINE'  
 '2003,' IS NOT A VALID RANGE FOR FILE 'MEDLINE'  
 SEARCH ENDED BY USER  
 FILE 'SCISEARCH'  
 0 PY=<1995  
 L205 0 L194 AND PY=<1995  
 FILE 'LIFESCI'  
 120 PY=<1995  
 L206 0 L195 AND PY=<1995  
 FILE 'BIOTECHDS'  
 6 PY=<1995  
 (PY=<1995)  
 L207 0 L196 AND PY=<1995  
 FILE 'BIOSIS'  
 34 PY=<1995  
 L208 0 L197 AND PY=<1995  
 FILE 'EMBASE'  
 5 PY=<1995  
 L209 0 L198 AND PY=<1995  
 FILE 'HCAPLUS'  
 632 PY=<1995  
 L210 0 L199 AND PY=<1995  
 FILE 'NTIS'  
 963 PY=<1995

L211 0 L200 AND PY=<1995

FILE 'ESBIOBASE'

0 PY=<1995

L212 0 L201 AND PY=<1995

FILE 'BIOTECHNO'

845083 PY=<1995

L213 75 L202 AND PY=<1995

FILE 'WPIDS'

4808 PY=<1995

(PY=<1995)

L214 0 L203 AND PY=<1995

TOTAL FOR ALL FILES

L215 75 L204 AND PY=<1995

=> fil medl

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

40.76

40.97

FILE 'MEDLINE' ENTERED AT 16:38:40 ON 13 MAY 2005

=> s l204 and py=<1995 range=2003000000,

11954 PY=<1995

L216 0 L193 AND PY=<1995

=> fil .becpat

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.38

41.35

FILES 'BIOTECHDS, HCAPLUS, WPIDS' ENTERED AT 16:39:18 ON 13 MAY 2005

ALL COPYRIGHTS AND RESTRICTIONS APPLY. SEE HELP USAGETERMS FOR DETAILS.

3 FILES IN THE FILE LIST

=> s l204 and wo/pc and pry=<1995 range=2003,

FILE 'BIOTECHDS'

17940 WO/PC

236 PRY=<1995

(PRY=<1995)

L217 0 L196 AND WO/PC AND PRY=<1995

FILE 'HCAPLUS'

129652 WO/PC

10295 PRY=<1995

L218 0 L199 AND WO/PC AND PRY=<1995

FILE 'WPIDS'

275190 WO/PC

20949 PRY=<1995

(PRY=<1995)

L219 0 L203 AND WO/PC AND PRY=<1995

TOTAL FOR ALL FILES

L220 0 L204 AND WO/PC AND PRY=<1995

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

7.97

49.32



STN INTERNATIONAL LOGOFF AT 16:40:05 ON 13 MAY 2005